<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 15%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 15%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YAMBEAR BIO-TECH, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 15%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 33%; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2833</B></FONT></TD>
    <TD STYLE="width: 33%; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>46-1992903</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Primary&nbsp;Standard&nbsp;Industrial</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S.&nbsp;Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">incorporation&nbsp;or&nbsp;organization)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Classification&nbsp;Code&nbsp;Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Identification&nbsp;Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 15%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3F., No.10, Yuanxi 2nd Rd.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pingtung Agricultural Biotechnology Park,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Changzhi Township, Pingtung 908,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Taiwan, Republic of China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">+00886 08 7621913</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number, including area code, of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 15%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Hsin-Lung Lin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Suite 806, 1220 N. Market Street,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Wilmington, DE19801,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">County of New Castle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">(Name, address, including
zip code, and telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 15%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copies to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Ryan Nail, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Chiang Law Offices, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">1700 North First Street, Suite 343,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Jose, CA 95112</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: 415 488-5581</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Facsimile: 415 882-7239</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 15%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approximate Date of Commencement of
Proposed Sale to the Public:&nbsp;&nbsp;</B> from time to time after the effective date of this Registration Statement as determined
by market conditions and other factors.</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box:&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering.&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule
12b-2 of the Exchange Act.&nbsp;&nbsp;(Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated filer</FONT></TD>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-accelerated filer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller reporting company</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Do not check if a smaller
    reporting company) &nbsp; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Title&nbsp;Of&nbsp;Each <BR>Class&nbsp;of&nbsp;Securities <BR>To&nbsp;be&nbsp;Registered</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Amount&nbsp;To <BR>Be&nbsp;Registered</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Proposed <BR>Maximum <BR>Offering&nbsp;Price <BR>Per&nbsp;Share</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Proposed <BR>Maximum <BR>Aggregate <BR>Offering&nbsp;Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Amount&nbsp;of <BR>Registration&nbsp;Fee</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: justify">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Common Stock, par value $0.0001</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,625,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.008</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">13,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.77</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering price has been estimated
solely for the purpose of computing the amount of the registration fee in accordance with Rule 457(c). Our common stock is not
traded on any national exchange and in accordance with Rule 457, the offering price was determined by the price of the shares
that were recently sold to our shareholders. The price of $0.008 is a fixed price at which the selling stockholders may sell their
shares until our common stock is quoted on the OTC Bulletin Board at which time the shares may be sold at prevailing market prices
or privately negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with section 8(a) of
the securities act of 1933 or until the registration statement shall become effective on such date as the commission, acting pursuant
to said section 8(a), may determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">The information in this preliminary
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the
U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and
it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>PROSPECTUS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Subject to completion, dated
February 14, 2013</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,625,000 shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YAMBEAR BIO-TECH, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders named in this
prospectus are offering all of the shares of common stock offered through this prospectus. Our common stock is presently not traded
on any market or securities exchange. The 1,625,000 shares of our common stock can be sold by selling stockholders at a fixed
price of $0.008 per share until our shares are quoted on the OTC Bulletin Board (&ldquo;OTCBB&rdquo;) and thereafter at prevailing
market prices or privately negotiated prices. There can be no assurance that a market maker will agree to file the necessary documents
with the Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;), which operates the OTCBB, nor can there be any assurance
that such an application for quotation will be approved. We have agreed to bear the expenses relating to the registration of the
shares of the selling stockholders. We will receive no proceeds from the sale or other disposition of the shares, or interests
therein, by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>An investment in shares of our common
stock involves a high degree of risk.&nbsp; We urge you to carefully consider the Risk Factors beginning on page 8</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the U.S.&nbsp;Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Date of this Prospectus is _______________.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PROSPECTUS SUMMARY </FONT></TD>
    <TD STYLE="width: 10%; text-align: center">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RISK FACTORS </FONT></TD>
    <TD STYLE="text-align: center">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FORWARD LOOKING STATEMENTS </FONT></TD>
    <TD STYLE="text-align: center">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USE OF PROCEEDS </FONT></TD>
    <TD STYLE="text-align: center">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DIVIDEND POLICY </FONT></TD>
    <TD STYLE="text-align: center">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MARKET FOR OUR COMMON STOCK </FONT></TD>
    <TD STYLE="text-align: center">19</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
    OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </FONT></TD>
    <TD STYLE="text-align: center">20</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">BUSINESS </FONT></TD>
    <TD STYLE="text-align: center">21</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MANAGEMENT </FONT></TD>
    <TD STYLE="text-align: center">42</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SECURITY OWNERSHIP </FONT></TD>
    <TD STYLE="text-align: center">47</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
    </FONT></TD>
    <TD STYLE="text-align: center">47</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DESCRIPTION OF SECURITIES </FONT></TD>
    <TD STYLE="text-align: center">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SELLING STOCKHOLDERS </FONT></TD>
    <TD STYLE="text-align: center">48</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PLAN OF DISTRIBUTION </FONT></TD>
    <TD STYLE="text-align: center">49</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LEGAL MATTERS </FONT></TD>
    <TD STYLE="text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EXPERTS </FONT></TD>
    <TD STYLE="text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AVAILABLE INFORMATION </FONT></TD>
    <TD STYLE="text-align: center">50</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
    </FONT></TD>
    <TD STYLE="text-align: center">52</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This summary highlights selected information
contained elsewhere in this prospectus.&nbsp; This summary does not contain all the information that you should consider before
investing in the common stock.&nbsp; You should carefully read the entire prospectus, including &ldquo;Risk Factors&rdquo;, &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the Consolidated Financial Statements, before
making an investment decision<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Company Structure</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yambear Bio-tech, Inc. (&ldquo;Yambear&rdquo;
or the &ldquo;Company&rdquo;) is a Delaware corporation organized on April 12, 2012 by Hsin-Lung Lin, a Taiwanese citizen, as
a holding company for Yambear Bio-Tech Co. Ltd. Taiwan (&ldquo;Yambear Taiwan&rdquo;), Taiwanese limited liability company. Yambear
Taiwan, being the operating company of Yambear in Taiwan, was established on August 17, 2012 and is a wholly owned subsidiary
of Yambear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2012, we issued a total
of 12,500,000 shares of our common stock, $0.0001 par value per share, to several non U.S. persons in consideration for their
previous investment of $100,000 in the Company, among which $93,560 has been contributed into its wholly-owned subsidiary Yambear
Taiwan on July 19, 2012 as its capital contribution. The issuance was made pursuant to an exemption from registration contained
in Regulation S under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following flow chart illustrates our
companies&rsquo; organizational structure:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="tpg5.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Our Business</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a development stage company. We
do not have significant revenues. We have minimal assets and have incurred losses since inception. We are currently selling enzymes
products manufactured in Taiwan through Yambear Taiwan, our operating company in Taiwan, to public consumers across Taiwan, and
we intend to expand business operations by distributing and exporting our enzymes products to Hong Kong, mainland China, Singapore
and Malaysia in 2013. Our goal is to distribute and market our enzymes products to high-end consumers by exploring a variety of
marketing channels, including, without limitation, telephone selling, sales on TV shopping channels, as well as selling in special
counters located in big shopping malls and our self-operated stores.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our enzymes products are manufactured
in Taiwan by our designated manufacturer in accordance with our formula, with substantially all of the ingredients purchased within
Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive office is located in 3F.,
No.10, Yuanxi 2nd Rd., Pingtung Agricultural Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of China, where
we lease approximately 572 square meters with a monthly rent of $1,669 (NT$48,480).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the period from inception (April 12,
2012) to December 31, 2012, we generated revenues of $21,502 and incurred a net loss of $29,391.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2012, the Company&rsquo;s
current assets exceeded its current liabilities by $70,153 and the Company&rsquo;s total assets exceeded its total liabilities
by $73,149. The Company generated a net loss of $29,391for the period from inception (April 12, 2012) to December 31, 2012 and
the Company&rsquo;s cash position on December 31, 2012 was $16,302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Summary of the Offering</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders named in this
prospectus are offering all of the shares of common stock offered through this prospectus. The selling stockholders are selling
shares of common stock covered by this prospectus for their own account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any of the proceeds
from the sale of these shares. The offering price of $0.008 was determined by the price for certain shares issued to our shareholders
in a private placement issuance in exchange for $100,000 investment, which has been used for the contribution into the capital
account of Yambear Taiwan. The offering price of $0.008 is a fixed price at which the selling stockholders may sell their shares
until our common stock is quoted on the OTCBB, at which time the shares may be sold at prevailing market prices or privately negotiated
prices. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering will conclude upon the earliest
of (i) such time as all of the common stock has been sold pursuant to the registration statement or (ii) such time as all of the
common stock becomes eligible for resale without volume limitations pursuant to Rule 144 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is currently no public market for
our securities and you may not be able to liquidate your investment since there is no assurance that a public market will develop
for our common stock or that our common stock will ever be approved for trading on a recognized exchange.&nbsp; After this document
is declared effective by the U.S. Securities and Exchange Commission, we intend to seek a market maker to apply for a quotation
on the OTCBB in the United States. Our shares are not and have not been listed or quoted on any exchange or quotation system.
We cannot assure you that a market maker will agree to file the necessary documents with the OTCBB, nor can there be any assurance
that such an application for quotation will be approved or that a regular trading market will develop or that if developed, will
be sustained. In the absence of a trading market, an investor may be unable to liquidate its investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to apply for quoting of our
common stock on the OTCBB, which we estimate will cost around $100,000. The breakdown of such costs is estimated as following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left">Legal Counsel</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">70,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Auditor</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other vendors</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">Total:</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">100,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that to maintain a quoting
status will cost us $80,000to $150,000 annually which will include legal and auditing expenses.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will rely on professional services
to carry out this plan, which includes, but is not limited to, a U.S. law firm with corporate and securities practice, a PCAOB
registered auditor and consultants. We have engaged The Chiang Law Offices as our legal counsel. We have engaged Goldman Kurland
Mohidin, LLP, as our independent auditor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To be quoted on the OTCBB, we must engage
a market maker to file an application for a trading symbol on our behalf with the Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;).
This process may take between three (3) to six (6) months. We plan to engage a market maker after our registration statement is
declared effective by the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Common Stock offered hereby involves
a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investments. See &ldquo;Risk
Factors&rdquo; beginning on page 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Where You Can Find Us</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We presently maintain our executive office
at 3F., No.10, Yuanxi 2nd Rd., Pingtung Agricultural Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of
China. Our telephone number is +00886 08 7621913. Our Taiwan subsidiary Yambear Taiwan maintains a website at <FONT STYLE="color: windowtext"><U>www.yambear.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See &ldquo;RISK FACTORS&rdquo; for a discussion
of the above factors and certain additional factors that should be considered in evaluating an investment in the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY OF FINANCIAL AND OPERATING INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following selected financial information
is derived from the Consolidated Financial Statements appearing elsewhere in this prospectus and should be read in conjunction
with the Consolidated Financial Statements, including the notes thereto, appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; padding-bottom: 1pt">Summary&nbsp;of&nbsp;Operations</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Inception&nbsp;(April&nbsp;12, <BR>&nbsp;2012)&nbsp;to <BR>December&nbsp;31,&nbsp;2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: justify">Net&nbsp;revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">21,502</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net profit (loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(29,391</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Net profit (loss) per common share (basic and diluted)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Weighted average common shares outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; padding-bottom: 1pt">Statement&nbsp;of&nbsp;Financial&nbsp;Position</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: left; border-bottom: Black 1pt solid">As&nbsp;of <BR>December 31, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: justify">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">16,302</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">77,086</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,937</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Long-term Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">73,149</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to pay the dividends only when
our net income exceeds the total amount due and when the payment will not have a significant impact on our financial position.
Our Delaware corporation, Yambear, has not declared any dividends since its inception on April 12, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of our common stock being offered
for resale by the selling stockholders are highly speculative in nature, involve a high degree of risk and should be purchased
only by persons who can afford to lose the entire amount invested in the common stock. Before purchasing any of the shares of
common stock, you should carefully consider the following factors relating to our business and prospects. If any of the following
risks actually occurs, our business, financial condition or operating results could be materially adversely affected. In such
case, the trading price of our common stock could decline and you may lose all or part of your investment.&nbsp; This Risk Factors
section has addressed all material risks that should be considered in evaluating an investment in the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Relating to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>We lack an operating history
and have not generated significant revenues or any profit to date. There is no assurance our future operations will result in
profitable revenues. If we cannot generate sufficient revenues to operate profitably, we may have to cease operations. .</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company was incorporated on April
12, 2012 and our operating company in Taiwan, Yambear Taiwan, was incorporated on August 17, 2012. We only have a limited operating
history, which may not provide a meaningful basis for you to evaluate our business, financial performance and prospects. Our ability
to achieve and maintain profitability and positive cash flow is dependent upon our ability to earn profit by developing, expanding
and marketing our enzymes products. We cannot assure you that we will be successful in generating revenues and profit from our
enzymes products business in the future. Failure to generate revenues and profit may cause us to suspend or cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Our business and prospects
could be materially and adversely affected if we are not able to manage our growth successfully.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a development stage company. We
are currently selling enzymes products manufactured in Taiwan through Yambear Taiwan, our operating company in Taiwan, to public
consumers across Taiwan, and we intend to expand business operations by distributing and exporting our enzymes products to Hong
Kong, mainland China, Singapore and Malaysia in 2013 through a variety of marketing channels. We only offer limited enzymes products
now and we intend to broaden our line of products through investment in research and development. We anticipate continued growth
in the future through internal expansion as well as external strategic partnerships or alliances. Our expansion will place substantial
demands on our managerial, operational, technological and other resources. To manage and support our continued growth, we must
continue to improve our operational, administrative, financial and technological systems, procedures and controls, and expand,
train and manage our growing employee base. Furthermore, our management will be required to maintain and expand our relationships
with our suppliers, manufacturers, regulators and other third parties. We cannot assure you that our current and planned personnel,
systems, procedures and controls will be adequate to support our future operations. Any failure to effectively and efficiently
manage our expansion could materially and adversely affect our ability to capitalize on new business opportunities, which in turn
could have a material adverse effect on our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Because our auditors have
issued a going concern opinion, there is substantial uncertainty that we will continue operations in which case you could lose
your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our auditors have issued a going concern
opinion.&nbsp; This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months.&nbsp;
The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in
business.&nbsp; As such we may have to cease operations and you could lose your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Competition in our industry
is intense and, if we are unable to compete effectively, we may lose customers and our financial results may be negatively affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The enzymes business in Taiwan is highly
competitive for new players. The market share is largely dominated by two well-established companies and many smaller companies
competing for the remaining share. We expect competition to persist and intensify. We compete for customers on the basis of product
qualities and name recognition. Though we believe that our enzymes products have been manufactured according to our unique formula
and special fermentation process and are better in key parameters for enzymes products, there&rsquo;s no assurance that the customers
will recognize the quality of our enzymes products or be willing to pay any premium for them. Many of our competitors have greater
financial and marketing resources than we do and may be able to offer products and services that we do not currently offer and
may not offer in the future. If we are unable to compete effectively against those competitors, we may lose customers and our
financial results may be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Unfavorable publicity or
consumer perception of our enzymes products and any similar products distributed by other companies could cause fluctuations in
our operating results and could have a material adverse effect on our reputation, the demand for our enzymes products, and our
ability to generate revenues. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are highly dependent upon consumer perception of the safety and quality of our enzymes products, as well as similar products distributed
by other companies. Consumer perception of enzymes products can be significantly influenced by scientific research or findings,
national media attention, and other publicity about product use. An enzymes product may be received favorably, resulting in high
sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity
could be unfavorable to our industry or any of our particular enzymes products and may not be consistent with earlier favorable
research or publicity. A future research report or publicity that is perceived by our consumers as less favorable or that questions
earlier research or publicity could have a material adverse effect on our ability to generate revenues. As such, period-to-period
comparisons of our results should not be relied upon as a measure of our future performance. Adverse publicity in the form of
published scientific research or otherwise, whether or not accurate, that associates consumption of enzymes products or any other
similar products with illness or other adverse effects, that questions the benefits of our or similar products, or that claims
that such products are ineffective could have a material adverse effect on our reputation, the demand for our enzymes products,
and our ability to generate revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>We lack risk management
methods, our business, reputation and financial results may be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not have methods to identify,
monitor and manage risks with respect to our enzymes products business. If any of such risks to which we are, or may be, exposed
materialize, our business, reputation, financial condition and operating results could be materially and adversely affected. In
addition, our insurance policies may not provide adequate coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>If we cannot explore various
marketing channels for our enzymes products on schedule and profitably, our planned future growth will be impeded, which would
adversely affect sales. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our growth is dependent on increases in
sales through our successful exploration of a variety of marketing channels. Our ability to timely expand our market share through
a combination of marketing channels, including telephone sales, sales on TV shopping channels, as well as selling in special counters
located in big shopping malls and our self-operated stores, depends in part on the following factors: the availability of such
channels; the ability to negotiate acceptable terms with third party service providers; the ability to identify customer demand
in different geographic areas; the hiring, training and retention of competent sales personnel; the effective management of inventory
to meet the needs of increased orders on a timely basis; general economic conditions; and the availability of sufficient funds
for expansion. Many of these factors are beyond our control. Delays or failures in utilizing these marketing channels, or achieving
lower than expected sales through such marketing channels, could materially adversely affect our growth and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Our future success depends
on the continuing efforts of our senior management team and other key personnel, and our business may be harmed if we lose their
services.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future success depends heavily upon
(i) the continuing services of our current senior management team and (ii) the recruitment of other key personnel, in particular
the Chief Executive Officer and the Chief Marketing Officer. If we fail to recruit the key personnel, or one or more of our senior
management team, are unable or unwilling to continue in their present positions, we may not be able to replace them easily, or
at all. As such, our business may be disrupted and our financial condition and results of operations may be materially and adversely
affected. Competition for senior management and key personnel is intense, the pool of qualified candidates is very limited, and
we may not be able to retain the services of our senior executives or key personnel, or attract and retain high-quality senior
executives or key personnel in the future. As is customary in the Taiwan, we do not have insurance coverage for the loss of our
senior management team or other key personnel.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, if any member of our senior
management team or any of our other key personnel joins a competitor or forms a competing company, we may lose customers, sensitive
trade information and key professionals and staff members. Each of our current employees has entered into an employment agreement
as well as confidentiality agreement, with Yambear Taiwan.<B> </B>See &ldquo;Management&mdash;Employment Agreements&rdquo; for
a more detailed description of the key terms of these employment agreements. If any disputes arise between any of our senior executives
or key personnel and us, we cannot assure you of the extent to which any of these agreements may be enforced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Our directors and certain
senior management have other business interests, which may limit the amount of time they can devote to our company and potentially
create conflicts of interest. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors and certain senior management
have other business interests. For example, our director, Mr. Johnson Chang, also acts as the Senior Customer Development Manager
of Hawley &amp; Hazel Taiwan.&nbsp; Our senior management, Mr. Vincent Chang, also play key management roles in other businesses,
which may lead to periodic interruptions of our business operations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Compliance with new and
existing governmental regulations could increase our costs significantly and adversely affect our results of operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enzymes products, like the similar
products offered by our competitors in Taiwan, are categorized as dietary products, rather than nutritional products, which is
subject to more stringent governmental regulations. The processing, formulation, manufacturing, packaging, labeling, advertising,
and distribution of our enzymes products are subject to applicable laws and regulations of Ministry of Economic Affaires and Department
of Health, both of which are under the leadership of the Executive Yuan of Taiwan. Additional or more stringent regulations of
dietary products have been considered from time to time. The enactment of such new regulations or other regulation re-categorizing
enzymes products as nutritional products, thus subject to more intense regulations, could impose more stringent standards on enzymes
products. We may not be able to comply with any of such new regulations without incurring additional expenses, which could be
significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>We may incur material product
liability claims, which could increase our costs and adversely affect our reputation, revenues, and operating income. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a retailer and distributor of enzymes
products designed for human consumption, we may be subject to product liability claims if the use of our products has allegedly
resulted in injury. Our enzymes products consist of enzymes fluid extracted from fruits and vegetables, herbs and other ingredients
that are classified as foods or dietary supplements and are not subject to pre-market regulatory approval in Taiwan. Our products
could contain contaminated substances, and some of our products contain ingredients that do not have long histories of human consumption.
Previously unknown adverse reactions resulting from human consumption of these ingredients could occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we have engaged a third-party
manufacturer to produce all of our enzymes products that we sell. As a distributor of products manufactured by third parties,
we may also be liable for various product liability claims for products we do not manufacture. Though we have purchased product
liability insurance to cover the enzymes products we sell, we can not assure you that the insured amount is sufficient. We may
be unable to obtain full recovery from the insurer or any indemnifying third party in respect of any claims against us in connection
with products manufactured by such party. Any product liability claim against us could result in increased costs and could adversely
affect our reputation with our customers, which in turn could adversely affect our revenues and operating income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>We do not have any patent
for the formula of our enzymes products or the manufacturing process.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not applied and will not apply
the patent right for the formula of our enzymes products or the manufacturing process due to legal restrictions and our business
concerns. We have taken various measures to protect know-hows on formula as well as manufacturing process of our enzymes products.
If the formula of our enzymes products is stolen or analyzed out by other competitors, we could lose our competition strengths,
which could adversely affect our ability to expand our market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Intellectual property litigation
and infringement claims against us could cause us to incur significant expenses or prevent us from manufacturing, selling, or
using some aspect of our products, which could adversely affect our revenues and market share. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently and may in the future
be subject to intellectual property litigation and infringement claims, which could cause us to incur significant expenses or
prevent us from manufacturing, selling or using some aspect of our products. Claims of intellectual property infringement also
may require us to enter into costly royalty or license agreements. However, we may be unable to obtain royalty or license agreements
on terms acceptable to us or at all. Claims that our technology or products infringe on intellectual property rights could be
costly and would divert the attention of management and key personnel, which in turn could adversely affect our revenues and profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>If we fail to maintain
an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results
or prevent fraud.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After this Registration Statement is declared
effective by the SEC, we will be subject to reporting obligations under U.S. securities laws. Pursuant to Section&nbsp;404 of
the Sarbanes-Oxley Act of 2002 and the related rules adopted by the Securities and Exchange Commission, every public company is
required to include a management report on the company&rsquo;s internal controls over financial reporting in its annual report,
which contains management&rsquo;s assessment of the effectiveness of the company&rsquo;s internal controls over financial reporting.
These requirements will first apply to our annual report on Form 10-K for the fiscal year ending on December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that we will be
able to maintain effective internal controls over financial reporting in the future. If we fail to do so, we may not be able to
produce reliable financial reports and prevent fraud. Moreover, if we were not able to conclude that we have effective internal
controls over financial reporting, investors may lose confidence in the reliability of our financial statements, which would negatively
impact the trading price of our shares. Our reporting obligations as a public company, including our efforts to comply with Section&nbsp;404
of the Sarbanes-Oxley Act, will continue to place a significant strain on our management, operational and financial resources
and systems for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Our network and communications
systems are dependent on third-party providers and are vulnerable to system interruption and damage, which could limit our ability
to operate our business and could have a material adverse effect on our business, financial condition or results of operations.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.9pt">We intend to expand
sales of our enzymes products through a variety of marketing channels, among which include telephone sales and sales on TV shopping
channels. Our systems and operations and those of our third-party Internet and telecommunication service providers, are vulnerable
to damage or interruption from fire, flood, earthquakes, power loss, server failure, telecommunications and Internet service failure,
acts of war or terrorism, computer viruses and denial-of-service attacks, physical or electronic breaches, sabotage, human error
and similar events. Any of these events could lead to system interruptions, processing and order fulfillment delays, and loss
of critical data for us, our suppliers, or our Internet service providers, and could prevent us from processing customer purchases.
Any significant interruption in the availability or functionality of our website or our customer processing, distribution, or
communications systems, for any reason, could seriously harm our business, financial condition, and operating results. The occurrence
of any of these factors could have a material adverse effect on our business, financial condition or results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>We may require additional
funds to continue our business plan.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business plan and growth strategy
call for ongoing expenses in connection with the distribution of enzymes products. We have not generated any significant revenue
from operations to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2012, we had cash on
hand of $16,302, and we have accumulated a deficit of $29,391. At this rate, we anticipate that additional funding will be needed
for general administrative expenses and marketing costs within the next three months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to expand our business operations,
we anticipate that we will have to raise additional funding. If we are not able to raise the capital necessary to fund our business
expansion objectives, we may have to delay the implementation of our business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not currently have any arrangements
for financing. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor
acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount,
terms or conditions of additional financing available to us. The most likely source of future funds available to us is through
the sale of additional shares of common stock or advances from our major shareholders or directors and, if we are able to obtain
equity financing, it will likely result in significant additional dilution to the interests of our current stockholders and may
include liquidation or other preferences that adversely affect your right as a stockholder. The Company may obtain financing by
issuing debt which may involve agreements that include covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that we will
be able to obtain such additional financing and if we cannot receive such financing we may be forced to suspend or cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.45pt; text-align: justify"><B><I>General economic conditions,
including a prolonged weakness in the economy, may affect consumer purchases, which could adversely affect our sales. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the nature of dietary supplement
products, our sales results are dependent on a number of factors impacting consumer spending, including general economic and business
conditions; consumer confidence; wages and employment levels; the housing market; consumer debt levels; availability of consumer
credit; credit and interest rates; taxes; general political conditions, both domestic and abroad. Consumer product purchases,
including purchases of our enzymes products, may decline during recessionary periods. A prolonged downturn or an uncertain outlook
in the economy may materially adversely affect our business and our revenues and profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>We do not expect to pay
dividends in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never paid any dividends on our
common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable future. The future payment
of dividends directly depends upon our future earnings, capital requirements, financial requirements and other factors that our
board of directors will consider. Since we do not anticipate paying cash dividends on our common stock, return on your investment,
if any, will depend solely on an increase, if any, in the market value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>We have no experience as
a public company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never operated as a public company.
We have no experience in complying with the various rules and regulations, which are required of a public company. As a result,
we may not be able to operate successfully as a public company, even if our operations are successful. We plan to comply with
all of the various rules and regulations, which are required of a public company. However, if we cannot operate successfully as
a public company, your investment may be materially adversely affected. Our inability to operate as a public company could be
the basis of your losing your entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>We have outsourced the
manufacturing of all of our enzymes products to one company.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our enzymes products are being
manufactured by a Taiwan local company, Bioenergy Biotechnology Corp. (&ldquo;Bioenergy&rdquo;) pursuant to the orders we place
to them from time to time. Bienergy is one of the biggest enzymes products manufacturers in Taiwan and we&rsquo;ve started our
cooperation with it since our inception. If they choose to terminate our cooperation or materially change terms of our cooperation,
we may not be able to find a replacement in time or on terms acceptable to us, which could have a material adverse effect on our
business operation. We have entered into confidentiality agreement with Bioenergy, however, if Bioenergy breaches its confidentiality
obligation and discloses our formula of enzymes products to the public or any third party, we could lose our competition strength
and our operation could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21pt"><B><I>We are an Emerging
Growth Company as defined under the Jumpstart Our Business Startups Act.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48pt">An &ldquo;emerging
growth company&rdquo; is an issuer whose initial public offering was or will be completed after Dec. 8, 2011, and had total annual
gross revenues of less than $1 billion during its most recently completed fiscal year. An issuer&rsquo;s EGC status terminates
on the earliest of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The last day of the first fiscal
year of the issuer during which it had total annual gross revenues of $1 billion or more;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The last day of the fiscal year
of the issuer following the fifth anniversary of the date of the issuer&rsquo;s initial public offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The date on which such issuer has
issued more than $1 billion in non-convertible debt securities during the prior three-year period determined on a rolling basis;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The date on which the issuer is
deemed to be a &ldquo;large accelerated<B><I> </I></B>filer&rdquo; under the Exchange Act, which means, among other things, that
it has a public float in excess of $700 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48pt">Pursuant to the JOBS
Act of 2012, as an emerging growth company the Company can elect to opt out of the extended transition period for any new or revised
accounting standards that may be issued by the PCAOB or the SEC. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the standard for the private company. This may make comparison of the Company's
financial statements with any other public company which is not either an emerging growth company nor an emerging growth company
which has opted out of using the extended transition period difficult or impossible as possible different or revised standards
may be used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48pt">The Company has elected
to use the extended transition period for complying with new or revised financial accounting standards available under Section
102(b)(2)(B) of the Act. Among other things, this means that the Company's independent registered public accounting firm will
not be required to provide an attestation report on the effectiveness of the Company's internal control over financial reporting
so long as it qualifies as an emerging growth company, which may increase the risk that weaknesses or deficiencies in the internal
control over financial reporting go undetected. Likewise, so long as it qualifies as an emerging growth company, the Company may
elect not to provide certain information, including certain financial information and certain information regarding compensation
of executive officers that would otherwise have been required to provide in filings with the SEC, which may make it more difficult
for investors and securities analysts to evaluate the Company. As a result, investor confidence in the Company and the market
price of its common stock may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 48pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Doing Business in
Taiwan </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Our operations and financial
results could be severely harmed by natural disasters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive office is located in Taiwan,
which is susceptible to earthquakes. Taiwan is also exposed to typhoons and tsunamis. If a major earthquake, typhoon, tsunami
or other natural disaster were to affect the operations of our suppliers and manufacturers, our sales and delivery of enzymes
products to our customers could be interrupted or delayed. As a result, our normal business operations could be severely disrupted
and our financial condition and results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Fluctuation in the value
of the NT$ may have a material adverse effect on your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The value of the NT$ against the US dollar
(&ldquo;USD&rdquo;) and other currencies may fluctuate and is affected by, among other things, changes in political and economic
conditions. As of December 31, 2012, the exchange rate of NT$ to the USD was 29.05NT$=1USD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our revenues and costs are denominated
in the NT$, and our financial assets are also denominated in NT$. We completely rely on dividends payable to us by our operating
company in Taiwan, Yambear Taiwan. Any significant appreciation or depreciation of the NT$ against the USD may affect our cash
flows, revenues, earnings and financial position, and the value of, and any dividends payable on, our shares in USD. For example,
a further appreciation of the NT$ against the USD would make any new NT$-denominated investments or expenditures more costly to
us, to the extent that we need to convert USD into the NT$ for such purposes. An appreciation of the NT$ against the USD would
also result in foreign currency translation losses for financial reporting purposes when we translate our USD denominated financial
assets into the NT$, as the NT$ is our reporting currency in Taiwan. Conversely, a significant depreciation of the NT$ against
the USD may significantly reduce the USD equivalent of our reported earnings, and may adversely affect the price of our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Increase in the price and
shortage of supply of key raw materials could adversely affect our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Substantially all of our key raw materials
for the production of our enzymes products are harvested in Taiwan. If the prices of these raw materials were to increase significantly,
or it experiences a shortage of supply of these raw materials due to abnormal climate change or natural disasters, we could incur
significant cost increase or fail to accumulate our products inventory to meet our customers&rsquo; needs. Raw material prices
may increase from time to time in the future and we may not be able to pass on such increases to our customers. A significant
increase in the price of raw materials that cannot be passed on to customers could have a material adverse effect on our results
of operations and financial condition. In addition, the interruption in supply of certain key raw materials essential to the manufacturing
of our products may have an adverse impact on our suppliers and manufacturers' ability to provide us with the necessary products
needed to maintain our customer relationships and an adequate level of sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Our controlling shareholders
may take actions that are not in, or may conflict with, our public shareholders&rsquo; best interest.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After this offering, Yambear Holding
Limited will own, directly or indirectly, a controlling interest of approximately 45.60% of our outstanding common shares.
Accordingly, these shareholders will continue to have the ability to exercise a controlling influence over our business and may
take actions that you may not agree with or that are not in our or our public shareholders&rsquo; best interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Our primary operation is
located in Taiwan, and because the rights of shareholders under Taiwan law differ from those under U.S. law, you may have difficulty
protecting your shareholder rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conduct all of our business operations
through our operating entity in Taiwan, whose corporate affairs are governed by its Articles of Incorporation and by the laws
governing corporations incorporated in Taiwan. The rights of shareholders and the responsibilities of management and the members
of the board of directors under Taiwan law are different from those applicable to a corporation incorporated in the United States.
For example, directors and controlling shareholders of Taiwan companies do not owe fiduciary duties to minority shareholders.
Therefore, public shareholders of Taiwan companies may have more difficulty in protecting their interest in connection with actions
taken by management or members of the board of directors than they would as public shareholders of a U.S. corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>U.S. investors may experience
difficulties in attempting to effect service of process and to enforce judgments based upon U.S. federal securities laws against
the company and its non-U.S. resident directors and senior officers.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our directors and senior officers
are non-residents of the United States. Consequently, it may be difficult for investors to effect service of process on any of
them in the United States and to enforce judgments obtained in United States courts against them based on the civil liability
provisions of the United States securities laws. Since all our assets are located in Taiwan it may be difficult or impossible
for U.S. investors to collect a judgment against us. As well, any judgment obtained in the United States against us may not be
enforceable in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Strained relations between
the Republic of China and the People&rsquo;s Republic of China could negatively affect our business and the market value of your
investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to expand our business operations in mainland China
through self-operated stores as well as authorized agents for the marketing of our enzymes products, which may become a more and
more important market for our enzymes products as well as revenue and profit source for our business. The Republic of China has
a unique international political status. Both the Republic of China and the People&rsquo;s Republic of China assert sovereignty
over all of China, including Taiwan. The People&rsquo;s Republic of China government does not recognize the legitimacy of the
Republic of China government. Although significant economic and cultural relations have been established in recent years between
the Republic of China and the People&rsquo;s Republic of China, relations have often been strained and the government of the People&rsquo;s
Republic of China government has indicated that it may use military force to gain control over Taiwan under certain circumstances,
such as the declaration of independence by the Republic of China. Relations between the Republic of China and the People&rsquo;s
Republic of China have been particularly strained in recent years. Past developments in relations between the Republic of China
and the People&rsquo;s Republic of China have on occasion depressed the market price of the shares of Taiwanese companies. Relations
between the Republic of China and the People&rsquo;s Republic of China and other factors affecting the political or economic conditions
in Taiwan could have a material adverse effect on our financial condition and results of operations, as well as the market price
and the liquidity of our common shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Associated with Our Shares of
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>You may not be able to
liquidate your investment since there is no assurance that a public market will develop for our common stock or that our common
stock will ever be approved for trading on a recognized exchange.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading
market for our securities. After this document is declared effective by the U.S. Securities and Exchange Commission, we intend
to seek a market maker to apply for a quotation on the OTCBB in the United States. Our shares are not and have not been listed
or quoted on any exchange or quotation system. We cannot assure you that a market maker will agree to file the necessary documents
with the OTCBB, nor can there be any assurance that such an application for quotation will be approved or that a regular trading
market will develop or that if developed, will be sustained. In the absence of a trading market, you may be unable to liquidate
its investment, which will result in the loss of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>The offering price of the
shares was arbitrarily determined, and therefore should not be used as an indicator of the future market price of the securities.
Therefore, the offering price bears no relationship to our actual value, and may make our shares difficult to sell.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The offering price of $0.008 for the shares
of common stock was based upon the sale price in our recent private placement. The sale price in the private placement was arbitrarily
determined. The factors considered in determining the sale price were our financial condition and prospects, our limited operating
history and the general condition of the securities market. Therefore, the offering price is not an indication of and is not based
upon our actual value. The offering price bears no relationship to our book value, assets or earnings&nbsp;or any other recognized
criteria of value. The offering price should not be regarded as an indicator of the future market price of the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>Future sales by our stockholders
may negatively affect our stock price and our ability to raise funds in new stock offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of our common stock in the public
market could lower the market price of our common stock. Sales may also make it more difficult for us to sell equity securities
or equity-related securities in the future at a time and price that our management deems acceptable or at all. Of the 12,500,001
shares of common stock outstanding as of February 8, 2012, 1,625,000 shares are, or will be, freely tradable without restriction
upon the effective date of this registration statement, unless held by our &ldquo;affiliates&rdquo;. The remaining 10,875,001
shares of common stock, which will be held by existing stockholders, including the officers and directors, are &ldquo;restricted
securities&rdquo; and may be resold in the public market only if registered or pursuant to an exemption from registration. Some
of these shares may be resold under Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&ldquo;Penny Stock&rdquo;
rules may make buying or selling our common stock difficult.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trading in our securities will be subject
to the &ldquo;penny stock&rdquo; rules. The SEC has adopted regulations that generally define a penny stock to be any equity security
that has a market price of less than $5.00 per share, subject to certain exceptions. These rules require that any broker-dealer
who recommends our securities to persons other than prior customers and accredited investors, must, prior to the sale, make a
special written suitability determination for the purchaser and receive the purchaser&rsquo;s written agreement to execute the
transaction. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny
stock, of a disclosure schedule explaining the penny stock market and the risks associated with trading in the penny stock market.
In addition, broker-dealers must disclose commissions payable to both the broker-dealer and the registered representative and
current quotations for the securities they offer. The additional burdens imposed upon broker- dealers by such requirements may
discourage broker-dealers from effecting transactions in our securities, which could severely limit the market price and liquidity
of our securities. Broker-dealers who sell penny stocks to certain types of investors are required to comply with the Commission&rsquo;s
regulations concerning the transfer of penny stocks. These regulations require broker- dealers to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Make a suitability determination prior
    to selling a penny stock to the purchaser;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Receive the purchaser&rsquo;s written
    consent to the transaction; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Provide certain written disclosures
    to the purchaser.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These requirements may restrict the ability
of broker-dealers to sell our common stock and may affect your ability to resell our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information included or incorporated by
reference in this prospectus may contain forward-looking statements.&nbsp; This information may involve known and unknown risks,
uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from
the future results, performance or achievements expressed or implied by any forward-looking statements.&nbsp; Forward-looking
statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by
use of the words &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;intend&rdquo; or &ldquo;project&rdquo; or the negative of these words or other variations on these
words or comparable terminology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains forward-looking
statements, including statements regarding, among other things, (a) our projected sales and profitability, (b) our technology,
(c) our manufacturing, (d) the regulation to which we are subject, (e) anticipated trends in our industry and (f) our needs for
working capital. These statements may be found under &ldquo;Management&rsquo;s Discussion and Analysis or Plan of Operations&rdquo;
and &ldquo;Business,&rdquo; as well as in this prospectus generally.&nbsp; Actual events or results may differ materially from
those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks outlined
under &ldquo;Risk Factors&rdquo; and matters described in this prospectus generally.&nbsp; In light of these risks and uncertainties,
there can be no assurance that the forward-looking statements contained in this prospectus will in fact occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise required by applicable
laws, we undertake no obligation to publicly update or revise any forward-looking statements or the risk factors described in
the prospectus, whether as a result of new information, future events, changed circumstances or any other reason after the date
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders are selling shares
of common stock covered by this prospectus for their own account. We will not receive any portion of the proceeds from the sale
or other disposition of the shares of common stock covered hereby, or interests therein, by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to bear the expenses of
the registration of the shares. We anticipate that these expenses will be approximately $80,000.&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our common stock are entitled
to receive dividends when, as and if declared by the board of directors out of funds legally available therefore. To date, we
have not declared nor paid any cash dividends. The board of directors does not intend to declare any dividends in the foreseeable
future, but instead intends to retain all earnings, if any, for use in our business operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DETERMINATION OF OFFERING PRICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No market currently exists for our common
stock. Therefore, the offering price of $0.008 was based on the offering price of shares sold pursuant to our Regulation S issuance
completed in July 2012 in which we issued a total of 12,500,000 shares of our common stock to 26 shareholders at a price per share
of $0,008 for an aggregate offering price of $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The common stock to be sold by the selling
stockholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing
shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PENNY STOCK CONSIDERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broker-dealer practices in connection
with transactions in &ldquo;penny stocks&rdquo; are regulated by certain penny stock rules adopted by the U.S. Securities and
Exchange Commission. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered
on certain national securities exchanges or quoted on the NASDAQ system). Penny stock rules require a broker-dealer, prior to
a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides
information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with
current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction,
and monthly account statements showing the market value of each penny stock held in the customer&rsquo;s account. The broker-dealer
must also make a special written determination that the penny stock is a suitable investment for the purchaser and receive the
purchaser&rsquo;s written agreement to the transaction. These requirements may have the effect of reducing the level of trading
activity, if any, in the secondary market for a security that becomes subject to the penny stock rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MARKET FOR OUR COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Public Market for Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is presently no public market for
our common stock. We anticipate applying for trading of our common stock on the Over the Counter Bulletin Board upon the effectiveness
of the registration statement of which this prospectus forms a part. However, we can provide no assurance that our shares will
be traded on the OTCBB or, if traded, that a public market will materialize.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Holders of Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this registration statement,
we had 26 registered shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not granted registration rights
to the selling stockholders or to any other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND RESULTS OF OPERATIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>You should read the following discussion
of our financial condition and results of operations together with the audited financial statements and the notes to the audited
financial statements included in the registration statement on Form S-1. This discussion contains forward-looking statements that
reflect our plans, estimates and beliefs. Our actual results may differ materially from those anticipated in these forward-looking
statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were incorporated in the State of Delaware
on April 12, 2012. Through our subsidiary we are engaged in selling enzymes products to public consumers across Taiwan, and we
intend to expand business operations by distributing and exporting our enzymes products to Hong Kong, mainland China, Singapore
and Malaysia in 2013. Our goal is to distribute and market our enzymes products to high-end consumers by exploring a variety of
marketing channels, including, without limitation, telephone sales, sales on TV shopping channels, as well as selling in special
counters located in big shopping malls and self-operated stores. Our goal is to establish an international brand on enzymes products
with high quality and name recognition. With our competitive strengths discussed below, we expect to become a major player in
dietary supplements industry and grow into an internationally recognized brand on enzymes products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have a limited line of enzymes
products, consisting of five-phases enzymes products. We&rsquo;ve been marketing the five enzymes products in one package to our
customers, as we have deliberately designed the formula for each of them to contain ingredients, especially certain Chinese traditional
medicine, allegedly with corresponding nutritional effect on each of five key organs of human bodies, namely, heart, liver, stomach,
lung and kidney. Each of the above-mentioned enzymes products, other than the water enzymes product, requires over 60 different
ingredients, which is substantially more than those in similar enzymes products distributed in Taiwan. Furthermore, we specifically
instructed our manufacturer to apply a six-stage fermentation manufacturing process on all of our enzymes products. Though the
production cycle for our enzymes products usually take approximately fourteen months, almost twice the time period for similar
enzymes products manufactured with one-stage traditional method in Taiwan, it creates the unique feature as well as superior quality
in certain key parameters of our enzymes products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enzymes products fall into the dietary
supplements category and are solely for human consumption. To ensure the safety of our enzymes products, we have selected Bioenergy
Biotechnology Corp., one of the well-established Taiwanese companies specializing on enzymes production and with both International
Organization for Standardization (ISO) 9001: 2008 and Hazard Analysis Critical Control Point (HACCP) certifications, to be our
manufacturer. In addition, substantially all of raw material ingredients for our enzymes products are from local plantations in
Taiwan, where the climate, soil and environment are most suitable for the growing of such ingredients. Furthermore, to effectively
monitor quality of our enzymes products, we have voluntarily submitted sampled products in each manufacturing batch to well-recognized
inspection agencies, such as SGS, on a regular basis and implemented our Dr. Chip Biotech Examination, where micro-chip will be
pre-installed into to sampled products for later inspection, to ensure that there&rsquo;s no dead bacteria generated during the
manufacturing process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Going Concern</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements included elsewhere in
this Form S-1 have been prepared in conformity with accounting principles generally accepted in the United States of America,
which contemplate continuation as a going concern. We have an accumulated deficit of $29,391, as of December 31, 2012 and have
used cash in operations of $84,992 from our inception to December 31, 2012. These conditions raise substantial doubt as to our
ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty. The consolidated financial statements do not include any adjustments relating to the recoverability
and classification of recorded asset amounts, or amounts and classification of liabilities that might be necessary should we be
unable to continue as a going concern. We are planning to open a retail location in a shopping mall in the coming months to create
brand image and brand awareness and are currently negotiating an agency agreement with an insurance company in Taiwan. Major shareholders
will continue to fund the Company until it is able to sustain positive cash flows from operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From our inception (April 12, 2012) to December 31, 2012, we
had revenue and cost of revenue of $21,502 and $8,933, respectively. Our gross margin was $12,569 or 58.5% of revenue. We also
incurred selling expenses and general and administrative expenses of $5,153 and $36,883, respectively. Our net loss from our inception
(April 12, 2012) to December 31, 2012 was $29,391. As we have only commenced operation since April 2012, we anticipate that our
revenues will increase significantly in 2013 as compared to 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 16, 2012, we raised $100,000 from the sale of 12,500,000
shares of our common stock that was been used to fund our operations. As of December 31, 2012, we had cash on hand of $16,302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We used $84,992 of cash in our operations which was principally
related to our net loss and the build-up of inventory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we are just commencing our operations,
we plan to fund our operations from loans from our major shareholders and we plan to raise equity capital by offering shares of
our common stock to investors. Over the next 12 months, we plan on opening three self-operated stores. One planned location is
located in Jet&rsquo;s Burg Mall Tianmoo Taipei.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated budget of our operation
expenses over the next twelve months is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 87%; text-align: left">Salaries and benefits</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,360,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Mgt overhead</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">168,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">General overhead</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">230,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,888,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe we will be able to raise the
necessary capital to carry out our business plan, but there is no guarantee that we will be able to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial statements and related public
financial information are based on the application of accounting principles generally accepted in the United States (&quot;US
GAAP&quot;). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles
that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental
information contained in our external disclosures including information regarding contingencies, risk and financial condition.
We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied.
We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances.
Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant
estimates made during the preparation of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the following is among the
most critical accounting policies that impact our consolidated financial statements. We suggest that our significant accounting
policies, as described in our financial statements in the Summary of Significant Accounting Policies, be read in conjunction with
this Management's Discussion and Analysis of Financial Condition and Results of Operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Foreign Currency Translation </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounts of the Taiwanese subsidiary are maintained in
the Taiwan Dollar (&ldquo;Taiwan $&rdquo;) and the accounts of the U.S. parent company are maintained in the United States Dollar
(&ldquo;USD&rdquo;). The accounts of the Taiwanese subsidiary are translated into USD in accordance with ASC Topic 830 &ldquo;Foreign
Currency Matters,&rdquo; with the Taiwan $ as the functional currency for the Taiwanese subsidiary. <FONT STYLE="color: black">According
to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders&rsquo; equity
is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the
period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220,
&ldquo;Comprehensive Income.&rdquo; Gains and losses resulting from the translations of foreign currency transactions and balances
are reflected in the statement of operations. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenue Recognition </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our revenue recognition policies comply with SEC Staff Accounting
Bulletin 104 (codified in FASB ASC Topic 605). Sales revenue is recognized at the date of shipment to customers when a formal
arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of ours exists
and collectability is reasonably assured. We provide sales incentive such as buy a dozen and get one free. We recognize the cost
of the free product at the time of sale. We do not provide unconditional return or any other sales incentives. Payments received
before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sales represent the invoiced value of products, net of value-added
tax (&ldquo;VAT&rdquo;). All of our products sold in Taiwan are subject to a value-added tax of 5% of the gross sales price. This
VAT may be offset by VAT paid by us on raw materials and other materials included in the cost of producing the finished product.
We record VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the
payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as we act as an agent for the
government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes
in accordance with ASC Topic 740, &ldquo;Income Taxes.&rdquo; ASC 740 requires a company to use the asset and liability method
of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred
tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported
amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion
of management, it is more likely than not that some portion, or all of, the deferred tax assets will&nbsp;not be realized. Deferred
tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized
as a benefit only if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50%
likely of being realized on examination. For tax positions not meeting the &ldquo;more likely than not&rdquo; test, no tax benefit
is recorded. The adoption had no effect on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2011, the FASB issued ASU&nbsp;2011-04
to provide a consistent definition of FV and ensure the FV measurement and disclosure requirements are similar between US GAAP
and IFRS. ASU 2011-04 changes certain FV measurement principles and enhances the disclosure requirements particularly for Level
3 FV measurements. &nbsp;This guidance was effective on January 1, 2012.&nbsp; The adoption of ASU 2011-04 did not have a significant
impact on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2011, the FASB issued ASU 2011-05,
<I>Presentation of Comprehensive Income</I>. ASU 2011-05 revises the manner in which entities present comprehensive income in
their financial statements. The new guidance removes the presentation options in Accounting Standards Codification (ASC) 220,
<I>Comprehensive Income</I>, and requires entities to report components of comprehensive income in either (1)&nbsp;a continuous
statement of comprehensive income or (2)&nbsp;two separate but consecutive statements. The new guidance does not change the items
that must be reported in other comprehensive income. In December 2011, the FASB issued ASU&nbsp;2011-12 which defers the requirement
in ASU&nbsp;2011-05 that companies present reclassification adjustments for each component of accumulated other comprehensive
income in both net income and other comprehensive income on the face of the financial statements. ASU&nbsp;2011-05 is effective
for fiscal years and interim reporting periods within those years beginning after December&nbsp;15, 2011, with early adoption
permitted. The adoption of ASU&nbsp;2011-05, as amended by ASU&nbsp;2011-12, did not have a significant impact on our consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2011, the FASB issued ASU&nbsp;2011-08
which provides an entity the option to first assess qualitative factors to determine whether it is necessary to perform the two-step
test for goodwill impairment.&nbsp;&nbsp;If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not
the FV of a reporting unit is less than its carrying amount, the quantitative impairment test is required.&nbsp;&nbsp;Otherwise,
no further testing is required. The revised standard is effective&nbsp;for the Company for its annual and interim goodwill impairment
tests performed for fiscal years beginning after December 15, 2011.&nbsp;&nbsp;The adoption of ASU 2011-08 did not significantly
impact our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2012, the FASB issued ASU 2012-02,
Intangibles-Goodwill and Other (Topic 350) - Testing Indefinite-Lived Intangible Assets for Impairment.&nbsp; The ASU provides
entities with an option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely
than not the indefinite-lived intangible asset is impaired.&nbsp; If an entity concludes it is more than 50% likely that an indefinite-lived
intangible asset is not impaired, no further analysis is required.&nbsp; However, if an entity concludes otherwise, it would be
required to determine the FV of the indefinite-lived intangible asset to measure the amount of impairment, if any, as currently
required under US GAAP. The ASU is effective for annual and interim impairment tests performed for fiscal years beginning after
September 15, 2012.&nbsp; Early adoption is permitted.<FONT STYLE="color: black"> The adoption of this pronouncement will not
have a material impact on our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a development stage company focusing
on the sales and distribution of enzymes products manufactured in Taiwan to public consumers across Taiwan, and we intend to commence
business operations by distributing and exporting our enzymes products to Hong Kong, mainland China, Singapore and Malaysia in
2013. Our primary current sales channel is through telephone selling and we intend to utilize a combination of various marketing
channels, including, without limitation, telephone sales, self-operated retail stores in and out of Taiwan, special counters located
in big shopping malls, third-party sales agents, e-commerce, sales on TV shopping channels and corporate strategic partnerships
and alliances. Our goal is to establish an international brand on enzymes products with high quality and name recognition. With
our competitive strengths discussed below, we expect to become a major player in dietary supplements industry and grow into an
internationally recognized brand on enzymes products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have a limited line of enzymes
products, consisting of five-phases enzymes products. We&rsquo;ve been marketing the five enzymes products in one package to our
customers, as we have deliberately designed the formula for each of them to contain ingredients, especially certain Chinese traditional
medicine, allegedly with corresponding nutritional effect on each of five key organs of human bodies, namely, heart, liver, stomach,
lung and kidney. Each of the above-mentioned enzymes products, other than the water enzymes product, requires over 60 different
ingredients, which is substantially more than those in similar enzymes products distributed in Taiwan. Furthermore, we specifically
instructed our manufacturer to apply a six-stage fermentation manufacturing process on all of our enzymes products. Though the
production cycle for our enzymes products usually take approximately fourteen months, almost twice the time period for similar
enzymes products manufactured with one-stage traditional method in Taiwan, it creates the unique feature as well as superior quality
in certain key parameters of our enzymes products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enzymes products fall into the dietary
supplements category and are solely for human consumption. To ensure the safety of our enzymes products, we have selected Bioenergy
Biotechnology Corp., one of the well-established Taiwanese companies specializing on enzymes production and with both International
Organization for Standardization (ISO) 9001: 2008 and Hazard Analysis Critical Control Point (HACCP) certifications, to be our
manufacturer. In addition, substantially all of raw material ingredients for our enzymes products are from local plantations in
Taiwan, where the climate, soil and environment are most suitable for the growing of such ingredients. Furthermore, to effectively
monitor quality of our enzymes products, we have voluntarily submitted sampled products in each manufacturing batch to well-recognized
inspection agencies, such as SGS, on a regular basis and implemented our Dr. Chip Biotech Examination, where micro-chip will be
pre-installed into to sampled products for later inspection, to ensure that there&rsquo;s no dead bacteria generated during the
manufacturing process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the innovation and timely
introduction of new products is essential to catch the constantly changing consumption trend of our existing or potential customers.
As we are still at our early start-up stage, we do not have any information system or team for that matter now. We have maintained
close connections with National Pingtung University of Science and Technology (&ldquo;NPUST&rdquo;), a well-recognized university
in Taiwan,&nbsp;since our incorporation. In fact, we&nbsp;are currently cooperating with&nbsp;NPUST on a joint program focusing
on improving enterprise management and brand development of Yambear. Pursuant to this program, NPUST will commit its experienced
academic team to assist us with respect to the enterprise management and brand establishment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have established our business operation
within the Pingtung Agricultural Biotechnology Park, one and only bio-tech park established in Taiwan focusing on bio-tech agricultural
products, which is also located within the affinity of NPUST. We are currently cooperating with NPUST on a joint program focusing
on improving enterprise management and brand development, which, once approved by Department of Education of Taiwan, will be available
for government subsidies. Pursuant to this program, NPUST will commit its experienced academic team to assist us with respect
to the enterprise management and brand establishment. On November 1, 2012, we rented our current office and intend to use it as
our research and development center (&ldquo;R&amp;D Center&rdquo;) for our pipeline products in the future. From time to time,
we will recruit professional bio-tech personnel to work full time in our R&amp;D Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that our commitment to products
quality and investment in products research and development, combined with our multiple marketing channels, will enable us to
provide our customers with a unique shopping experience that will be distinct from our competitors and give us competitive advantage
to gradually grow into a well-recognized business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We&rsquo;ve generated revenues in the
amount of $21,502 for the period from inception (April 12, 2012) to December 31, 2012. We are not making any profit so far.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless context indicates otherwise, reference
to the &ldquo;Company&rdquo; throughout this prospectus refers to Yambear and Yambear Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a holding company with no business
other than holding equity interest of our operating subsidiary in Taiwan, Yambear Taiwan, we rely principally on dividends to
be paid by Yambear Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Company Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yambear was incorporated on April 12,
2012 under the laws of the state of Delaware by Hsin-Lung Lin, a Taiwanese citizen. Our executive office is located at 3F., No.
10, Yuanxi 2<SUP>nd</SUP>. Rd., Pingtung Agricultural Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of
China. Our telephone number is +00886 08 7621913.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
wholly owned subsidiary, Yambear Bio-technology Co., Ltd. (</FONT>&#30058;&#34223;&#29066;&#29983;&#25216;&#20107;&#19994;&#26377;&#38480;&#20844;&#21496;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
(&ldquo;Yambear Taiwan&rdquo;) was founded on August 17, 2012 in Taiwan, the Republic of China. The registered capital of Yambear
Taiwan, in the amount of $96,386 (NT$2.8 million) has been fully contributed and we expect to invest another $592,083(NT$17.2
million) in the coming years. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2012, Yambear issued 12,500,000
shares of common stock, $0.0001 par value per share, to several non U.S. persons for their investment of $100,000 in cash in the
Company, among which, $93,560 has been contributed into Yambear Taiwan on July 19, 2012, the operating company in Taiwan, as registered
capital. The issuance was made pursuant to an exemption from registration contained in Regulation S under the Securities Act of
1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following flow chart illustrates our
Company&rsquo;s organizational structure:<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="tpg25.jpg" ALT="Z:\TQData\VINEYARD\Live Jobs\2013\02 Feb\13 Feb\Shift I\v334937 - S-1 - YAMBEAR BIO-TECH, INC\Draft\03-Production"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Industry and Market Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Enzymes products business is a rising
industry in Taiwan. According to the Strategies and Plans of Agricultural Bio-technology Industry published by Taiwan Institute
of Economic Research on December 31, 2005, the value for imported enzymes products (including industrial and dietary use) reached
$22,719,449 (NT$660 million) for the year 2005 and the domestic production value is $8,605,852 (NT$250 million). In 2002, the
value of global enzymes production (including dietary and feeding use) reached $1.176 billion.. According to the Global Markets
for Enzymes in Industrial Applications published by BCC Research on April 24, 2012, the market size for the global enzymes industry
is $3.9 billion in 2011. It is expected that the whole market size for global enzymes industry will increase to $6.1 billion by
the year of 2016. With ever-increasing pressures in modern life and people&rsquo;s growing awareness and pursuit to healthy life,
we anticipate that enzymes business will continue to prosper in a foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The enzymes business in Taiwan is subject
to fierce competition, especially for new players. The market share is largely dominated by two well-established companies and
many smaller companies competing for the remaining share. We expect competition to persist and intensify. We believe that our
commitment to products quality and investment in products research and development, combined with our multiple marketing channels,
will enable us to provide our customers with a unique shopping experience that will be distinct from our competitors and give
us competitive advantage to gradually capturing our market share in the future. Based on our understanding of the enzymes products
market, we expect several key demographic and lifestyle trends to drive the continued growth of enzymes industry. These trends
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Increasing awareness of enzymes products
benefits.&nbsp;</I>&nbsp;&nbsp;&nbsp;We believe that awareness of dietary supplement benefits, including those of enzymes products,
will continue rising as more and more people nowadays are paying more attention to the health and quality of life. Taiwan is relatively
small market with only over 23 million population, yet it has already attracted well-established companies as well as multiple
new entrants providing various enzymes products to the local market. Enzymes industry in Taiwan is still at its developing stage.
We believe as the local customers become more and more familiar to and knowledgeable about the enzymes products, they are likely
to appreciate more and more of enzymes products with high quality. We have also noticed that the historical trend in Taiwan of
enzymes products seems to repeat itself in mainland China and other potential markets with substantial higher potentials for dietary
supplements. We expect our competitive strength to distinguish our enzymes products and increase our market share in Taiwan as
well as those emerging markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Increasing appeal of enzymes products
across younger population</I>.&nbsp;&nbsp;&nbsp;&nbsp;Currently we are targeting middle class individuals and family members within
the range of 35 - 50 years age. With the development of modern society and ever-increasing awareness and pursuit to healthier
lifestyle, we anticipate that more and more younger populations will start purchasing enzymes products, expanding the foundation
of our customer base for the future. In addition, we have also noticed that younger customers are more likely to continuously
purchase enzymes products once they like it, and generally have higher levels of disposable income to pursue healthier lifestyles.
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competitive Strengths </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that we are well-positioned
to capitalize on the favorable enzymes industry trends as a result of the following competitive strengths:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Unique product offerings. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current enzymes products line only
consists of five-phases enzymes products. The formulas of these five basic products have been the achievements of joint efforts
of our staffs teamed up with certain specialists, who have dedicated most of their leisure time to research. In addition to the
basic ingredients for enzymes products, we have added certain Chinese traditional medicine, allegedly with corresponding nutritional
effect on each of five key organs of human bodies, namely, heart, liver, stomach, lung and kidney, to each of our five enzymes
products. Therefore, each of the above-mentioned enzymes products, other than the water enzymes product, requires over 60 different
ingredients, which is substantially more than those in similar enzymes products distributed in Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To ensure the high quality of our enzymes
products, we have selected a local enzymes manufacturer Bioenergy, one of the well-established Taiwanese companies specializing
on enzymes production and with both International Organization for Standardization (ISO) 9001: 2008 and Hazard Analysis Critical
Control Point (HACCP) certifications, to be the manufacturer of our enzymes products. Substantially all of raw material ingredients
used for our enzymes products are from local plantations in Taiwan, where the climate, soil and environment are most suitable
for the growing of such ingredients. Furthermore, to effectively monitor quality of our enzymes products, we have voluntarily
submitted sampled products in each manufacturing batch to well-recognized inspection agencies, such as SGS, on a regular basis
and implemented our Dr. Chip Biotech Examination, where micro-chip will be pre-installed into to sampled products for later inspection,
to ensure that there&rsquo;s no dead bacteria generated during the manufacturing process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, we specifically instructed
our manufacturer Bioenergy to apply a six-stage fermentation manufacturing process and the smashed raw materials for all of our
enzymes products. Though the production cycle for our enzymes products usually take two years, almost twice the time period for
similar enzymes products in Taiwan, it creates the unique feature as well as superior quality in certain key parameters of our
enzymes products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Product innovation is critical to our
growth, brand image superiority and competitive advantage. We have rented our current office and intend to use it as our research
and development center (&ldquo;R&amp;D Center&rdquo;) for our pipeline products in the future. After our R&amp;D Center is fully
established, our research and development team will focus on the development and formulation of proprietary supplements of high
growth categories. We will seek to maintain the pace of Yambear's proprietary products innovation to get ahead of our competitors
and attract consumers with our newly-introduced products from time to time. Our in-house research and development team, once recruited,
will be able to commit all of their time and energy on products development, so as to enable us to quickly take a concept for
a new product from the idea stage, to product development, testing and trials, and ultimately to the shelf to be sold to our customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the new products development, we will
make a quarterly review of our product line and get feedback from our customers. Based on such data and statistics, we shall determine
whether one or more new products are needed. Once we determine that new products are needed, our research and development team
will start their research work and develop new products to adapt to the changing requirement in the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Multiple marketing channels</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our multi-channel approach is unlike many
other competitors as we expect to derive revenues across a combination of distribution channels in multiple geographies, including
retail sales from self-operated retail stores, retail sales in big shopping centers, retail sales from yambear.com, sales on TV
shopping channels and revenue from third-party sales agents in different countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our diverse sources of revenue will help
provide stability to our earnings and provide management numerous avenues through which they can pursue growth opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently approaching certain candidates
who are specialized in sales and marketing, some of whom has more than thirty years experience in sales and marketing. Once these
people are formally recruited, we are going to have systematic training over our sales associates. We are aiming to have our sales
associates well-trained and capable of offering educated service and trusted advice to our customers. We will invest considerable
capital and human resources in providing comprehensive associate training. We expect that our expansive retail network, differentiated
products offering and quality customer service shall result in a unique shopping experience.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a development stage company. We
expect that with our commitment to products quality and investment in products research and development, combined with our multiple
marketing channels, Yambear will gradually grow into a well known brand in enzymes products industry and provide more and more
healthy, high quality, unique enzymes products to our customers in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Growth Strategy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to execute several strategies
in the future to promote growth in revenue and operating income, and capture market share, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to take a series of activities
to stimulate the increase of our revenue and the growth of our business. These activities include the following aspects:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Building up our research and development
team and expand our line of products.</I> We currently do not have any full-time research and development team, but we&rsquo;ve
managed to cooperate with certain specialists, through their leisure time, to jointly develop our products. We intend to recruit
these specialists along with the growth of our Company, subsequent to which, they will be able to commit all of their time and
energy on products development, so as to enable us to quickly take a concept for a new product from the idea stage, to product
development, testing and trials, and ultimately to the shelf to be sold to our customers. Our present offering of enzymes products
are fairly limited, and the nature of dietary supplements industry require the capability of the players to timely respond to
constant change of trend of customers and continuously offer a variety of products to attract all types of consumer groups. On
November 1, 2012, we leased approximately 572 square meters office space in Pingtung Agriculture Biotechnology Park, which is
within the affinity of NPUST. We are in the process of decorating this office into a research and development center, where we
will deploy our full-time research and development team to conduct experiments and develop our new products. Research and development
will always be an significant part of our business strategy in the long run.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exploring multiple marketing channels
and expanding our sales and distribution network</I>. We intend to distribute and market our enzymes products to high-end consumers
by exploring a variety of marketing channels, including, without limitation, telephone sales, TV sales, as well as selling in
special counters located in big shopping malls and our self-operated stores. We expect to open a self-operated store in Taiwan
in 2013. We will recruit personnel specialized in sales and marketing and deploy them in key positions to lead our multiple marketing
channels.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Initiating promotional activities and
brand establishing</I>. Our promotion and brand establishing will primarily consist of the following parts: (i) we will enhance
the promotional functions of our official website and Yambear&rsquo;s facebook interface; (ii) we will explore a series of direct
promotional activities, such as free electronic mails, direct staff promotion, on-site store promotion, etc., (iii) we will invest
in advertisement through both traditional print media and Internet media; (iv) we will introduce special promotional sales events
on Chinese traditional holidays, such as the Dragon Boat Festival, the Mid-Autumn Festival and the Spring Festival; and (v) we
will apply for trademarks in the foreign markets where we will sell our enzymes products, to strengthen our brand recognition
and management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the above-mentioned internal
growth plan, we are also considering to set up strategic cooperation relationships in foreign markets, in particular, mainland
China, Hong Kong, Singapore and Malaysia. The strategic cooperation could be in the manner of sales agent on provincial or district
level, joint ventures, or other forms of alliance. After our business is materialized in such foreign markets, we will also consider
setting up branches or subsidiaries there.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>New product lines</I>. We currently
have four new enzymes products in the testing stage, namely, (i) slimming enzymes product, designed for the consumers desiring
to lose weight; (ii) nerves-soothing enzymes product, designed for the consumers under high pressures and seeking tranquilization
effect; (iii) special enzymes product for the senior (stomach improvement effect), designed for the aged consumers with stomach
issues; and (iv) special enzymes product for the senior (joint improvement effect), designed for aged consumers with arthralgia
issues, all anticipated to be launched in the first quarter of 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the four new enzymes products
mentioned above, we are researching and developing another new enzymes product, enzymes facial mask, which is designed for high-end
female consumers in Taiwan. We believe that these high-end female consumers prefer a more healthy and effective way to pursue
beauty. We are also planning to expand our business in SPA industry under the same conception of facilitating female consumers
a more healthy and effective way to pursue beauty. In addition, we are exploring the possibility of an unique product, enzymes
coffee, all of these products are expected to be launched in first quarter of 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Sales Channel </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2012, we entered into a
cooperation agreement with Fitness &amp; Beauty Corporation Limited (the &ldquo;Fitness&rdquo;), pursuant to which the Fitness
will be the exclusive distributor of Yambear products in China (including Hong Kong and Macau) through the following distribution
channels: (i) fitness clubs, (ii) facial and body SPA chain stores, and (ii) tea chain stores. Pursuant to such cooperation agreement,
the Fitness shall purchase a minimum of 5000 bottles of our five-phases enzymes products annually. The term of the cooperation
is two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the cooperation agreement mentioned
above and the sales by hotlines, we have not started other sales channels so far.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Website</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently our Yambear Taiwan&rsquo;s website
yambear.com only has the functions of presenting our enzymes products, brief introduction to Yambear Taiwan and contact information.
Our customers may place purchase orders through our selling hotlines specified on our website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Manufacturing, Distribution Network
and Marketing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our strategy is to focus on research and
development, distribution network and brand establishment, while outsourcing the whole manufacturing process to third party manufacturers.
To ensure the quality of our enzymes products, we are quite selective and strict when it comes to the engagement of our outsourced
manufacturers. As of December 31, 2012, we have outsourced the manufacturing of all of our enzymes products to Bioenergy Biotechnology
Corp., one of the well-established Taiwanese companies specializing on enzymes production and with both International Organization
for Standardization (ISO) 9001: 2008 and Hazard Analysis Critical Control Point (HACCP) certifications, To the knowledge of our
management team, there are several enzymes products manufactures in Taiwan competent for our manufacturing needs. In case there
is any a change or termination of the cooperation with our current manufacturer, we believe it is not difficult to find a replacement.
We have not yet devoted substantial resources in building up our distribution network and we intend to do so along with the development
and expansion of our business. Please refer to Our Growth Strategy section for details of our future sales and marketing strategies.
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Customers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are targeting middle class individuals
and their family members in the range of 35 - 50 years age to be our priority clients. All of our revenues are generated from
the sale of our enzymes products and we expect the continuous growth in this regard. However, we are also expecting an expansion
of our customer base. As discussed in details in Industry and Market Overview, we are hoping that younger population will grow
into another pillar for our customer base.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Manufacturing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of our enzymes products are being
manufactured by a Taiwan local company, Bioenergy Biotechnology Corp. (&ldquo;Bioenergy&rdquo;) pursuant to the orders we place
to them. Bienergy is one of the biggest enzymes products manufacturers in Taiwan and we&rsquo;ve started our cooperation with
Bioenergy since our incorporation. Other than producing our enzymes products, Bioenergy also produces and sells enzymes products
of their own. Due to the different products positioning, our management team does not view the enzymes products of Bioenergy as
competitive to our own enzymes products. We&rsquo;ve entered into confidential agreement with Bioenergy to prevent them from disclosing
our formula to the public or any third party or exploit it for its self-benefit. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Competition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The enzymes business in Taiwan is highly
fragmented by some major enzymes companies, among which two enzymes companies, Yamato Enzyme Co., Ltd. and Biozyme Biotechnology
Corp., have captured a dominating share of the market, while the other smaller enzymes companies competing for the remaining share.
Given the fact that we are a development stage company, our primary competitors are Sunmei Co. Ltd. (McHall&rsquo;s) Hsuan Yong
Biotechnology Co., Ltd. and One Power Biotechnology Co., Ltd. Competition in this market revolves around price, quality and reputation.
If we could properly execute our growth strategy and maintain our competitive strength, we believe that we could expand our market
share and gradually grow into a well-recognized brand name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Insurance</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have purchased a product liability
insurance with a coverage of $688,468 (NT$20 million) from MSIG Mingtai Insurance Co., Ltd., a member of MS &amp; AD Insurance
Group. The insurance policy is for a one-year term commencing from September 20, 2012 till September 20, 2013. We have also purchased
social insurance for all of our employees pursuant to the mandatory requirement of Taiwan laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Products and Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have a limited line of enzymes
products, consisting of five-phases enzymes products. We&rsquo;ve been marketing the five enzymes products in one package to our
customers, as we have deliberately designed the formula for each of them to contain ingredients, especially certain Chinese traditional
medicine, allegedly with corresponding nutritional effect on each of five key organs of human bodies, namely, heart, liver, stomach,
lung and kidney. Each of the above-mentioned enzymes products, other than the water enzymes product, requires over 60 different
ingredients, which is substantially more than those in similar enzymes products distributed in Taiwan. Furthermore, we specifically
instructed our manufacturer to apply a six-stage fermentation manufacturing process on all of our enzymes products. Though the
production cycle for our enzymes products usually take approximately fourteen months, almost twice the time period for similar
enzymes products manufactured with one-stage traditional method in Taiwan, it creates the unique feature as well as superior quality
in certain key parameters of our enzymes products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One of the unique features of our enzymes
products is that we have combined Chinese traditional medicine concept &ldquo;Five Fundamental Elements&rdquo;, namely, gold,
wood, water, fire and earth, with our enzymes products. The Five Fundamental Elements concept is a well-known concept in Chinese
culture, where it believes that each element represents and corresponds to a key organ in our bodies. Therefore, in addition to
the basic ingredients used for enzymes products, we also added certain Chinese herbs with special effect on improvement and reconciliation
of function for the corresponded organs. The formula for each of our enzymes products is the result of extensive research and
experiments conducted by our staffs teamed up with certain specialists. Details of our five enzymes products are illustrated as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>YAMIGO Five-phases Enzymes &ndash;
Metal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify"><IMG SRC="tpg30.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">We do not manufacture
the above enzyme product.&nbsp; It is specifically formulated for our distribution.&nbsp; It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.&nbsp; The brand name &ldquo;YAMIGO Five-phases
- Metal&rdquo; belongs to us, and the trademark applications for &ldquo;YAMIGO&rdquo; has been filed in Taiwan and Mainland China.&nbsp;
We currently market this product as one of the Five-phases series package, but we also sell this product alone. We have earned
revenues of $2,304.06 (NT$66,933) from the sale of it during the </FONT>period from inception (April 12, 2012) to <FONT STYLE="color: black">December
31, 2012. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds to one of the five key
organs of human bodies. This enzyme product contains over 60 different ingredients, which is substantially more than those in
similar enzyme products distributed in Taiwan. Other than the enzymes fluids extracted from fruit and vegetables, such as yam,
sweet potato, pumpkin, eggplant, black bean, we have deliberately designed the formula for this product to contain certain Chinese
traditional herbs, such as wolfberry, chuan qiong, poria, licorice, angelia, atracylodes, tangerine, which, according to the Chinese
traditional medicine theory, are allegedly with corresponding nutritional effect on improvement of lung functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>YAMIGO Five-phases Enzymes &ndash;
Wood</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify"><IMG SRC="tpg31.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">We do not manufacture
the above enzyme product.&nbsp; It is specifically formulated for our distribution.&nbsp; It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.&nbsp; The brand name &ldquo;YAMIGO Five-phases
&ndash; Wood&rdquo; belongs to us, and the trademark applications for &ldquo;YAMIGO&rdquo; has been filed in Taiwan and Mainland
China.&nbsp; We currently market this product as one of the Five-phases series package, but we also sell this product alone. We
have earned revenues of $6,619.83 (NT$192,306) from the sale of it during the </FONT>period from inception (April 12, 2012) to
<FONT STYLE="color: black">December 31, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds with one of the five key
organs of human bodies. This enzyme product contains over 60 different ingredients, which is substantially more than those in
similar enzyme products distributed in Taiwan. Other than the enzymes fluids extracted from fruit and vegetables, such as yam,
sweet potato, pumpkin, eggplant, balck bean, lemon, grape, we have deliberately designed the formula for this product to contain
certain Chinese traditional herbs, such as wolfberry, chuan qiong, poria, licorice, angelia, atracylodes, tangerine peel, antrodia
cinnamomea, which, according to the Chinese traditional medicine theory, are allegedly with corresponding nutritional effect on
improvement of liver functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>YAMIGO Five-phases Enzymes &ndash;
Water</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify"><B><IMG SRC="tpg32.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">We do not manufacture
the above enzyme product.&nbsp; It is specifically formulated for our distribution.&nbsp; It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.&nbsp; The brand name &ldquo;YAMIGO Five-phases
- Water&rdquo; belongs to us, and the trademark applications for &ldquo;YAMIGO&rdquo; has been filed in Taiwan and Mainland China.&nbsp;
We currently market this product as one of the Five-phases series package, but we also sell this product alone. We have earned
revenues of $4,128.85 (NT$119,943</FONT>) <FONT STYLE="color: black">from the sale of it during the </FONT>period from inception
(April 12, 2012) to <FONT STYLE="color: black">December 31, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds with one of the five key
organs of human bodies. This enzyme product is primarily made of pineapple enzymes fluids, glucosamine and collagen. We have deliberately
designed the formula, according to the Chinese traditional medicine theory, allegedly to have corresponding nutritional effect
on improvement of kidney functions.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>YAMIGO Five-phases Enzymes &ndash;
Fire</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify"><IMG SRC="tpg33.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">We do not manufacture
the above enzyme product.&nbsp; It is specifically formulated for our distribution.&nbsp; It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.&nbsp; The brand name &ldquo;YAMIGO Five-phases
&ndash; Fire&rdquo; belongs to us, and the trademark applications for &ldquo;YAMIGO&rdquo; has been filed in Taiwan and Mainland
China.&nbsp; We currently market this product as one of the Five-phases series package, but we also sell this product alone. We
have earned revenues of $3,195.77 (NT$92,837) from the sale of it during the </FONT>period from inception (April 12, 2012) to
<FONT STYLE="color: black">December 31, 2012. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds with one of the five key
organs of human bodies. This enzyme product contains over 60 different ingredients, which is substantially more than those in
similar enzyme products distributed in Taiwan. Other than the enzymes fluids extracted from fruit and vegetables, such as eggplant,
bitter gourd, melon, pumpkin, spinach, black bean, grapefruit, litchi, we have deliberately designed the formula for this product
to contain certain Chinese traditional herbs, such as rhodiola, jujube fine, black currant extract, glycine ferrous, and plant
collagen, which, according to the Chinese traditional medicine theory, are allegedly with corresponding nutritional effect on
improvement of heart functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>YAMIGO Five-phases Enzymes &ndash;
Earth</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify"><IMG SRC="tpg34.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">We do not manufacture
the above enzyme product.&nbsp; It is specifically formulated for our distribution.&nbsp; It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.&nbsp; The brand name &ldquo;YAMIGO Five-phases
&ndash; Earth&rdquo; belongs to us, and the trademark applications for &ldquo;YAMIGO&rdquo; has been filed in Taiwan and Mainland
China.&nbsp; We currently market this product as one of the Five-phases series package, but we also sell this product alone. We
have earned revenues of $4,300.55 (NT$124,931) from the sale of it during the </FONT>period from inception (April 12, 2012) to
<FONT STYLE="color: black">December 31, 2012. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds with one of the five key
organs of human bodies. This enzyme product contains over 60 different ingredients, which is substantially more than those in
similar enzyme products distributed in Taiwan. Other than the enzymes fluids extracted from fruit and vegetables ingredients,
such as black bean, pumpkin, spinach, cantaloupe, grape, potato, bitter gourd, eggplant, we have deliberately designed the formula
for this product to contain certain Chinese traditional herbs, such as atractylodes, poria, licorice, dandelion, pinellia ternata,
which, according to the Chinese traditional medicine theory, are allegedly with corresponding nutritional effect on improvement
of stomach and stomach functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In summary, our YAMIGO &ndash; Five-phases
enzyme products, namely Metal, Wood, Water, Fire and Earth, are displayed below:</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tpg35.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also have small package of the above
Five-phases enzymes products. The small package is designed for trial purchase. If the customers like our products, we expect
them to purchase big package products which are more cost-effective. The small package of Five-phases enzymes products are displayed
below, with 50 ml for each bottle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tpg35a.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will make a quarterly review of our
product line and get feedback from our customers. Based on such data and statistics, we shall determine whether one or more new
products are needed. Once we determine that new products are needed, our research and development team will start their research
work.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the five basic enzymes products
we are selling, we are also conducting an on-going new products research and development. We currently have four new enzymes products
in the testing stage, namely, (i) slimming enzymes product, designed for the consumers desiring to lose weight; (ii) nerves-soothing
enzymes product, designed for the consumers under high pressures and seeking tranquilization effect; (iii) special enzymes product
for the senior (stomach improvement effect), designed for the aged consumers with stomach issues; and (iv) special enzymes product
for the senior (joint improvement effect), designed for aged consumers with arthralgia issues, all anticipated to be launched
in the first quarter of 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the four new enzymes products
mentioned above, we are researching and developing another new enzymes product, enzymes facial mask, which is designed for high-end
female consumers in Taiwan. We believe that these high-end female consumers prefer a more healthy and effective way to pursue
beauty. We are also planning to expand our business in SPA industry under the same conception of facilitating female consumers
a more healthy and effective way to pursue beauty. In addition, we are exploring the possibility of a unique product, enzymes
coffee, all of these products are expected to be launched in first quarter of 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are providing full time, 24 hours per
day and seven days per week, hotline services. Our hotline receptionists are well trained with a comprehensive knowledge of our
products to address any of the Customers&rsquo; enquiries about our products or take their orders over our hotline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to open special counters in
big shopping malls, serving as both an exhibition center as well as an education center for our products, where customers or potential
customers could have a more intuitive observation on and experience with all of our enzymes products. Meanwhile, our well-trained
staffs in such special counters could introduce our enzymes products to them more effectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently applying for certain
trademarks both in Taiwan and in mainland China. Please refer to the following chart illustrating our trademarks application details:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trademark</FONT></TD>
    <TD STYLE="vertical-align: top; width: 14%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Categories</FONT></TD>
    <TD STYLE="width: 25%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Status</FONT></TD>
    <TD STYLE="vertical-align: top; width: 17%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jurisdiction</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><IMG SRC="tpg36.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Application filed on<BR>
 September 5, 2012</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taiwan</FONT></TD></TR>
<TR>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tpg36a.jpg" ALT=""></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">05</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Application filed on<BR>
 September 5, 2012</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taiwan</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 44%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tpg37.jpg" ALT=""></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; width: 14%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">05</FONT></TD>
    <TD STYLE="width: 25%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Application filed on<BR>
 September
    5, 2012</FONT></TD>
    <TD STYLE="vertical-align: top; width: 17%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taiwan</FONT></TD></TR>
<TR>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="tpg37a.jpg" ALT=""></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">05</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Application filed on<BR>
 September 5, 2012</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taiwan</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trademark</FONT></TD>
    <TD STYLE="vertical-align: top; width: 14%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Categories</FONT></TD>
    <TD STYLE="width: 25%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Status</FONT></TD>
    <TD STYLE="vertical-align: top; width: 17%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Jurisdiction</FONT></TD></TR>
<TR>
    <TD STYLE="text-align: justify"><IMG SRC="tpg36.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Application filed on<BR>
 February 6, 2013</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chian Mainland</FONT></TD></TR>
<TR>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yamigo</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">05</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Application filed on<BR>
February 6, 2013</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chian Mainland</FONT></TD></TR>
<TR>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yambear</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Application filed on<BR>
 February 6, 2013</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chian Mainland</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than the trademark applications
described above, we may also apply trademarks in other jurisdictions where we are going to expand our business.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Taiwan subsidiary, Yambear Taiwan,
owns the domain name yambear.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have patent rights regarding
the formula of our enzymes products since the formula, manufacturing process may not be patentable in the jurisdiction where we
conduct our business. Though some formula and manufacturing process may be patentable, we have determined that our business interests
are better served by trying to protect them as trade secrets or confidential information. We rely heavily on trade secret protection
and confidentiality agreements rather than patent laws to protect our rights in these formulas, manufacturing process, know-how
and data. We have taken a series of measures to keep the confidentiality of our formula, including entering into confidential
agreement with our employees and cooperation partners, segregating of duties among personnel involved in different stages of its
production process. This segregation reduces the risk that a breach of these protections by any single staff member would result
in a leakage of the entire production process of our enzymes products. We also implement other precautions, such as internal document
controls and network assurance procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development Expenditures
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently do not have any full-time
research and development team, but we&rsquo;ve managed to cooperate with certain specialists, through their leisure time, to jointly
develop our products. We intend to recruit these specialists along with the growth of our Company, subsequent to which, they will
be able to commit all of their time and energy on products development, so as to enable us to quickly take a concept for a new
product from the idea stage, to product development, testing and trials, and ultimately to the shelf to be sold to our customers..
On November 1, 2012, we leased approximately 572 square meters office space in Pingtung Agriculture Biotechnology Park, which
is within the affinity of NPUST. We are in the process of decorating this office into a research and development center, where
we will deploy our full-time research and development team to conduct experiments and develop our new products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current practice for research and
development is that we will make a quarterly review of our product line and get feedback from our customers. Based on such data
and statistics, we shall determine whether one or more new products are needed. Once we determine that new products are needed,
our research and development team will start their research work. Usually a new product requires one quarter a two quarters finishing
the research work. We anticipate that the cost is mostly in the range of $5,000 to $10,000 for the research and development of
each new product.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have researched and developed certain
new enzymes products, among which, four are in the testing stage, namely, slimming enzymes product, nerves-soothing enzymes product,
special enzymes product for the senior (stomach improvement effect) and for the senior (joint improvement effect). We have invested
approximately $5,000 for each of the above-mentioned products. Other than the four new enzymes products mentioned above, we are
in the process of researching and developing other new enzymes products, enzymes facial mask and enzymes coffee, on which we have
invested approximately $5,000 and $10,000 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development will always be
a significant part of our business strategy in the long run.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have three employees to whom
we are paying salaries or other compensation, the chief executive officer, the head of human resources and the director of accounting.
Other than these three employees, we have certain part-time employees, who are shareholders of the Company, who do not receive
compensation. Depending on the business needs, we intend to recruit some additional full-time employees in the future.<B> </B>All
of the Company&rsquo;s employees are employed by the Company&rsquo;s subsidiary Yambear Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Option Plan </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2012, <B>w</B>e do
not have any stock option plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Properties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business office is located at 3F.,
No.10, Yuanxi 2nd Rd., Pingtung Agriculture Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of China. Our
telephone number is +00886 08 7621913. We are paying a monthly rent of $1,669 (NT$48,480) for our office. Our offices occupy approximately
572 square meters. The term of the lease is two years, commencing from November 1, 2012 to October 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a development stage company with
very little assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yambear Taiwan is the only wholly owned
subsidiary of Yambear. Other than that, Yambear does not own any subsidiary for the time being. We are considering establishing
branches or subsidiaries in mainland China, Hong Kong, Singapore and Malaysia with the expansion and development of our business
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not currently a party to any legal
proceedings. Our address for service of process in Delaware is Suite 806, 1220 N. Market Street, Wilmington, DE 19801, County
of New Castle.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Regulations of the Enzymes Industry
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Taiwan Regulation on Consumer Protection</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current primary regulation protecting
consumers' rights in Taiwan is Consumer Protection Law, latest amended on February 5, 2005 (the &quot;CP Law&quot;), with a view
to better regulate the conduct of business operators and enforce consumer protection. The Industry Competent Authority at various
levels of the administration is responsible for the enforcement and supervision on any consumer protection related matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the CP Law, business operators
providing goods and services shall attach great value to consumers' health and safety, provide sufficient instruction on the goods
and services offered, maintain fairness of the trade and take any other necessary precautions to protect consumers&rsquo; rights.
In addition, business operators who design, produce and manufacture goods or provide services shall guarantee that the goods or
services offered should meet the safety criteria which is reasonably expected from the technological and professional perspective
at the time of launching such goods or offering services in the market. In case of intentionally wrongdoings of the business operators,
punitive damages up to three times of the actual damage may be imposed against such business operators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Taiwan Regulation on Food Sanitation
Management</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current primary regulation governing
food sanitation in Taiwan is the Food Sanitation Management Act, latest amended on August 8, 2012 (the &quot;FSM Act&quot;). The
Department of Health at various levels of the administration is responsible for the management and supervision on any food sanitation
related matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under this FSM Act, any business operators
of food or food additives must obtain and maintain the proper licenses from relevant government authorities before they could
manufacture, process, deploy, package, transform, store, sell, import and export food or food additives. The licenses generally
have a valid duration from one year to five years, which is set by the relevant government authorities, and the application for
extension must be filed for approval within three months before expiration. The FSM Act also set forth specific rules demanding
the compliance with good hygienic practices and safety control system of food or food additives by the business operators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General Regulations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Taiwan Regulation on Company Administration</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current primary regulation governing
companies in Taiwan is the Company Law, latest amended on January 16, 2013 by Legislative Yuan, which provided the fundamental
framework for regulating companies. The Ministry of Economic Affairs at various levels of the administration is responsible for
the management and supervision on any companies related matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Company Law, a company refers
to any profit-driven juridical association, organized, registered and established in accordance with this Company Law. Under the
Company Law, companies have been divided into four categories: unlimited liability company, limited liability company, joint liability
company and company limited by shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Company Law, a company cannot
be established unless properly registered with Ministry of Economic Affairs, and prior to such registration, no business or other
legal act can be conducted in the name of a company. In addition, the capital amount of a company must be fully contributed by
its shareholders of their own fund at the time of its establishment, rather than paid by installment or through external financing.
Furthermore, the capital contribution must be audited and certified by accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A limited liability company is a company
organized by more than one shareholder, where the shareholders are only liable to the extent of their contributed capital to the
company. Director(s) of a limited liability company is responsible for the management and operation of the company and subject
to duty of care and duty of loyalty while executing his business judgment with respect to the operation of the company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Taiwan Regulation on Foreign Exchange</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign exchange regulation in Taiwan
is primarily governed by the Ordinance of Foreign Exchange Administration, latest amended on April 29, 2009 (the &ldquo;Foreign
Exchange Ordinance&rdquo;). Under the Foreign Exchange Ordinance, foreign exchange refers to foreign currency, bills and marketable
securities. The authority managing the administration of foreign exchange is Ministry of Finance of Republic of China, while the
authority managing the practical operation of foreign exchange business is Central Bank of Republic of China. The Foreign Exchange
Ordinance also specifies the allocated power of Ministry of Finance and Central Bank, respectively. To the extent that any foreign
exchange receipts, payments or transactions reaches the threshold of $17,212 (NT$500,000) or equivalent in foreign currency, it
must be reported to the Central Bank or its designated authorities. Upon incurrence of any of the following events, the State
Council of Republic of China may determine and announce that for a period of time, to close the foreign exchange market, suspend
or restrict all or partial foreign exchange payment, order a mandatory sale or deposit of all or partial foreign exchange into
a designed bank, or dispose in any other manner as it deems necessary:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the disorder in domestic or international economy to the detriment
    of the stability of Taiwan&rsquo;s economy; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Taiwan suffers serious trade deficit.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Taiwan Regulation on Foreign Investment</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current principal regulation governing
foreign investment is Foreign Investment Regulation latest amended on November 19, 1997 (the &ldquo;Investment Regulation&rdquo;).
Under the Investment Regulation, investment refers to any activities involving (1) holding share capital of a company incorporated
in Taiwan; (2) establishing branches, wholly-owned or partnership enterprises in Taiwan; or (3) providing more than one-year term
loan to the above-mentioned investee enterprises. The authority in charge of foreign investment is Ministry of Economic Affairs
of Republic of China. The industries in Taiwan are categorized into permitted, restricted and prohibited foreign investment areas.
Investors may apply for settlement of exchange in accordance with the annual yield of their investment or the allocation of surplus.
<I><U>Eminent domain</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the investment made by an investor
constitutes less than 45% of the total amount of capital of the investee enterprise, and the investee enterprise has been expropriated
or acquired by the government for the purpose of national defense, reasonable government compensation shall be paid to the investors.
However, if the capital contribution made by the investor constitutes equal to or more than 45% of the total amount of capital
of the investee enterprise and continues remaining above 45% for two decades since its establishment, then the government may
not exercise its eminent domain power over such investee enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><U>Taiwan Regulations on Tax</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current principal regulations governing
tax in Taiwan include the following:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Income Tax Law, latest amended on August 8, 2012;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Implementation Rules of Income Tax Law, latest amended on September
    7, 2011;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Value-Added and Non-Value-Added Business Tax Law, latest amended
    on November 23, 2011; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Implementation Rules of Value-Added And Non-Value-Added Business
    Tax Law, latest amended on March 6, 2012.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Income Tax Law, there are two
kinds of income tax, comprehensive income tax for individuals and income tax for enterprises operating for profit, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Individuals who have income with a source
within Taiwan must pay comprehensive income tax on their income sourced within Taiwan; while non-resident individuals having income
with a source within Taiwan, except otherwise provided in the Income Tax Law, shall pay tax based on the amount attributable to
the sources of their income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The enterprise with head office located
in Taiwan shall pay profit-seeking income tax on its global income both within and outside Taiwan; while the enterprises with
head office outside Taiwan shall only pay profit-seeking income tax on its business income sourced from within Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Rate of income tax. The individual comprehensive income tax exemption
    threshold is NT$60,000 ($2,065) per person per year. Any income beyond such exemption threshold is subject to a progressive
    tax rate ranging from 5% to 40%.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">With respect to enterprise operating for profit, the exemption
    threshold is NT$120,000 ($4,131). Any income beyond such exemption threshold is subject to 17% tax rate on its taxable income.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sale of goods or service, import of goods in Taiwan shall be subject
    to Value-Added or Non-Value-Added Business Tax.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Rate of business tax. The rate of business tax, except otherwise
    stipulated in the relevant tax law, ranges from 5% to 10% as determined by the State Council of Taiwan.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2012, the sole member of the
board of directors, Hsin-Lung Lin, through an unanimous written consent, elects and appoints two individuals set forth below as
additional members of our board of directors and certain other individuals as executive officers. The following table sets forth,
as of December 31, 2012, the names and ages of our directors and executive officers. The directors will hold such office until
the next annual meeting of shareholders and until his or her successor has been elected and qualified.<B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; font-weight: bold; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; font-weight: bold; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Age</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 53%; font-weight: bold; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Position</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Hsin-Lung Lin</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman of the board of directors,
    Chief Executive Officer and Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Wen-Lang Chang*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">53</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director and Head of Sales Management</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Wei-Kung Lu</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Wei-Ming Tsai*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">57</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Project Vice General Manager</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Wen-Hsin Chang*</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">49</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research and Development Technical
    Advisor</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Executive Office held at Yambear Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Experience</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following summarizes the occupation
and business experience for our directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Hsin-Lung LIN, Chairman of the Board
of Directors, Chief Executive Officer and Chief Financial Officer </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hsin-Lung Lin has acted as
the director of the Company since April 12, 2012 and as the Chief Executive Officer of Yambear Taiwan since September 1,
2012. Hsin-Lung has served as Chief Executive Officer and Chief Financial Officer of the Company since February 13, 2013. He
graduated from National Pingtung University of Science and Technology Institute of Finance, Taiwan with a master degree in
2012. His majors include stock market analysis and financial statements analysis. Hsin-Lung has conducted extensive
researches on and is familiar with the stock markets in various jurisdictions, which gives him an insightful understanding of
the unique features of different stock markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Wen-Lang CHANG, Director </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wen-Lang Chang has acted as the director
of the Company since February 13, 2013. Wen-Lang Chang has acted as the Head of Sales Management of Yambear Taiwan since June
2012. He graduated from National Pingtung University of Science and Technology, Taiwan with a major in Management EMBA in 2006.
Wen-Lang has been working with Hawley &amp; Hazel Taiwan since 1985. During such period, Wen-Lang acted as Market Survey Executive
for the first two years, namely from 1985 to 1987. Then Wen-Lang focused&nbsp;on sales. He was promoted from the Sales Executive
(1987 &ndash; 1990) to Sales Supervisor (1990 &ndash; 1993), then further promoted to the Area Manager (1993 &ndash; 1999) and
Channel Manager (1999 -2001). Since 2001, Wen-Lang has been acting as the Senior Customer Development Manager. Wen-Lang started
his career&nbsp;acting as a Sales Representative at NICE Group from 1983 to 1985.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Wei-Kung LU, Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wei-Kung LU has acted as the director
of the Company since February 13, 2013. He graduated from National Pingtung University of Science and Technology, Taiwan with
a major in MBA in 2005. Wei-Kung had worked with ADATA Technology Co., Ltd. from 2007 to 2010 acted as a project sales manager.
From September 2010 to April 2011, Wei-Kung worked with BenQ Asia Pacific Corp acted as a business line manager. Wei-Kung has
been working with MSI Pacific International Holding Co., Ltd. from April 2011. During such period, Wei-Kung acted as a general
manager Malaysia Representative Office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Wei-Ming TSAI, Project Vice General
Manager</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wei-Ming TSAI has acted as the Project
Vice General Manager of Yambear Taiwan since January 30, 2013. He graduated from National Pingtung University of Science and Technology,
Taiwan with a major in Management EMBA in 2010. Wei-Ming had worked with Kaohsiung City Government from 2001 to 2009 acted as
a director in Kaosuing Fine Art Museum and Library. From September 2009 to April 2010, Wei-Ming worked with Kaohsiung City Government
acted as a director. Wei-Ming had worked with Pingtung County Government from 2010 to 2012. During such period, he acted as a
director in Cultural Events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Wen-Hsin CHANG, Research and Development
Technical Adviser</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: black">Wen-Hsin CHANG
</FONT>has acted as the Research and Development Technical Adviser of Yambear Taiwan since June 2012. He <FONT STYLE="color: black">graduated
from National Central University Institute of Chemical Engineering, Taiwan with a doctor degree in 1995. Since 1997, Wen-Hsin
has been working with ICT Technology Co., Ltd. Taiwan, where he first worked as a manager in research and development department
from 1999 to 2008, then he has been acting as the deputy general manager in the environmental catalysts international division
since 2008. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Family relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no family relationship among
the directors and executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Independence </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wei-Kung Lu is a &ldquo;independent director&rdquo;
as defined by the NYSE Amex Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Involvement in certain legal proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No bankruptcy petition has been filed
by or against any business of which any of our executive officers was a general partner or executive officer either at the time
of the bankruptcy or within two years prior to that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No director has been convicted in a criminal
proceeding and is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No director has been subject to any order,
judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily
enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No director has been found by a court
of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal
or state securities or commodities law, that has not been reversed, suspended, or vacated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Compensation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our directors do not currently receive
compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee and Audit Committee
Financial Expert</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our board of directors functions as an
audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent
accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal
controls and auditing matters; and (3) engaging outside advisors. We are not a &quot;listed company&quot; under SEC rules and
are therefore not required to have an audit committee comprised of independent directors. Our board of directors has determined
that its members do not include a person who is an &quot;audit committee financial expert&quot; within the meaning of the rules
and regulations of the SEC. Our board of directors has determined that each of its members is able to read and understand fundamental
financial statements and has substantial business experience that results in that member's financial sophistication. Accordingly,
the board of directors believes that each of its members have the sufficient knowledge and experience necessary to fulfill the
duties and obligations that an audit committee would have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Delaware law and pursuant to our
articles of incorporation and bylaws, we may indemnify our officers and directors for various expenses and damages resulting from
their acting in these capacities. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
to our officers or directors pursuant to those provisions, our counsel has informed us that, in the opinion of the SEC, this indemnification
is against public policy as expressed in the Securities Act, and is therefore unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth all compensation
awarded to, earned by or paid to our named executive officers. We do not anticipate adjusting our compensations to executive officers
and directors in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY COMPENSATION TABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Name&nbsp;and&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">principal&nbsp;position</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Fiscal&nbsp;Year</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Salary&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Bonus&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Stock&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">Awards&nbsp;</FONT><BR><FONT STYLE="font-size: 9pt"> ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Option&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">Awards&nbsp;</FONT><BR><FONT STYLE="font-size: 9pt"> ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Non-Equity&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">Incentive&nbsp;Plan&nbsp;</FONT><BR><FONT STYLE="font-size: 9pt"> Compensation&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Nonqualified&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">Deferred&nbsp;</FONT><BR><FONT STYLE="font-size: 9pt"> Compensation&nbsp;</FONT><BR><FONT STYLE="font-size: 9pt">
    Earnings&nbsp;</FONT><BR><FONT STYLE="font-size: 9pt"> ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">All&nbsp;Other&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">Compensation&nbsp;</FONT><BR><FONT STYLE="font-size: 9pt"> ($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 9pt">Total&nbsp;</FONT><BR>
    <FONT STYLE="font-size: 9pt">($)</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; width: 19%"><FONT STYLE="font-size: 9pt">Hsin-Lung Lin </FONT><BR><FONT STYLE="font-size: 9pt">Chairman,
    Chief Executive Officer, and Chief Financial Officer</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 9pt">2012</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 9pt">7,384</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-size: 9pt">7,384</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above table identifies all compensation
received by the Company&rsquo;s named executive officer directly or indirectly from the Company or its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to an employment agreement between
Yambear Taiwan and Hsin-Lung Lin dated September 1, 2012 (the &ldquo;Lin Agreement&rdquo;), Hsin-Lung earns a salary of NT$32,000
(approximately $1,101.55) per month to serve as Chief Executive Officer of Yambear Taiwan.&nbsp;The Lin Agreement is for an indefinite
term. The Lin Agreement also provides certain holiday bonuses, paid vacation as well as social insurance as required by applicable
laws.&nbsp;Hsin-Lung is subject to a non-compete provision which prohibits him from competing with Yambear Taiwan during the term
of the Lin Agreement.&nbsp;Either party may terminate the Lin Agreement with at least 30 days prior notice. In addition, Yambear
Taiwan may terminate the Lin Agreement with immediate effect in case Hsin-Lung is in material breach of the Lin Agreement. Yambear
Taiwan and Hsin-Lung Lin also entered into a confidentiality agreement dated September 1, 2012. Pursuant to the Lin Agreement,
Hsin-Lung is entitled to participate in our future stock option plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to an employment agreement between
Yambear Taiwan and Wei-Ming Tsai dated January 30, 2013 (the &ldquo;Tsai Agreement&rdquo;), Wei-Ming earns no salary other than
a monthly transportation subsidy in the amount of NT$5,000 (approximately $172.12) to serve as Project Vice General Manager of
Yambear Taiwan.&nbsp;The Tsai Agreement is for an indefinite term. Wei-Ming is also entitled to 3% of the aggregate annual sales
revenue of Yambear Taiwan attributable to the marketing channels that he assisted to develop and the direct sales made by him.
The Tsai Agreement also provides certain holiday bonuses, paid vacation as well as social insurance as required by applicable
laws.&nbsp;Wei-Ming is subject to a non-compete provision which prohibits him from competing with Yambear Taiwan during the term
of the Tsai Agreement.&nbsp;Either party may terminate the Tsai Agreement with at least 30 days prior notice. In addition, Yambear
Taiwan may terminate the Tsai Agreement with immediate effect in case Wei-Ming is in material breach of the Tsai Agreement. Yambear
Taiwan and Wei-Ming Tsai also entered into a confidentiality agreement dated January 30, 2013. Pursuant to the Tsai Agreement,
Wei-Ming is entitled to participate in our future stock option plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITY OWNERSHIP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth, as of February 12, 2013, certain
information regarding the beneficial ownership of Common Stock by (i) each person who is known by us to own beneficially more
than five percent of the outstanding Common Stock, (ii) each of our director and named executive officers, and (iii) all directors
and named executive officers as a group. Unless otherwise specified, the address of each of the persons set forth below is in
care of 3F., No.10, Yuanxi 2nd Rd., Pingtung Agricultural Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic
of China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">Name&nbsp;and&nbsp;Address&nbsp;of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: justify">Amount&nbsp;and&nbsp;Nature&nbsp;of</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: justify">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left; vertical-align: top">Title&nbsp;of&nbsp;Class</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: justify">Beneficial&nbsp;Owner</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: justify">Beneficial&nbsp;Owner</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: justify">Percent&nbsp;of&nbsp;Class&nbsp;(1)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left; vertical-align: top">Officers and Directors</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 20%; text-align: left; vertical-align: top">Common Stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 43%; text-align: justify">Hsin-Lung LIN <BR>Director/Chief Executive Officer</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Wen-Lang CHANG <BR>Director/Head of Sales Management</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Wei-Kung LU <BR>Director</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Wei-Ming TSAI <BR>Project Vice General Manager</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Wen-Hsin CHANG <BR>Research and Development Technical Adviser</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">*</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">All executive officers and directors (5) as a group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.08</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; font-style: italic; text-align: left; vertical-align: top">5% Beneficial Owners</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Yambear Holding Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,700,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">17/F, flat C, Siu Nin Bldg., 32 Tsat Tze Mui Road, North Point,&nbsp; Hong Kong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Orange Chang Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Room 2101-2103, Futura Plaza, 111 How Ming Street, Kwun Tong, Hong Kong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Inkstone Capital Limited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.6</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">26th Floor, Langham Place Office Tower, NO. 8. Argyle Street, Kowloon, Hong Kong</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Pi-Chen Chang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,130,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.04</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">No. 23, Yu&rsquo;an St., Annan Dist., Tainan City 709, Taiwan, Republic of China</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; vertical-align: top">Common Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Guo Chen</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">701 No. 50 Meihua Cun, Zhongshanyi Road, Yuexiu District, Guangzhou City, People&rsquo;s Republic of China</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Less than 1%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) Based on 12,500,000 shares outstanding
as of February 12, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not currently have an
insider transaction policy.<BR>
<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not had a promoter at any time
since inception. Therefore, we have never entered into transactions with a promoter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of February 12, 2013, we had not entered
into any related party transaction and none of the following persons has any direct or indirect material interest in any transaction
to which we are a party since our incorporation or in any proposed transaction to which we are proposed to be a party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(A)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any of our directors or officers;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(B)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any proposed nominee for election as
    our director;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(C)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any person who beneficially owns, directly
    or indirectly, shares carrying more than 10% of the voting rights attached to our Common Stock; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(D)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any relative or spouse of any of the
    foregoing persons, or any relative of such spouse, who has the same house as such person or who is a director or officer of
    any parent or subsidiary of us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are authorized to issue 100,000,000
shares of common stock, $0.0001 par value, of which 12,500,001 shares were issued and outstanding as of February 12, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each outstanding share of common stock
entitles the holder thereof to one vote per share on all matters. Our bylaws provide that any vacancy occurring in the board of
directors may be filled by the affirmative vote of a majority of the remaining directors though less than a quorum of the board
of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of shares of our common stock
are entitled to dividends out of funds legally available when and as declared by our board of directors. Our board of directors
has never declared a dividend and does not anticipate declaring a dividend in the foreseeable future. Should we decide in the
future to pay dividends, as a holding company, our ability to do so and meet other obligations depends upon the receipt of dividends
or other payments from our operating subsidiary in Taiwan and other holdings and investments. In the event of our liquidation,
dissolution or winding up, holders of our common stock are entitled to receive, ratably, the net assets available to shareholders
after payment of all creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the issued and outstanding shares
of our common stock are duly authorized, validly issued, fully paid and non-assessable. To the extent that additional shares of
our common stock are issued, the relative interests of existing shareholders will be diluted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have any issued and outstanding
or authorized preferred stock as of February 12, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Rule 144 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this registration statement,
we do not have any issued and outstanding common shares that are available for resale to the public market in accordance with
Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares being offered for resale by
the selling stockholders consist of 1,625,000 shares of our common stock held by 2 shareholders. Such shareholders include the
holders of 1,625,000 shares sold in our Regulation S offering which was completed on July 16, 2012. The following table sets forth
the name of the selling stockholders, the number of shares of common stock beneficially owned by each of the selling stockholders
as of February 12, 2013 and the number of shares of common stock being offered by the selling stockholders. The shares being offered
hereby are being registered to permit public secondary trading, and the selling stockholders may offer all or part of the shares
for resale from time to time. However, the selling stockholders are under no obligation to sell all or any portion of such shares
nor are the selling stockholders obligated to sell any shares immediately upon effectiveness of this prospectus. All information
with respect to share ownership has been furnished by the selling stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="margin: 0"></P>
<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Amount</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Percent</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Shares</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Beneficially</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Beneficially</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Beneficially</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Shares</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Owned</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Owned</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">Owned&nbsp;Prior</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">to&nbsp;be</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">After</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold">After</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">To&nbsp;Offering</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Offered</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Offering</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid">Offering</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 52%; text-align: left">Jiang Wei</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Chen Guo</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None of the Selling Stockholders are broker-dealers
or affiliates of broker dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR>
The Company currently serves as its own transfer agent. The Company is in the process of engaging a registered transfer agent and
plans to engage a transfer agent prior to the effectiveness of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the registration
of the resale of 1,625,000 shares of our common stock on behalf of the selling stockholders named herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders may sell some
or all of their shares at a fixed price of $0.008 per share until our shares are quoted on the Over the Counter Electronic Bulletin
Board (&ldquo;OTCBB&rdquo;) and thereafter at prevailing market prices or privately negotiated prices. Prior to being quoted on
the OTCBB, shareholders may sell their shares in private transactions to other individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no established public trading
market for our securities. Our shares are not and have not been listed or quoted on any exchange or quotation system. In order
for our shares to be quoted, a market maker must agree to file the necessary documents with the National Association of Securities
Dealers, which operates the OTCBB. In addition, it is possible that, such application for quotation may not be approved and even
if approved it is possible that a regular trading market will not develop or that if developed, will be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once a market has been developed for our
common stock, the shares may be sold or distributed from time to time by the selling stockholders directly to one or more purchasers
or through brokers or dealers who act solely as agents, at market prices prevailing at the time of sale, at prices related to such
prevailing market prices, at negotiated prices or at fixed prices, which may be changed. The distribution of the shares may be
effected in one or more of the following methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ordinary brokers transactions, which may include long or short sales,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Transactions involving cross or block trades on any securities or market where our common stock is trading,</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">through direct sales to purchasers or sales effected through agents,</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 92%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">through transactions in options, swaps or other derivatives (whether exchange listed or otherwise), or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any combination of the foregoing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders named in this
prospectus must comply with the requirements of the Securities Act and the Exchange Act in the offer and sale of the common stock
being offered by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders and any broker-dealers&nbsp;who
execute sales for the selling stockholders may be deemed to be an &quot;underwriter&quot; within the meaning of the Securities
Act in connection with such sales. During such times as the selling stockholders may be deemed to be engaged in a distribution
of the common&nbsp;stock, and therefore be considered to be an&nbsp;underwriter, they must comply with applicable laws and may
among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1.&nbsp; &nbsp;Not
engage in any stabilization&nbsp;activities&nbsp;in&nbsp;connection&nbsp;with our common stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">2.&nbsp; Furnish&nbsp;each&nbsp;broker&nbsp;or
dealer&nbsp;through&nbsp;which&nbsp;common&nbsp;stock may be offered,&nbsp;such copies of this&nbsp;prospectus from time to time,
as may be required by such broker or dealer, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.&nbsp; &nbsp;Not
bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities permitted under the
Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any commissions received by broker-dealers
and any profit on the resale of shares sold by them while acting as principals might be deemed to be underwriting discounts or
commissions under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the selling stockholders may
enter into hedging transactions with broker-dealers who may engage in short sales, if short sales were permitted, of shares in
the course of hedging the positions they assume with the selling stockholders. The selling stockholders may also enter into option
or other transactions with broker-dealers that require the delivery by such broker-dealers of the shares, which shares may be resold
thereafter pursuant to this prospectus. The selling stockholders may be deemed to be underwriters with respect to the shares that
they are offering for resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Brokers, dealers, or agents participating
in the distribution of the shares may receive compensation in the form of discounts, concessions or commissions from the selling
stockholders and/or the purchasers of shares for whom such broker-dealers may act as agent or to whom they may sell as principal,
or both (which compensation as to a particular broker-dealer may be in excess of customary commissions). Neither the selling stockholders
nor we can presently estimate the amount of such compensation. We know of no existing arrangements between the selling stockholders
and any other stockholder, broker, dealer or agent relating to the sale or distribution of the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any proceeds from the
sale of the shares of the selling stockholders pursuant to this prospectus. We have agreed to bear the expenses of the registration
of the shares, including legal and accounting fees, and such expenses are estimated to be approximately $80,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chiang Law Offices passed upon the
validity of the common stock being offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Included in the prospectus constituting
part of this registration statement are consolidated financial statements of (i) Yambear Bio-tech, Inc. and (ii) Yambear Bio-technology
Co., Ltd. for fiscal year ended December 31, 2012, which have been audited by Goldman Kurland Mohidin, LLP, an independent registered
public accounting firm, to the extent and for the periods set forth in their respective report appearing elsewhere herein. The
financial statements are included in reliance upon such report given upon the authority of such firms as experts in accounting
and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AVAILABLE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have filed with the SEC a registration
statement on Form S-1 under the Securities Act with respect to the common stock offered hereby. This prospectus, which constitutes
part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits
and schedule thereto, certain parts of which are omitted in accordance with the rules and regulations of the SEC. For further information
regarding our common stock and us, please review the registration statement, including exhibits, schedules and reports filed as
a part thereof. Statements in this prospectus as to the contents of any contract or other document filed as an exhibit to the registration
statement, set forth the material terms of such contract or other document but are not necessarily complete, and in each instance
reference is made to the copy of such document filed as an exhibit to the registration statement, each such statement being qualified
in all respects by such reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the effective date of this prospectus
we will also be subject to the informational requirements of the Exchange Act which requires us to file reports, proxy statements
and other information with the SEC. Such reports, proxy statements and other information along with the registration statement,
including the exhibits and schedules thereto, may be inspected at public reference facilities of the SEC at 100 F Street N.E, Washington
D.C. 20549. Copies of such material can be obtained from the Public Reference Section of the SEC at prescribed rates. You may call
the SEC at 1-800-SEC-0330 for further information on the operation of the public reference room. Because we file documents electronically
with the SEC, you may also obtain this information by visiting the SEC&rsquo;s Internet website at&nbsp;http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No dealer, salesperson or other person
has been authorized to give any information or to make any representations other than those contained in this prospectus in connection
with the offering made by this prospectus, and, if given or made, such information or representations must not be relied upon as
having been authorized by the Company or the selling stockholders.&nbsp; This prospectus does not constitute an offer to sell or
a solicitation of an offer to buy any securities other than those specifically offered hereby or an offer to sell or a solicitation
of an offer to buy any of these securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation.&nbsp;
Except where otherwise indicated, this prospectus speaks as of the effective date of the registration statement. &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YAMBEAR BIO-TECH, INC. AND SUBSIDIARY
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>From Inception (April 12, 2012) to December
31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: windowtext 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Page</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Report of Independent Registered Public Accounting Firm</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Financial Statements:</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Balance Sheet as of December 31, 2012</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Statement of Operations and Other Comprehensive</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from inception (April 12, 2012) to December 31, 2012</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Statement of Stockholders' Equity from inception</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(April 12, 2012) to December 31, 2012</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Statement of Cash Flows from inception</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(April 12, 2012) to December 31, 2012</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 27pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes to Consolidated Financial Statements</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">F-6</FONT></TD></TR>
</TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Independent Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Board of Directors and Stockholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Yambear Bio-Tech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Yambear Bio-Tech, Inc. and subsidiary as of December 31, 2012, and the related consolidated statements of operations
and other comprehensive loss, stockholders' equity, and cash flows from inception (April 12, 2012) to December 31, 2012. These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial
statements based on our audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.
The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. Our
audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate
in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control
over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that
our audit provides a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the consolidated financial position of Yambear Bio-Tech,
Inc. and subsidiary as of December 31, 2012, and the consolidated results of their operations and their consolidated cash flows
from inception (April 12, 2012) to December 31, 2012, in conformity with U.S. generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have
been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
has an accumulated deficit of $29,391, as of December 31, 2012 and has used cash in operations of $84,992. These matters, among
others, raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans concerning
these matters are described in Note 1. These accompanying financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Goldman Kurland and Mohidin LLP </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Encino, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">February 1, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>YAMBEAR BIO-TECH, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED BALANCE SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS OF DECEMBER
31, 2012&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 88%">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">16,302</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable, net of allowance for doubtful accounts of $0</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,519</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,539</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">Deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">7,063</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,090</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">INTANGIBLE ASSETS, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">757</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">OTHER LONG-TERM ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,239</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">77,086</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Salaries payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,080</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Advances from customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,672</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other payables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">185</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,937</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">STOCKHOLDERS' EQUITY:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Common stock, $0.0001 per share; 100,000,000 shares authorized, 12,500,000 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated other comprehensive income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Retained Earnings</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,391</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total stockholders' equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">73,149</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">77,086</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YAMBEAR BIO-TECH, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENT OF OPERATIONS
AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OTHER COMPREHENSIVE (LOSS)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FROM INCEPTION (APRIL 12, 2012) TO DECEMBER
31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 88%; font-weight: bold">Revenue</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">21,502</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Cost of revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,933</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,569</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Selling expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,153</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">36,883</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 27pt; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">42,036</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,467</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Non-operating income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Interest income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total non-operating income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">76</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Loss before provision for income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,391</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Provision for income taxes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,391</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Foreign currency translation gain</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(26,851</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Weighted average shares outstanding :</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,500,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,500,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YAMBEAR BIO-TECH, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENT OF STOCKHOLDERS'
EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FROM INCEPTION (APRIL 12, 2012) TO DECEMBER
31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Other</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Common Stock</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional Paid</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Comprehensive</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Stockholders'</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">in Capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Income</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Balance, April 12, 2012</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 28%; text-align: left">Purchase of common stock for cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,250</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">98,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">100,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Change in foreign currency translation gain</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(29,391</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(29,391</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance, December 31, 2011</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,500,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,250</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">98,750</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,540</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(29,391</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">73,149</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>YAMBEAR BIO-TECH, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENT OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FROM INCEPTION (APRIL 12, 2012) TO DECEMBER
31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: left; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(29,391</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">(Increase) / decrease in assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.375in">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,445</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,652</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.375in">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,186</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.375in">Deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,001</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.375in">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,219</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Increase / (decrease) in current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.375in">Salaries payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,062</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in">Advances from customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,657</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Other payables</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">183</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(84,992</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Payments for intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(750</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Proceeds from issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Effect of exchange rate changes on cash and cash equivalents</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,044</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">NET INCREASE IN CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,302</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">CASH, BEGINNING OF PERIOD</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">CASH, END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,302</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Interest paid</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Income taxes paid</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 1 - Organization and Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Organization and Line of Business</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yambear Bio-Tech, Inc. (the &ldquo;Company&rdquo; or &ldquo;Yambear&rdquo;)
was incorporated in the State of Delaware on April 12, 2012. The Company, through its subsidiary is engaged in selling enzymes
products to public consumers across Taiwan, and the Company intends to expand business operations by distributing and exporting
its enzymes products to Hong Kong, mainland China, Singapore and Malaysia in 2013. The Company&rsquo;s goal is to distribute and
market its enzymes products to high-end consumers by exploring a variety of marketing channels, including, without limitation,
telephone sales, sales on TV shopping channels, as well as selling in special counters located in big shopping malls and self-operated
stores.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Going Concern</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements
have been prepared in conformity with accounting principles generally accepted in the United States of America, which
contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $29,391, as of December
31, 2012 and has used cash in operations of $84,992 from its inception to December 31, 2012. These conditions raise
substantial doubt as to the Company&rsquo;s ability to continue as a going concern. These consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty. These consolidated financial
statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going
concern. The Company plans to open a retail location in a shopping mall to create brand image and brand awareness and is
currently negotiating an agency agreement with an insurance company in Taiwan. Major shareholders will continue to fund the
Company until it is able to sustain positive cash flows from operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Principles of Consolidation </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements include the
accounts of Yambear and its wholly-owned subsidiary, Yambear Bio-Tech Co. Ltd. Taiwan (&ldquo;Yambear Taiwan&rdquo;). All significant
intercompany transactions and balances were eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Basis of Presentation </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying consolidated financial statements were prepared
in conformity with accounting principles generally accepted in the United States (&ldquo;US GAAP&rdquo;). The Company&rsquo;s functional
currency is the Taiwanese Dollar (&ldquo;Taiwan $&rdquo;); however, the accompanying consolidated financial statements were translated
and presented in United States Dollars (&ldquo;$&rdquo; or &ldquo;USD&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Foreign Currency Translation </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounts of the Taiwanese subsidiary are maintained in the
Taiwan $ and the accounts of the U.S. parent company are maintained in the USD. The accounts of the Taiwanese subsidiary are translated
into USD in accordance with ASC Topic 830 &ldquo;Foreign Currency Matters,&rdquo; with the Taiwan $ as the functional currency
for the Taiwanese subsidiary. <FONT STYLE="color: black">According to Topic 830, all assets and liabilities are translated at the
exchange rate on the balance sheet date, stockholders&rsquo; equity is translated at historical rates and statement of operations
items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under
other comprehensive income in accordance with ASC Topic 220, &ldquo;Comprehensive Income.&rdquo; Gains and losses resulting from
the translations of foreign currency transactions and balances are reflected in the statement of operations. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 - Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Use of Estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preparation of financial statements in conformity with US
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Cash and Equivalents </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and equivalents include cash in hand and cash in time deposits,
certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Accounts Receivable </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company maintains reserves for potential credit losses on
accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations,
customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these
reserves. Reserves are recorded primarily on a specific identification basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Inventory </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory is valued at the lower of the inventory&rsquo;s cost
or the current market price of the inventory. Management compares the cost of inventory with its market value and an allowance
is made to write down inventory to market value, if lower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Long-Lived Assets </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company applies ASC Topic 360, &ldquo;Property, Plant, and
Equipment,&rdquo; which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360
requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and
the undiscounted cash flows estimated to be generated by those assets are less than the assets&rsquo; carrying amounts. In that
event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss
on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced to recognize the
cost of disposal. Based on its review, the Company believes that as of December 31, 2012, there was no significant impairment of
its long-lived assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Intangible Assets </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company evaluates intangible assets for impairment, at least
on an annual basis and whenever events or changes in circumstances indicate the carrying value may not be recoverable from its
estimated future cash flows. Recoverability of intangible and other long-lived assets is measured by comparing their net book value
to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results,
budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related
undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Fair Value of Financial Instruments </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For certain of the Company&rsquo;s financial instruments, including
cash, accounts receivable, other receivables, salaries payable, advances from customers and other payables, the carrying amounts
approximate their fair values due to their short maturities. The carrying amounts of the line of credit and other long-term liabilities
approximate their fair values based on current rates of interest for instruments with similar characteristics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ASC Topic 820, &ldquo;Fair Value Measurements and Disclosures,&rdquo;
requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, &ldquo;Financial Instruments,&rdquo;
defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure
requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current
liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest. The
three levels of valuation hierarchy are defined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 65.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Level 1 inputs to the valuation methodology are quoted
prices for identical assets or liabilities in active markets.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.25pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 65.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Level 2 inputs to the valuation methodology include
quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets,
and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the
financial instrument.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 83.25pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 65.25pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Level 3 inputs to the valuation methodology use one
or more unobservable inputs which are significant to the fair value measurement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company analyzes all financial instruments with features
of both liabilities and equity under ASC Topic 480, &ldquo;Distinguishing Liabilities from Equity,&rdquo; and ASC Topic 815, &ldquo;Derivatives
and Hedging.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2012, the Company did not identify any assets
and liabilities required to be presented on the balance sheet at fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Revenue Recognition </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s revenue recognition policies comply with
SEC Staff Accounting Bulletin 104 (codified in FASB ASC Topic 605). Sales revenue is recognized at the date of shipment to customers
when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations
of the Company exist and collectability is reasonably assured. The Company provides sales incentive such a buy a dozen and get
one free. The Company recognizes the cost of the free product at the time of sale. The Company does not provide unconditional return
or any other sales incentives. Payments received before all of the relevant criteria for revenue recognition are satisfied are
recorded as advances from customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sales represent the invoiced value of products, net of value-added
tax (&ldquo;VAT&rdquo;). All of the Company&rsquo;s products sold in Taiwan are subject to a value-added tax of 5% of the gross
sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing
the finished product. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax
return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid
as the Company acts as an agent for the government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Income Taxes </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for income taxes in accordance with ASC
Topic 740, &ldquo;Income Taxes.&rdquo; ASC 740 requires a company to use the asset and liability method of accounting for income
taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized
for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities
and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely
than not that some portion, or all of, the deferred tax assets will&nbsp;not be realized. Deferred tax assets and liabilities are
adjusted for the effects of changes in tax laws and rates on the date of enactment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under ASC 740, a tax position is recognized as a benefit only
if it is &ldquo;more likely than not&rdquo; that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The amount recognized is the largest amount of tax benefit that is more than 50% likely of being realized
on examination. For tax positions not meeting the &ldquo;more likely than not&rdquo; test, no tax benefit is recorded. The adoption
had no effect on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Basic and Diluted Earnings (Loss) Per Share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">Earnings per share is calculated
in accordance with the ASC Topic 260, &ldquo;Earnings Per Share.&rdquo; Basic earnings per share (&ldquo;EPS&rdquo;) is based upon
the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible
shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method,
warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained
thereby were used to purchase common stock at the average market price during the period. </FONT>There were no options, warrants
or other instruments convertible into common stock outstanding as of December 31, 2012, therefore basic and diluted loss per share
are the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Foreign Currency Translation </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accounts of the Company&rsquo;s Taiwanese subsidiary are
maintained in <FONT STYLE="color: black">Taiwan $</FONT> and the accounts of the U.S. parent company are maintained in USD. The
accounts of the Taiwanese subsidiary were translated into USD in accordance with ASC Topic 830, &ldquo;Foreign Currency Matters,&rdquo;
with the <FONT STYLE="color: black"> Taiwan $</FONT> as the functional currency for the Taiwanese subsidiary. <FONT STYLE="color: black">According
to ASC Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date, stockholders&rsquo;
equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate
for the year. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic
220, &ldquo;Comprehensive Income.&rdquo; Gains and losses resulting from the translations of foreign currency transactions and
balances are reflected in the statement of operations. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Foreign Currency Transactions and Comprehensive Income </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US GAAP generally requires recognized revenue, expenses, gains
and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities,
such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such
items, along with net income, are components of comprehensive income. The functional currency of the Company&rsquo;s Taiwanese
subsidiary is the Taiwan $. Translation gains of $2,540 at December 31, 2012, are classified as an item of other comprehensive
income in the stockholders&rsquo; equity section of the consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Statement of Cash Flows </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with ASC Topic 230, &ldquo;Statement of Cash Flows,&rdquo;
cash flows from the Company&rsquo;s operations are calculated based upon the local currencies using the average translation rates.
As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily
agree with changes in the corresponding balances on the consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Recent Accounting Pronouncements </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2011, the FASB issued ASU&nbsp;2011-04
to provide a consistent definition of FV and ensure the FV measurement and disclosure requirements are similar between US GAAP
and IFRS. ASU 2011-04 changes certain FV measurement principles and enhances the disclosure requirements particularly for Level
3 FV measurements. &nbsp;This guidance was effective for the Company on January 1, 2012.&nbsp; The adoption of ASU 2011-04 did
not have a significant impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2011, the FASB issued ASU 2011-05,
<I>Presentation of Comprehensive Income</I>. ASU 2011-05 revises the manner in which entities present comprehensive income in their
financial statements. The new guidance removes the presentation options in Accounting Standards Codification (ASC) 220, <I>Comprehensive
Income</I>, and requires entities to report components of comprehensive income in either (1)&nbsp;a continuous statement of comprehensive
income or (2)&nbsp;two separate but consecutive statements. The new guidance does not change the items that must be reported in
other comprehensive income. In December 2011, the FASB issued ASU&nbsp;2011-12 which defers the requirement in ASU&nbsp;2011-05
that companies present reclassification adjustments for each component of accumulated other comprehensive income in both net income
and other comprehensive income on the face of the financial statements. ASU&nbsp;2011-05 is effective for fiscal years and interim
reporting periods within those years beginning after December&nbsp;15, 2011, with early adoption permitted. The adoption of ASU&nbsp;2011-05,
as amended by ASU&nbsp;2011-12, did not have a significant impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2011, the FASB issued ASU&nbsp;2011-08
which provides an entity the option to first assess qualitative factors to determine whether it is necessary to perform the two-step
test for goodwill impairment.&nbsp;&nbsp;If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not
the FV of a reporting unit is less than its carrying amount, the quantitative impairment test is required.&nbsp;&nbsp;Otherwise,
no further testing is required. The revised standard is effective&nbsp;for the Company for its annual and interim goodwill impairment
tests performed for fiscal years beginning after December 15, 2011.&nbsp;&nbsp;The adoption of ASU 2011-08 did not significantly
impact the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2012, the FASB issued ASU 2012-02,
Intangibles-Goodwill and Other (Topic 350) - Testing Indefinite-Lived Intangible Assets for Impairment.&nbsp; The ASU provides
entities with an option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely
than not the indefinite-lived intangible asset is impaired.&nbsp; If an entity concludes it is more than 50% likely that an indefinite-lived
intangible asset is not impaired, no further analysis is required.&nbsp; However, if an entity concludes otherwise, it would be
required to determine the FV of the indefinite-lived intangible asset to measure the amount of impairment, if any, as currently
required under US GAAP. The ASU is effective for annual and interim impairment tests performed for fiscal years beginning after
September 15, 2012.&nbsp; Early adoption is permitted.<FONT STYLE="color: black"> The adoption of this pronouncement will not have
a material impact on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 3 - Inventory </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory at December 31, 2012 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 79%; color: black; text-align: left">Packing Material</TD><TD STYLE="width: 1%; color: black">&nbsp;</TD>
    <TD STYLE="width: 1%; color: black; text-align: left">$</TD><TD STYLE="width: 18%; color: black; text-align: right">11,317</TD><TD STYLE="width: 1%; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="color: black; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; color: black; text-align: right">29,222</TD><TD STYLE="padding-bottom: 1pt; color: black; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="color: black; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; color: black; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; color: black; text-align: right">40,539</TD><TD STYLE="padding-bottom: 2.5pt; color: black; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 - Intangible Assets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intangible assets at December 31, 2012 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 79%">Trademark</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">757</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: Accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(-</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">757</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s intangible asset consists of a trademark
application fee which will be amortized over its estimate life of 10 years beginning when the trademark is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amortization of intangible assets is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Year ending December 31,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 79%; text-align: left">2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">76</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">377</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">757</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 5 &ndash; Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has authorized 100,000,000 shares of common stock
with a par value of $0.0001 per shares. July 16, 2012, the Company issued 12,500,000 shares of its common stock for $100,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6 - Income Taxes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s subsidiary is governed by the Income Tax
Law of Taiwan, and is generally subject to tax at 17% on income reported in the statutory financial statements after appropriate
adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income tax expense reflected in the consolidated statements
of operations and other comprehensive loss consists of the following for the period from inception (April 12, 2012) to December
31, 2012:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.7pt">Current expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 79%; padding-left: 9pt">Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Foreign</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.7pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.7pt">Deferred expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 9pt">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Foreign</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.7pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.7pt">Total income tax expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The components of deferred income tax assets and liabilities
as of December 31, 2012 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 79%; text-align: left; padding-bottom: 1pt; text-indent: 10pt">Net operating loss</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 18%; border-bottom: Black 1pt solid; text-align: right">4,996</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.7pt">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,996</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Less valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,996</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0.7pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A reconciliation of tax at United States federal statutory rate
to provision for income tax recorded in the financial statements is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 55%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 79%; text-align: left; padding-left: 0.7pt">Tax provision at statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">-34</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.7pt">Foreign tax rate difference</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.7pt">Taiwanese current NOL for which no benefit is realized</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17</TD><TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.7pt">Effective rate</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has a net operating loss carryforward in Taiwan
of approximately $29,000 that expires in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7 &ndash; Commitments and Contingencies </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company leases office space located at 3F., No.10, Yuanxi
2nd Rd., Pingtung Agriculture Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of China for $1,669 (NT$48,480)
per month Which expire on October 31, 2014. Future annual minimum lease payments for this non cancelable operating lease are as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 45%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Year ending December 31,</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 75%; text-align: left">2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">20,028</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">2014</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,690</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">36,718</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Employment Agreements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an employment agreement between the Yambear Taiwan
and Hsin-Lung Lin dated September 1, 2012, Hsin-Lung earns a salary of NT$32,000 (approximately $1,102) per month to serve as Chief
Executive Officer of Yambear Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, pursuant to an employment agreement between Yambear
Taiwan and Wei-Ming Tsai dated January 30, 2013, Wei-Ming earns no salary other than a monthly transportation subsidy in the amount
of NT$5,000 (approximately $172) to serve as Project Vice General Manager of Yambear Taiwan.&nbsp;The agreement is for an indefinite
term. Wei-Ming is also entitled to 3% of the aggregate annual sales revenue of Yambear Taiwan attributable to the marketing channels
that he assisted to develop and the direct sales made by him.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1,625,000 Shares of</B> <B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Yambear Bio-tech, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROSPECTUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________, 20__</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DEALER PROSPECTUS DELIVERY OBLIGATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Until __________, all dealers that effect
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This
is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold
allotments or subscriptions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 13.&nbsp; Other Expenses of Issuance
and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated expenses of this offering
in connection with the issuance and distribution of the securities being registered, all of which are to be paid by the Registrant,
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 88%; text-align: justify">Registration Fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.77</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Legal Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify">Accounting Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Printing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Miscellaneous Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">80,002</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 14.&nbsp; Indemnification of Directors
and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 145 of the Delaware General Corporation
Law authorizes a corporation&rsquo;s board of directors to grant, and authorizes a court to award, indemnity to officers, directors
and other corporate agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As permitted by Section 102(b)(7) of the
Delaware General Corporation Law, our company&rsquo;s certificate of incorporation includes provisions that eliminate the personal
liability of its directors for monetary damages for breach of their fiduciary duty as directors. To the extent Section 102(b)(7)
is interpreted, or the Delaware General Corporation Law is amended, to allow similar protections for officers of a corporation,
such provisions of our company&rsquo;s certificate of incorporation shall also extend to those persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as permitted by Section 145
of the Delaware General Corporation Law, the bylaws, and certificate of incorporation of our company provide that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any director of the Company shall not
be liable to the Company or its stockholders for monetary damages from breach of fiduciary duty as a director, except to the extent
such exemption from liability or limitation thereof is not permitted under the General Corporation Law of the State of Delaware
as the same exists or may hereafter be amended. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except the advances in connection with
indemnification, no loan shall be made by the Company to any director unless it is authorized by vote of the stockholders without
counting any shares of the director who would be the borrower or unless the director who would be the borrower is the sole shareholder
of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Company will not be obligated pursuant
to the bylaws to indemnify a person with respect to proceedings initiated by that person, except with respect to proceedings authorized
by our company&rsquo;s board of directors. </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The rights conferred in the bylaws are
not exclusive, and our company is authorized to enter into indemnification agreements with its directors, officers, employees and
agents and to obtain insurance to indemnify such persons.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Company may not retroactively amend
the bylaw provisions to reduce its indemnification obligations to directors, officers, employees and agents. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Options: NewSection; Value: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These indemnification provisions may be
sufficiently broad to permit indemnification of our company&rsquo;s officers and directors for liabilities (including reimbursement
of expenses incurred) arising under the Securities Act of 1933.&nbsp;&nbsp;The Company may at the discretion of the board of directors
purchase and maintain insurance on behalf of any person who holds or who has held any position identified in the paragraph above
against any and all liability incurred by such person in any such position or arising out of his status as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification by us for liabilities
arising under the Securities Act may be permitted to our directors, officers or persons controlling the company pursuant to provisions
of our articles of incorporation and bylaws, or otherwise, we have been advised that in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification
by such director, officer or controlling person of us in the successful defense of any action, suit or proceeding is asserted by
such director, officer or controlling person in connection with the securities being offered, we will, unless in the opinion of
our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 15.&nbsp; Recent Sales of Unregistered
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 16, 2012, we issued a total of
12,500,000 shares of our common stock, $0.0001 par value per share, to 26 non U.S. persons in consideration for their previous
investment of $100,000 to the Company. The issuance was made
pursuant to an exemption from registration contained in Regulation S under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 16. Exhibits and Financial Statement
Schedules </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%; border-bottom: windowtext 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B>&nbsp;</P></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 87%; border-bottom: windowtext 1pt solid; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description&nbsp;of&nbsp;Exhibit </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Incorporation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1*</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Opinion of&nbsp;The Chiang Law Offices</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>Form of <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stock Purchase Agreement</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Translation of Employment Agreement between the Company and
    Hsin-Lung Lin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Translation of Employment Agreement between the Company and
    Wei-Ming Tsai</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Translation of Tenancy Contract dated January 10, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Translation of Distribution Agreement between the Company and
    Fitness &amp; Beauty Corporation Limited,     dated     November     1,     2012</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subsidiaries of the registrant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of Goldman Kurland Mohidin, LLP</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.2</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consent of The Chiang Law Offices (contained in Exhibit 5.1)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Powers of Attorney (included on the signature page)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* To be filed by amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17.&nbsp; Undertakings </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) To file, during
any period in which offers or sales are being made, a post-effective amendment to this registration statement to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) include any prospectus
required by Section 10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (&sect; 230.424(b)
of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate
offering price set forth in the &quot;Calculation of Registration Fee&quot; table in the effective registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) That, for the purpose
of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) To remove from
registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) That, for the purpose of determining
liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned registrant undertakes that
in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of
the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (&sect;
230.424 of this chapter);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) Any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3) The portion of
any other free writing prospectus relating to the offering containing material information about the undersigned registrant or
its securities provided by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant
to the foregoing provisions, the registrant has been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by
the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; (d) The undersigned registrant hereby
undertakes that, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed
pursuant to Rule 424(b) as part of a registration statement relating to an offering shall be deemed to be part of and included
in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in
a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to
a purchaser with a time of contract of sale prior to such a first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date
of first use.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Changzhi Township, Pingtung, Taiwan, Republic of China, on the 14th day of February 2013.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Yambear Bio-tech, Inc.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: windowtext 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Hsin-Lung Lin</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Hsin-Lung Lin, Chief Executive Officer and Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">KNOW ALL PERSONS BY
THESE PRESENTS that each person whose signature appears below hereby constitutes and appoints Hsin-Lung Lin as his true and lawful
attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities,
to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to
be done in connection therewith, as fully to all intents and purposes as he might or could do them in person, hereby ratifying
and confirming all that said attorney-in-fact and agent or any of them, or their or his substitute or substitutes, shall do or
cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates
indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: windowtext 1pt solid; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: windowtext 1pt solid; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; border-bottom: windowtext 1pt solid; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: windowtext 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Hsin-Lung Lin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 14, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Hsin-Lung Lin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Wen-Lang Chang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 14, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Wen-Lang Chang</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Wei-Kung Lu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February 14, 2013</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Wei-Kung Lu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>
</BODY>
</HTML>
[{"type": "S-1", "sequence": "1", "filename": "v334937_s1.htm", "description": "FORM S-1", "secsgml_size_bytes": 498736}]
{"company-data": {"conformed-name": "YAMBEAR BIO-TECH, INC.", "cik": "0001569737", "irs-number": "461992903", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-186689", "film-number": "13616186"}, "business-address": {"street1": "3F., NO. 10, YUANXI 2ND RD., PINGTUNG", "city": "TAIWAN", "state": "F4", "zip": "908", "phone": "886087621913"}, "mail-address": {"street1": "3F., NO. 10, YUANXI 2ND RD., PINGTUNG", "city": "TAIWAN", "state": "F4", "zip": "908"}}
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
YAMBEAR BIO-TECH, INC.
(Exact name of registrant as specified
in its charter)
Delaware
2833
46-1992903
(State or other jurisdiction of
(Primary Standard Industrial
(I.R.S. Employer
incorporation or organization)
Classification Code Number)
Identification Number)
3F., No.10, Yuanxi 2nd Rd.,
Pingtung Agricultural Biotechnology Park,
Changzhi Township, Pingtung 908,
Taiwan, Republic of China
+00886 08 7621913
(Address, including zip code, and telephone
number, including area code, of registrant's principal executive offices)
Hsin-Lung Lin
Suite 806, 1220 N. Market Street,
Wilmington, DE19801,
County of New Castle
(Name, address, including
zip code, and telephone number, including area code, of agent for service)
Copies to:
Ryan Nail, Esq.
The Chiang Law Offices, P.C.
1700 North First Street, Suite 343,
San Jose, CA 95112
Telephone: 415 488-5581
Facsimile: 415 882-7239
Approximate Date of Commencement of
Proposed Sale to the Public:
from time to time after the effective date of this Registration Statement as determined
by market conditions and other factors.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under
the Securities Act of 1933, check the following box:
x
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please
check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering.
¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.
¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.
¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule
12b-2 of the Exchange Act.  (Check one):
Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated filer
¨
Smaller reporting company
x
(Do not check if a smaller
    reporting company)
CALCULATION OF REGISTRATION FEE
Title Of Each
Class of Securities
To be Registered
Amount To
Be Registered
Proposed
Maximum
Offering Price
Per Share
Proposed
Maximum
Aggregate
Offering Price
Amount of
Registration Fee
Common Stock, par value $0.0001
1,625,000
$
0.008
$
13,000
$
1.77
The offering price has been estimated
solely for the purpose of computing the amount of the registration fee in accordance with Rule 457(c). Our common stock is not
traded on any national exchange and in accordance with Rule 457, the offering price was determined by the price of the shares
that were recently sold to our shareholders. The price of $0.008 is a fixed price at which the selling stockholders may sell their
shares until our common stock is quoted on the OTC Bulletin Board at which time the shares may be sold at prevailing market prices
or privately negotiated prices.
The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this registration statement shall thereafter become effective in accordance with section 8(a) of
the securities act of 1933 or until the registration statement shall become effective on such date as the commission, acting pursuant
to said section 8(a), may determine.
2
The information in this preliminary
prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the
U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and
it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
PROSPECTUS
Subject to completion, dated
February 14, 2013
1,625,000 shares of Common Stock
YAMBEAR BIO-TECH, INC.
The selling stockholders named in this
prospectus are offering all of the shares of common stock offered through this prospectus. Our common stock is presently not traded
on any market or securities exchange. The 1,625,000 shares of our common stock can be sold by selling stockholders at a fixed
price of $0.008 per share until our shares are quoted on the OTC Bulletin Board ("OTCBB") and thereafter at prevailing
market prices or privately negotiated prices. There can be no assurance that a market maker will agree to file the necessary documents
with the Financial Industry Regulatory Authority ("FINRA"), which operates the OTCBB, nor can there be any assurance
that such an application for quotation will be approved. We have agreed to bear the expenses relating to the registration of the
shares of the selling stockholders. We will receive no proceeds from the sale or other disposition of the shares, or interests
therein, by the selling stockholders.
An investment in shares of our common
stock involves a high degree of risk.  We urge you to carefully consider the Risk Factors beginning on page 8
.
Neither the U.S. Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The Date of this Prospectus is _______________.
3
TABLE OF CONTENTS
PROSPECTUS SUMMARY
4
RISK FACTORS
7
FORWARD LOOKING STATEMENTS
18
USE OF PROCEEDS
18
DIVIDEND POLICY
18
MARKET FOR OUR COMMON STOCK
19
MANAGEMENT'S DISCUSSION AND ANALYSIS
    OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
20
BUSINESS
21
MANAGEMENT
42
SECURITY OWNERSHIP
47
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
47
DESCRIPTION OF SECURITIES
48
SELLING STOCKHOLDERS
48
PLAN OF DISTRIBUTION
49
LEGAL MATTERS
50
EXPERTS
50
AVAILABLE INFORMATION
50
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
52
4
PROSPECTUS SUMMARY
This summary highlights selected information
contained elsewhere in this prospectus.  This summary does not contain all the information that you should consider before
investing in the common stock.  You should carefully read the entire prospectus, including "Risk Factors", "Management's
Discussion and Analysis of Financial Condition and Results of Operations" and the Consolidated Financial Statements, before
making an investment decision
.
THE COMPANY
Company Structure
Yambear Bio-tech, Inc. ("Yambear"
or the "Company") is a Delaware corporation organized on April 12, 2012 by Hsin-Lung Lin, a Taiwanese citizen, as
a holding company for Yambear Bio-Tech Co. Ltd. Taiwan ("Yambear Taiwan"), Taiwanese limited liability company. Yambear
Taiwan, being the operating company of Yambear in Taiwan, was established on August 17, 2012 and is a wholly owned subsidiary
of Yambear.
On July 16, 2012, we issued a total
of 12,500,000 shares of our common stock, $0.0001 par value per share, to several non U.S. persons in consideration for their
previous investment of $100,000 in the Company, among which $93,560 has been contributed into its wholly-owned subsidiary Yambear
Taiwan on July 19, 2012 as its capital contribution. The issuance was made pursuant to an exemption from registration contained
in Regulation S under the Securities Act of 1933, as amended.
The following flow chart illustrates our
companies' organizational structure:
5
Our Business
We are a development stage company. We
do not have significant revenues. We have minimal assets and have incurred losses since inception. We are currently selling enzymes
products manufactured in Taiwan through Yambear Taiwan, our operating company in Taiwan, to public consumers across Taiwan, and
we intend to expand business operations by distributing and exporting our enzymes products to Hong Kong, mainland China, Singapore
and Malaysia in 2013. Our goal is to distribute and market our enzymes products to high-end consumers by exploring a variety of
marketing channels, including, without limitation, telephone selling, sales on TV shopping channels, as well as selling in special
counters located in big shopping malls and our self-operated stores.
All of our enzymes products are manufactured
in Taiwan by our designated manufacturer in accordance with our formula, with substantially all of the ingredients purchased within
Taiwan.
Our executive office is located in 3F.,
No.10, Yuanxi 2nd Rd., Pingtung Agricultural Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of China, where
we lease approximately 572 square meters with a monthly rent of $1,669 (NT$48,480).
For the period from inception (April 12,
2012) to December 31, 2012, we generated revenues of $21,502 and incurred a net loss of $29,391.
As of December 31, 2012, the Company's
current assets exceeded its current liabilities by $70,153 and the Company's total assets exceeded its total liabilities
by $73,149. The Company generated a net loss of $29,391for the period from inception (April 12, 2012) to December 31, 2012 and
the Company's cash position on December 31, 2012 was $16,302.
Summary of the Offering
The selling stockholders named in this
prospectus are offering all of the shares of common stock offered through this prospectus. The selling stockholders are selling
shares of common stock covered by this prospectus for their own account.
We will not receive any of the proceeds
from the sale of these shares. The offering price of $0.008 was determined by the price for certain shares issued to our shareholders
in a private placement issuance in exchange for $100,000 investment, which has been used for the contribution into the capital
account of Yambear Taiwan. The offering price of $0.008 is a fixed price at which the selling stockholders may sell their shares
until our common stock is quoted on the OTCBB, at which time the shares may be sold at prevailing market prices or privately negotiated
prices. We have agreed to bear the expenses relating to the registration of the shares for the selling stockholders.
The offering will conclude upon the earliest
of (i) such time as all of the common stock has been sold pursuant to the registration statement or (ii) such time as all of the
common stock becomes eligible for resale without volume limitations pursuant to Rule 144 under the Securities Act.
There is currently no public market for
our securities and you may not be able to liquidate your investment since there is no assurance that a public market will develop
for our common stock or that our common stock will ever be approved for trading on a recognized exchange.  After this document
is declared effective by the U.S. Securities and Exchange Commission, we intend to seek a market maker to apply for a quotation
on the OTCBB in the United States. Our shares are not and have not been listed or quoted on any exchange or quotation system.
We cannot assure you that a market maker will agree to file the necessary documents with the OTCBB, nor can there be any assurance
that such an application for quotation will be approved or that a regular trading market will develop or that if developed, will
be sustained. In the absence of a trading market, an investor may be unable to liquidate its investment.
6
We intend to apply for quoting of our
common stock on the OTCBB, which we estimate will cost around $100,000. The breakdown of such costs is estimated as following:
Legal Counsel
$
70,000
Auditor
$
20,000
Other vendors
$
10,000
Total:
$
100,000
We estimate that to maintain a quoting
status will cost us $80,000to $150,000 annually which will include legal and auditing expenses.
We will rely on professional services
to carry out this plan, which includes, but is not limited to, a U.S. law firm with corporate and securities practice, a PCAOB
registered auditor and consultants. We have engaged The Chiang Law Offices as our legal counsel. We have engaged Goldman Kurland
Mohidin, LLP, as our independent auditor.
To be quoted on the OTCBB, we must engage
a market maker to file an application for a trading symbol on our behalf with the Financial Industry Regulatory Authority ("FINRA").
This process may take between three (3) to six (6) months. We plan to engage a market maker after our registration statement is
declared effective by the U.S. Securities and Exchange Commission (the "SEC").
The Common Stock offered hereby involves
a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investments. See "Risk
Factors" beginning on page 8.
Where You Can Find Us
We presently maintain our executive office
at 3F., No.10, Yuanxi 2nd Rd., Pingtung Agricultural Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of
China. Our telephone number is +00886 08 7621913. Our Taiwan subsidiary Yambear Taiwan maintains a website at
www.yambear.com
.
RISK FACTORS
See "RISK FACTORS" for a discussion
of the above factors and certain additional factors that should be considered in evaluating an investment in the common stock.
SUMMARY OF FINANCIAL AND OPERATING INFORMATION
The following selected financial information
is derived from the Consolidated Financial Statements appearing elsewhere in this prospectus and should be read in conjunction
with the Consolidated Financial Statements, including the notes thereto, appearing elsewhere in this prospectus.
Summary of Operations
Inception (April 12,
2012) to
December 31, 2012
Net revenue
$
21,502
Net profit (loss)
$
(29,391
)
Net profit (loss) per common share (basic and diluted)
$
(0.00
)
Weighted average common shares outstanding, basic and diluted
12,500,000
Statement of Financial Position
As of
December 31, 2012
Cash and cash equivalents
$
16,302
Total assets
$
77,086
Current Liabilities
$
3,937
Long-term Liabilities
$
-
Stockholders' equity
$
73,149
7
We plan to pay the dividends only when
our net income exceeds the total amount due and when the payment will not have a significant impact on our financial position.
Our Delaware corporation, Yambear, has not declared any dividends since its inception on April 12, 2012.
RISK FACTORS
The shares of our common stock being offered
for resale by the selling stockholders are highly speculative in nature, involve a high degree of risk and should be purchased
only by persons who can afford to lose the entire amount invested in the common stock. Before purchasing any of the shares of
common stock, you should carefully consider the following factors relating to our business and prospects. If any of the following
risks actually occurs, our business, financial condition or operating results could be materially adversely affected. In such
case, the trading price of our common stock could decline and you may lose all or part of your investment.  This Risk Factors
section has addressed all material risks that should be considered in evaluating an investment in the common stock.
Risks Relating to Our Business
We lack an operating history
and have not generated significant revenues or any profit to date. There is no assurance our future operations will result in
profitable revenues. If we cannot generate sufficient revenues to operate profitably, we may have to cease operations. .
The Company was incorporated on April
12, 2012 and our operating company in Taiwan, Yambear Taiwan, was incorporated on August 17, 2012. We only have a limited operating
history, which may not provide a meaningful basis for you to evaluate our business, financial performance and prospects. Our ability
to achieve and maintain profitability and positive cash flow is dependent upon our ability to earn profit by developing, expanding
and marketing our enzymes products. We cannot assure you that we will be successful in generating revenues and profit from our
enzymes products business in the future. Failure to generate revenues and profit may cause us to suspend or cease operations.
Our business and prospects
could be materially and adversely affected if we are not able to manage our growth successfully.
We are a development stage company. We
are currently selling enzymes products manufactured in Taiwan through Yambear Taiwan, our operating company in Taiwan, to public
consumers across Taiwan, and we intend to expand business operations by distributing and exporting our enzymes products to Hong
Kong, mainland China, Singapore and Malaysia in 2013 through a variety of marketing channels. We only offer limited enzymes products
now and we intend to broaden our line of products through investment in research and development. We anticipate continued growth
in the future through internal expansion as well as external strategic partnerships or alliances. Our expansion will place substantial
demands on our managerial, operational, technological and other resources. To manage and support our continued growth, we must
continue to improve our operational, administrative, financial and technological systems, procedures and controls, and expand,
train and manage our growing employee base. Furthermore, our management will be required to maintain and expand our relationships
with our suppliers, manufacturers, regulators and other third parties. We cannot assure you that our current and planned personnel,
systems, procedures and controls will be adequate to support our future operations. Any failure to effectively and efficiently
manage our expansion could materially and adversely affect our ability to capitalize on new business opportunities, which in turn
could have a material adverse effect on our results of operations.
8
Because our auditors have
issued a going concern opinion, there is substantial uncertainty that we will continue operations in which case you could lose
your investment.
Our auditors have issued a going concern
opinion.  This means that there is substantial doubt that we can continue as an ongoing business for the next twelve months. 
The financial statements do not include any adjustments that might result from the uncertainty about our ability to continue in
business.  As such we may have to cease operations and you could lose your investment.
Competition in our industry
is intense and, if we are unable to compete effectively, we may lose customers and our financial results may be negatively affected.
The enzymes business in Taiwan is highly
competitive for new players. The market share is largely dominated by two well-established companies and many smaller companies
competing for the remaining share. We expect competition to persist and intensify. We compete for customers on the basis of product
qualities and name recognition. Though we believe that our enzymes products have been manufactured according to our unique formula
and special fermentation process and are better in key parameters for enzymes products, there's no assurance that the customers
will recognize the quality of our enzymes products or be willing to pay any premium for them. Many of our competitors have greater
financial and marketing resources than we do and may be able to offer products and services that we do not currently offer and
may not offer in the future. If we are unable to compete effectively against those competitors, we may lose customers and our
financial results may be negatively affected.
Unfavorable publicity or
consumer perception of our enzymes products and any similar products distributed by other companies could cause fluctuations in
our operating results and could have a material adverse effect on our reputation, the demand for our enzymes products, and our
ability to generate revenues.
We
are highly dependent upon consumer perception of the safety and quality of our enzymes products, as well as similar products distributed
by other companies. Consumer perception of enzymes products can be significantly influenced by scientific research or findings,
national media attention, and other publicity about product use. An enzymes product may be received favorably, resulting in high
sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity
could be unfavorable to our industry or any of our particular enzymes products and may not be consistent with earlier favorable
research or publicity. A future research report or publicity that is perceived by our consumers as less favorable or that questions
earlier research or publicity could have a material adverse effect on our ability to generate revenues. As such, period-to-period
comparisons of our results should not be relied upon as a measure of our future performance. Adverse publicity in the form of
published scientific research or otherwise, whether or not accurate, that associates consumption of enzymes products or any other
similar products with illness or other adverse effects, that questions the benefits of our or similar products, or that claims
that such products are ineffective could have a material adverse effect on our reputation, the demand for our enzymes products,
and our ability to generate revenues.
We lack risk management
methods, our business, reputation and financial results may be adversely affected.
We currently do not have methods to identify,
monitor and manage risks with respect to our enzymes products business. If any of such risks to which we are, or may be, exposed
materialize, our business, reputation, financial condition and operating results could be materially and adversely affected. In
addition, our insurance policies may not provide adequate coverage.
9
If we cannot explore various
marketing channels for our enzymes products on schedule and profitably, our planned future growth will be impeded, which would
adversely affect sales.
Our growth is dependent on increases in
sales through our successful exploration of a variety of marketing channels. Our ability to timely expand our market share through
a combination of marketing channels, including telephone sales, sales on TV shopping channels, as well as selling in special counters
located in big shopping malls and our self-operated stores, depends in part on the following factors: the availability of such
channels; the ability to negotiate acceptable terms with third party service providers; the ability to identify customer demand
in different geographic areas; the hiring, training and retention of competent sales personnel; the effective management of inventory
to meet the needs of increased orders on a timely basis; general economic conditions; and the availability of sufficient funds
for expansion. Many of these factors are beyond our control. Delays or failures in utilizing these marketing channels, or achieving
lower than expected sales through such marketing channels, could materially adversely affect our growth and profitability.
Our future success depends
on the continuing efforts of our senior management team and other key personnel, and our business may be harmed if we lose their
services.
Our future success depends heavily upon
(i) the continuing services of our current senior management team and (ii) the recruitment of other key personnel, in particular
the Chief Executive Officer and the Chief Marketing Officer. If we fail to recruit the key personnel, or one or more of our senior
management team, are unable or unwilling to continue in their present positions, we may not be able to replace them easily, or
at all. As such, our business may be disrupted and our financial condition and results of operations may be materially and adversely
affected. Competition for senior management and key personnel is intense, the pool of qualified candidates is very limited, and
we may not be able to retain the services of our senior executives or key personnel, or attract and retain high-quality senior
executives or key personnel in the future. As is customary in the Taiwan, we do not have insurance coverage for the loss of our
senior management team or other key personnel.
In addition, if any member of our senior
management team or any of our other key personnel joins a competitor or forms a competing company, we may lose customers, sensitive
trade information and key professionals and staff members. Each of our current employees has entered into an employment agreement
as well as confidentiality agreement, with Yambear Taiwan.
See "Management—Employment Agreements" for
a more detailed description of the key terms of these employment agreements. If any disputes arise between any of our senior executives
or key personnel and us, we cannot assure you of the extent to which any of these agreements may be enforced.
Our directors and certain
senior management have other business interests, which may limit the amount of time they can devote to our company and potentially
create conflicts of interest.
Our directors and certain senior management
have other business interests. For example, our director, Mr. Johnson Chang, also acts as the Senior Customer Development Manager
of Hawley & Hazel Taiwan.  Our senior management, Mr. Vincent Chang, also play key management roles in other businesses,
which may lead to periodic interruptions of our business operations.
Compliance with new and
existing governmental regulations could increase our costs significantly and adversely affect our results of operations.
Our enzymes products, like the similar
products offered by our competitors in Taiwan, are categorized as dietary products, rather than nutritional products, which is
subject to more stringent governmental regulations. The processing, formulation, manufacturing, packaging, labeling, advertising,
and distribution of our enzymes products are subject to applicable laws and regulations of Ministry of Economic Affaires and Department
of Health, both of which are under the leadership of the Executive Yuan of Taiwan. Additional or more stringent regulations of
dietary products have been considered from time to time. The enactment of such new regulations or other regulation re-categorizing
enzymes products as nutritional products, thus subject to more intense regulations, could impose more stringent standards on enzymes
products. We may not be able to comply with any of such new regulations without incurring additional expenses, which could be
significant.
10
We may incur material product
liability claims, which could increase our costs and adversely affect our reputation, revenues, and operating income.
As a retailer and distributor of enzymes
products designed for human consumption, we may be subject to product liability claims if the use of our products has allegedly
resulted in injury. Our enzymes products consist of enzymes fluid extracted from fruits and vegetables, herbs and other ingredients
that are classified as foods or dietary supplements and are not subject to pre-market regulatory approval in Taiwan. Our products
could contain contaminated substances, and some of our products contain ingredients that do not have long histories of human consumption.
Previously unknown adverse reactions resulting from human consumption of these ingredients could occur.
In addition, we have engaged a third-party
manufacturer to produce all of our enzymes products that we sell. As a distributor of products manufactured by third parties,
we may also be liable for various product liability claims for products we do not manufacture. Though we have purchased product
liability insurance to cover the enzymes products we sell, we can not assure you that the insured amount is sufficient. We may
be unable to obtain full recovery from the insurer or any indemnifying third party in respect of any claims against us in connection
with products manufactured by such party. Any product liability claim against us could result in increased costs and could adversely
affect our reputation with our customers, which in turn could adversely affect our revenues and operating income.
We do not have any patent
for the formula of our enzymes products or the manufacturing process.
We have not applied and will not apply
the patent right for the formula of our enzymes products or the manufacturing process due to legal restrictions and our business
concerns. We have taken various measures to protect know-hows on formula as well as manufacturing process of our enzymes products.
If the formula of our enzymes products is stolen or analyzed out by other competitors, we could lose our competition strengths,
which could adversely affect our ability to expand our market share.
Intellectual property litigation
and infringement claims against us could cause us to incur significant expenses or prevent us from manufacturing, selling, or
using some aspect of our products, which could adversely affect our revenues and market share.
We are currently and may in the future
be subject to intellectual property litigation and infringement claims, which could cause us to incur significant expenses or
prevent us from manufacturing, selling or using some aspect of our products. Claims of intellectual property infringement also
may require us to enter into costly royalty or license agreements. However, we may be unable to obtain royalty or license agreements
on terms acceptable to us or at all. Claims that our technology or products infringe on intellectual property rights could be
costly and would divert the attention of management and key personnel, which in turn could adversely affect our revenues and profitability.
If we fail to maintain
an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results
or prevent fraud.
After this Registration Statement is declared
effective by the SEC, we will be subject to reporting obligations under U.S. securities laws. Pursuant to Section 404 of
the Sarbanes-Oxley Act of 2002 and the related rules adopted by the Securities and Exchange Commission, every public company is
required to include a management report on the company's internal controls over financial reporting in its annual report,
which contains management's assessment of the effectiveness of the company's internal controls over financial reporting.
These requirements will first apply to our annual report on Form 10-K for the fiscal year ending on December 31, 2014.
11
There is no assurance that we will be
able to maintain effective internal controls over financial reporting in the future. If we fail to do so, we may not be able to
produce reliable financial reports and prevent fraud. Moreover, if we were not able to conclude that we have effective internal
controls over financial reporting, investors may lose confidence in the reliability of our financial statements, which would negatively
impact the trading price of our shares. Our reporting obligations as a public company, including our efforts to comply with Section 404
of the Sarbanes-Oxley Act, will continue to place a significant strain on our management, operational and financial resources
and systems for the foreseeable future.
Our network and communications
systems are dependent on third-party providers and are vulnerable to system interruption and damage, which could limit our ability
to operate our business and could have a material adverse effect on our business, financial condition or results of operations.
We intend to expand
sales of our enzymes products through a variety of marketing channels, among which include telephone sales and sales on TV shopping
channels. Our systems and operations and those of our third-party Internet and telecommunication service providers, are vulnerable
to damage or interruption from fire, flood, earthquakes, power loss, server failure, telecommunications and Internet service failure,
acts of war or terrorism, computer viruses and denial-of-service attacks, physical or electronic breaches, sabotage, human error
and similar events. Any of these events could lead to system interruptions, processing and order fulfillment delays, and loss
of critical data for us, our suppliers, or our Internet service providers, and could prevent us from processing customer purchases.
Any significant interruption in the availability or functionality of our website or our customer processing, distribution, or
communications systems, for any reason, could seriously harm our business, financial condition, and operating results. The occurrence
of any of these factors could have a material adverse effect on our business, financial condition or results of operations.
We may require additional
funds to continue our business plan.
Our business plan and growth strategy
call for ongoing expenses in connection with the distribution of enzymes products. We have not generated any significant revenue
from operations to date.
As of December 31, 2012, we had cash on
hand of $16,302, and we have accumulated a deficit of $29,391. At this rate, we anticipate that additional funding will be needed
for general administrative expenses and marketing costs within the next three months.
In order to expand our business operations,
we anticipate that we will have to raise additional funding. If we are not able to raise the capital necessary to fund our business
expansion objectives, we may have to delay the implementation of our business plan.
We do not currently have any arrangements
for financing. Obtaining additional funding will be subject to a number of factors, including general market conditions, investor
acceptance of our business plan and initial results from our business operations. These factors may impact the timing, amount,
terms or conditions of additional financing available to us. The most likely source of future funds available to us is through
the sale of additional shares of common stock or advances from our major shareholders or directors and, if we are able to obtain
equity financing, it will likely result in significant additional dilution to the interests of our current stockholders and may
include liquidation or other preferences that adversely affect your right as a stockholder. The Company may obtain financing by
issuing debt which may involve agreements that include covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that we will
be able to obtain such additional financing and if we cannot receive such financing we may be forced to suspend or cease operations.
12
General economic conditions,
including a prolonged weakness in the economy, may affect consumer purchases, which could adversely affect our sales.
Due to the nature of dietary supplement
products, our sales results are dependent on a number of factors impacting consumer spending, including general economic and business
conditions; consumer confidence; wages and employment levels; the housing market; consumer debt levels; availability of consumer
credit; credit and interest rates; taxes; general political conditions, both domestic and abroad. Consumer product purchases,
including purchases of our enzymes products, may decline during recessionary periods. A prolonged downturn or an uncertain outlook
in the economy may materially adversely affect our business and our revenues and profits.
We do not expect to pay
dividends in the foreseeable future.
We have never paid any dividends on our
common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable future. The future payment
of dividends directly depends upon our future earnings, capital requirements, financial requirements and other factors that our
board of directors will consider. Since we do not anticipate paying cash dividends on our common stock, return on your investment,
if any, will depend solely on an increase, if any, in the market value of our common stock.
We have no experience as
a public company.
We have never operated as a public company.
We have no experience in complying with the various rules and regulations, which are required of a public company. As a result,
we may not be able to operate successfully as a public company, even if our operations are successful. We plan to comply with
all of the various rules and regulations, which are required of a public company. However, if we cannot operate successfully as
a public company, your investment may be materially adversely affected. Our inability to operate as a public company could be
the basis of your losing your entire investment.
We have outsourced the
manufacturing of all of our enzymes products to one company.
All of our enzymes products are being
manufactured by a Taiwan local company, Bioenergy Biotechnology Corp. ("Bioenergy") pursuant to the orders we place
to them from time to time. Bienergy is one of the biggest enzymes products manufacturers in Taiwan and we've started our
cooperation with it since our inception. If they choose to terminate our cooperation or materially change terms of our cooperation,
we may not be able to find a replacement in time or on terms acceptable to us, which could have a material adverse effect on our
business operation. We have entered into confidentiality agreement with Bioenergy, however, if Bioenergy breaches its confidentiality
obligation and discloses our formula of enzymes products to the public or any third party, we could lose our competition strength
and our operation could be adversely affected.
We are an Emerging
Growth Company as defined under the Jumpstart Our Business Startups Act.
An "emerging
growth company" is an issuer whose initial public offering was or will be completed after Dec. 8, 2011, and had total annual
gross revenues of less than $1 billion during its most recently completed fiscal year. An issuer's EGC status terminates
on the earliest of:
·     The last day of the first fiscal
year of the issuer during which it had total annual gross revenues of $1 billion or more;
·     The last day of the fiscal year
of the issuer following the fifth anniversary of the date of the issuer's initial public offering;
13
·     The date on which such issuer has
issued more than $1 billion in non-convertible debt securities during the prior three-year period determined on a rolling basis;
or
·     The date on which the issuer is
deemed to be a "large accelerated
filer" under the Exchange Act, which means, among other things, that
it has a public float in excess of $700 million.
Pursuant to the JOBS
Act of 2012, as an emerging growth company the Company can elect to opt out of the extended transition period for any new or revised
accounting standards that may be issued by the PCAOB or the SEC. The Company has elected not to opt out of such extended transition
period which means that when a standard is issued or revised and it has different application dates for public or private companies,
the Company, as an emerging growth company, can adopt the standard for the private company. This may make comparison of the Company's
financial statements with any other public company which is not either an emerging growth company nor an emerging growth company
which has opted out of using the extended transition period difficult or impossible as possible different or revised standards
may be used.
The Company has elected
to use the extended transition period for complying with new or revised financial accounting standards available under Section
102(b)(2)(B) of the Act. Among other things, this means that the Company's independent registered public accounting firm will
not be required to provide an attestation report on the effectiveness of the Company's internal control over financial reporting
so long as it qualifies as an emerging growth company, which may increase the risk that weaknesses or deficiencies in the internal
control over financial reporting go undetected. Likewise, so long as it qualifies as an emerging growth company, the Company may
elect not to provide certain information, including certain financial information and certain information regarding compensation
of executive officers that would otherwise have been required to provide in filings with the SEC, which may make it more difficult
for investors and securities analysts to evaluate the Company. As a result, investor confidence in the Company and the market
price of its common stock may be adversely affected.
Risks Related to Doing Business in
Taiwan
Our operations and financial
results could be severely harmed by natural disasters.
Our executive office is located in Taiwan,
which is susceptible to earthquakes. Taiwan is also exposed to typhoons and tsunamis. If a major earthquake, typhoon, tsunami
or other natural disaster were to affect the operations of our suppliers and manufacturers, our sales and delivery of enzymes
products to our customers could be interrupted or delayed. As a result, our normal business operations could be severely disrupted
and our financial condition and results of operations could be adversely affected.
Fluctuation in the value
of the NT$ may have a material adverse effect on your investment.
The value of the NT$ against the US dollar
("USD") and other currencies may fluctuate and is affected by, among other things, changes in political and economic
conditions. As of December 31, 2012, the exchange rate of NT$ to the USD was 29.05NT$=1USD.
Our revenues and costs are denominated
in the NT$, and our financial assets are also denominated in NT$. We completely rely on dividends payable to us by our operating
company in Taiwan, Yambear Taiwan. Any significant appreciation or depreciation of the NT$ against the USD may affect our cash
flows, revenues, earnings and financial position, and the value of, and any dividends payable on, our shares in USD. For example,
a further appreciation of the NT$ against the USD would make any new NT$-denominated investments or expenditures more costly to
us, to the extent that we need to convert USD into the NT$ for such purposes. An appreciation of the NT$ against the USD would
also result in foreign currency translation losses for financial reporting purposes when we translate our USD denominated financial
assets into the NT$, as the NT$ is our reporting currency in Taiwan. Conversely, a significant depreciation of the NT$ against
the USD may significantly reduce the USD equivalent of our reported earnings, and may adversely affect the price of our shares.
14
Increase in the price and
shortage of supply of key raw materials could adversely affect our business.
Substantially all of our key raw materials
for the production of our enzymes products are harvested in Taiwan. If the prices of these raw materials were to increase significantly,
or it experiences a shortage of supply of these raw materials due to abnormal climate change or natural disasters, we could incur
significant cost increase or fail to accumulate our products inventory to meet our customers' needs. Raw material prices
may increase from time to time in the future and we may not be able to pass on such increases to our customers. A significant
increase in the price of raw materials that cannot be passed on to customers could have a material adverse effect on our results
of operations and financial condition. In addition, the interruption in supply of certain key raw materials essential to the manufacturing
of our products may have an adverse impact on our suppliers and manufacturers' ability to provide us with the necessary products
needed to maintain our customer relationships and an adequate level of sales.
Our controlling shareholders
may take actions that are not in, or may conflict with, our public shareholders' best interest.
After this offering, Yambear Holding
Limited will own, directly or indirectly, a controlling interest of approximately 45.60% of our outstanding common shares.
Accordingly, these shareholders will continue to have the ability to exercise a controlling influence over our business and may
take actions that you may not agree with or that are not in our or our public shareholders' best interest.
Our primary operation is
located in Taiwan, and because the rights of shareholders under Taiwan law differ from those under U.S. law, you may have difficulty
protecting your shareholder rights.
We conduct all of our business operations
through our operating entity in Taiwan, whose corporate affairs are governed by its Articles of Incorporation and by the laws
governing corporations incorporated in Taiwan. The rights of shareholders and the responsibilities of management and the members
of the board of directors under Taiwan law are different from those applicable to a corporation incorporated in the United States.
For example, directors and controlling shareholders of Taiwan companies do not owe fiduciary duties to minority shareholders.
Therefore, public shareholders of Taiwan companies may have more difficulty in protecting their interest in connection with actions
taken by management or members of the board of directors than they would as public shareholders of a U.S. corporation.
U.S. investors may experience
difficulties in attempting to effect service of process and to enforce judgments based upon U.S. federal securities laws against
the company and its non-U.S. resident directors and senior officers.
All of our directors and senior officers
are non-residents of the United States. Consequently, it may be difficult for investors to effect service of process on any of
them in the United States and to enforce judgments obtained in United States courts against them based on the civil liability
provisions of the United States securities laws. Since all our assets are located in Taiwan it may be difficult or impossible
for U.S. investors to collect a judgment against us. As well, any judgment obtained in the United States against us may not be
enforceable in the United States.
15
Strained relations between
the Republic of China and the People's Republic of China could negatively affect our business and the market value of your
investment.
We intend to expand our business operations in mainland China
through self-operated stores as well as authorized agents for the marketing of our enzymes products, which may become a more and
more important market for our enzymes products as well as revenue and profit source for our business. The Republic of China has
a unique international political status. Both the Republic of China and the People's Republic of China assert sovereignty
over all of China, including Taiwan. The People's Republic of China government does not recognize the legitimacy of the
Republic of China government. Although significant economic and cultural relations have been established in recent years between
the Republic of China and the People's Republic of China, relations have often been strained and the government of the People's
Republic of China government has indicated that it may use military force to gain control over Taiwan under certain circumstances,
such as the declaration of independence by the Republic of China. Relations between the Republic of China and the People's
Republic of China have been particularly strained in recent years. Past developments in relations between the Republic of China
and the People's Republic of China have on occasion depressed the market price of the shares of Taiwanese companies. Relations
between the Republic of China and the People's Republic of China and other factors affecting the political or economic conditions
in Taiwan could have a material adverse effect on our financial condition and results of operations, as well as the market price
and the liquidity of our common shares.
Risks Associated with Our Shares of
Common Stock
You may not be able to
liquidate your investment since there is no assurance that a public market will develop for our common stock or that our common
stock will ever be approved for trading on a recognized exchange.
There is no established public trading
market for our securities. After this document is declared effective by the U.S. Securities and Exchange Commission, we intend
to seek a market maker to apply for a quotation on the OTCBB in the United States. Our shares are not and have not been listed
or quoted on any exchange or quotation system. We cannot assure you that a market maker will agree to file the necessary documents
with the OTCBB, nor can there be any assurance that such an application for quotation will be approved or that a regular trading
market will develop or that if developed, will be sustained. In the absence of a trading market, you may be unable to liquidate
its investment, which will result in the loss of your investment.
The offering price of the
shares was arbitrarily determined, and therefore should not be used as an indicator of the future market price of the securities.
Therefore, the offering price bears no relationship to our actual value, and may make our shares difficult to sell.
The offering price of $0.008 for the shares
of common stock was based upon the sale price in our recent private placement. The sale price in the private placement was arbitrarily
determined. The factors considered in determining the sale price were our financial condition and prospects, our limited operating
history and the general condition of the securities market. Therefore, the offering price is not an indication of and is not based
upon our actual value. The offering price bears no relationship to our book value, assets or earnings or any other recognized
criteria of value. The offering price should not be regarded as an indicator of the future market price of the securities.
Future sales by our stockholders
may negatively affect our stock price and our ability to raise funds in new stock offerings.
Sales of our common stock in the public
market could lower the market price of our common stock. Sales may also make it more difficult for us to sell equity securities
or equity-related securities in the future at a time and price that our management deems acceptable or at all. Of the 12,500,001
shares of common stock outstanding as of February 8, 2012, 1,625,000 shares are, or will be, freely tradable without restriction
upon the effective date of this registration statement, unless held by our "affiliates". The remaining 10,875,001
shares of common stock, which will be held by existing stockholders, including the officers and directors, are "restricted
securities" and may be resold in the public market only if registered or pursuant to an exemption from registration. Some
of these shares may be resold under Rule 144.
16
"Penny Stock"
rules may make buying or selling our common stock difficult.
Trading in our securities will be subject
to the "penny stock" rules. The SEC has adopted regulations that generally define a penny stock to be any equity security
that has a market price of less than $5.00 per share, subject to certain exceptions. These rules require that any broker-dealer
who recommends our securities to persons other than prior customers and accredited investors, must, prior to the sale, make a
special written suitability determination for the purchaser and receive the purchaser's written agreement to execute the
transaction. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny
stock, of a disclosure schedule explaining the penny stock market and the risks associated with trading in the penny stock market.
In addition, broker-dealers must disclose commissions payable to both the broker-dealer and the registered representative and
current quotations for the securities they offer. The additional burdens imposed upon broker- dealers by such requirements may
discourage broker-dealers from effecting transactions in our securities, which could severely limit the market price and liquidity
of our securities. Broker-dealers who sell penny stocks to certain types of investors are required to comply with the Commission's
regulations concerning the transfer of penny stocks. These regulations require broker- dealers to:
¨
Make a suitability determination prior
    to selling a penny stock to the purchaser;
¨
Receive the purchaser's written
    consent to the transaction; and
¨
Provide certain written disclosures
    to the purchaser.
These requirements may restrict the ability
of broker-dealers to sell our common stock and may affect your ability to resell our common stock.
17
FORWARD LOOKING STATEMENTS
Information included or incorporated by
reference in this prospectus may contain forward-looking statements.  This information may involve known and unknown risks,
uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from
the future results, performance or achievements expressed or implied by any forward-looking statements.  Forward-looking
statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by
use of the words "may," "should," "expect," "anticipate," "estimate,"
"believe," "intend" or "project" or the negative of these words or other variations on these
words or comparable terminology.
This prospectus contains forward-looking
statements, including statements regarding, among other things, (a) our projected sales and profitability, (b) our technology,
(c) our manufacturing, (d) the regulation to which we are subject, (e) anticipated trends in our industry and (f) our needs for
working capital. These statements may be found under "Management's Discussion and Analysis or Plan of Operations"
and "Business," as well as in this prospectus generally.  Actual events or results may differ materially from
those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks outlined
under "Risk Factors" and matters described in this prospectus generally.  In light of these risks and uncertainties,
there can be no assurance that the forward-looking statements contained in this prospectus will in fact occur.
Except as otherwise required by applicable
laws, we undertake no obligation to publicly update or revise any forward-looking statements or the risk factors described in
the prospectus, whether as a result of new information, future events, changed circumstances or any other reason after the date
of this prospectus.
USE OF PROCEEDS
The selling stockholders are selling shares
of common stock covered by this prospectus for their own account. We will not receive any portion of the proceeds from the sale
or other disposition of the shares of common stock covered hereby, or interests therein, by the selling stockholders.
We have agreed to bear the expenses of
the registration of the shares. We anticipate that these expenses will be approximately $80,000.
DIVIDEND POLICY
The holders of our common stock are entitled
to receive dividends when, as and if declared by the board of directors out of funds legally available therefore. To date, we
have not declared nor paid any cash dividends. The board of directors does not intend to declare any dividends in the foreseeable
future, but instead intends to retain all earnings, if any, for use in our business operations.
DETERMINATION OF OFFERING PRICE
No market currently exists for our common
stock. Therefore, the offering price of $0.008 was based on the offering price of shares sold pursuant to our Regulation S issuance
completed in July 2012 in which we issued a total of 12,500,000 shares of our common stock to 26 shareholders at a price per share
of $0,008 for an aggregate offering price of $100,000.
DILUTION
The common stock to be sold by the selling
stockholders is common stock that is currently issued and outstanding. Accordingly, there will be no dilution to our existing
shareholders.
18
PENNY STOCK CONSIDERATIONS
Broker-dealer practices in connection
with transactions in "penny stocks" are regulated by certain penny stock rules adopted by the U.S. Securities and
Exchange Commission. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered
on certain national securities exchanges or quoted on the NASDAQ system). Penny stock rules require a broker-dealer, prior to
a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides
information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with
current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction,
and monthly account statements showing the market value of each penny stock held in the customer's account. The broker-dealer
must also make a special written determination that the penny stock is a suitable investment for the purchaser and receive the
purchaser's written agreement to the transaction. These requirements may have the effect of reducing the level of trading
activity, if any, in the secondary market for a security that becomes subject to the penny stock rules.
MARKET FOR OUR COMMON STOCK
No Public Market for Common Stock
There is presently no public market for
our common stock. We anticipate applying for trading of our common stock on the Over the Counter Bulletin Board upon the effectiveness
of the registration statement of which this prospectus forms a part. However, we can provide no assurance that our shares will
be traded on the OTCBB or, if traded, that a public market will materialize.
Holders of Our Common Stock
As of the date of this registration statement,
we had 26 registered shareholders.
Registration Rights
We have not granted registration rights
to the selling stockholders or to any other persons.
19
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
You should read the following discussion
of our financial condition and results of operations together with the audited financial statements and the notes to the audited
financial statements included in the registration statement on Form S-1. This discussion contains forward-looking statements that
reflect our plans, estimates and beliefs. Our actual results may differ materially from those anticipated in these forward-looking
statements.
Overview
We were incorporated in the State of Delaware
on April 12, 2012. Through our subsidiary we are engaged in selling enzymes products to public consumers across Taiwan, and we
intend to expand business operations by distributing and exporting our enzymes products to Hong Kong, mainland China, Singapore
and Malaysia in 2013. Our goal is to distribute and market our enzymes products to high-end consumers by exploring a variety of
marketing channels, including, without limitation, telephone sales, sales on TV shopping channels, as well as selling in special
counters located in big shopping malls and self-operated stores. Our goal is to establish an international brand on enzymes products
with high quality and name recognition. With our competitive strengths discussed below, we expect to become a major player in
dietary supplements industry and grow into an internationally recognized brand on enzymes products.
We currently have a limited line of enzymes
products, consisting of five-phases enzymes products. We've been marketing the five enzymes products in one package to our
customers, as we have deliberately designed the formula for each of them to contain ingredients, especially certain Chinese traditional
medicine, allegedly with corresponding nutritional effect on each of five key organs of human bodies, namely, heart, liver, stomach,
lung and kidney. Each of the above-mentioned enzymes products, other than the water enzymes product, requires over 60 different
ingredients, which is substantially more than those in similar enzymes products distributed in Taiwan. Furthermore, we specifically
instructed our manufacturer to apply a six-stage fermentation manufacturing process on all of our enzymes products. Though the
production cycle for our enzymes products usually take approximately fourteen months, almost twice the time period for similar
enzymes products manufactured with one-stage traditional method in Taiwan, it creates the unique feature as well as superior quality
in certain key parameters of our enzymes products.
Our enzymes products fall into the dietary
supplements category and are solely for human consumption. To ensure the safety of our enzymes products, we have selected Bioenergy
Biotechnology Corp., one of the well-established Taiwanese companies specializing on enzymes production and with both International
Organization for Standardization (ISO) 9001: 2008 and Hazard Analysis Critical Control Point (HACCP) certifications, to be our
manufacturer. In addition, substantially all of raw material ingredients for our enzymes products are from local plantations in
Taiwan, where the climate, soil and environment are most suitable for the growing of such ingredients. Furthermore, to effectively
monitor quality of our enzymes products, we have voluntarily submitted sampled products in each manufacturing batch to well-recognized
inspection agencies, such as SGS, on a regular basis and implemented our Dr. Chip Biotech Examination, where micro-chip will be
pre-installed into to sampled products for later inspection, to ensure that there's no dead bacteria generated during the
manufacturing process.
Going Concern
The consolidated financial statements included elsewhere in
this Form S-1 have been prepared in conformity with accounting principles generally accepted in the United States of America,
which contemplate continuation as a going concern. We have an accumulated deficit of $29,391, as of December 31, 2012 and have
used cash in operations of $84,992 from our inception to December 31, 2012. These conditions raise substantial doubt as to our
ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result
from the outcome of this uncertainty. The consolidated financial statements do not include any adjustments relating to the recoverability
and classification of recorded asset amounts, or amounts and classification of liabilities that might be necessary should we be
unable to continue as a going concern. We are planning to open a retail location in a shopping mall in the coming months to create
brand image and brand awareness and are currently negotiating an agency agreement with an insurance company in Taiwan. Major shareholders
will continue to fund the Company until it is able to sustain positive cash flows from operations.
20
Results of Operations
From our inception (April 12, 2012) to December 31, 2012, we
had revenue and cost of revenue of $21,502 and $8,933, respectively. Our gross margin was $12,569 or 58.5% of revenue. We also
incurred selling expenses and general and administrative expenses of $5,153 and $36,883, respectively. Our net loss from our inception
(April 12, 2012) to December 31, 2012 was $29,391. As we have only commenced operation since April 2012, we anticipate that our
revenues will increase significantly in 2013 as compared to 2012.
Liquidity and Capital Resources
On July 16, 2012, we raised $100,000 from the sale of 12,500,000
shares of our common stock that was been used to fund our operations. As of December 31, 2012, we had cash on hand of $16,302.
We used $84,992 of cash in our operations which was principally
related to our net loss and the build-up of inventory.
As we are just commencing our operations,
we plan to fund our operations from loans from our major shareholders and we plan to raise equity capital by offering shares of
our common stock to investors. Over the next 12 months, we plan on opening three self-operated stores. One planned location is
located in Jet's Burg Mall Tianmoo Taipei.
The estimated budget of our operation
expenses over the next twelve months is as follows:
Salaries and benefits
$
3,360,000
Marketing
900,000
Mgt overhead
168,000
Professional fees
230,000
General overhead
230,000
$
4,888,000
We believe we will be able to raise the
necessary capital to carry out our business plan, but there is no guarantee that we will be able to do so.
Critical Accounting Policies
Our financial statements and related public
financial information are based on the application of accounting principles generally accepted in the United States ("US
GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles
that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental
information contained in our external disclosures including information regarding contingencies, risk and financial condition.
We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied.
We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances.
Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant
estimates made during the preparation of our financial statements.
21
We believe the following is among the
most critical accounting policies that impact our consolidated financial statements. We suggest that our significant accounting
policies, as described in our financial statements in the Summary of Significant Accounting Policies, be read in conjunction with
this Management's Discussion and Analysis of Financial Condition and Results of Operations.
Foreign Currency Translation
The accounts of the Taiwanese subsidiary are maintained in
the Taiwan Dollar ("Taiwan $") and the accounts of the U.S. parent company are maintained in the United States Dollar
("USD"). The accounts of the Taiwanese subsidiary are translated into USD in accordance with ASC Topic 830 "Foreign
Currency Matters," with the Taiwan $ as the functional currency for the Taiwanese subsidiary.
According
to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders' equity
is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the
period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220,
"Comprehensive Income." Gains and losses resulting from the translations of foreign currency transactions and balances
are reflected in the statement of operations.
Revenue Recognition
Our revenue recognition policies comply with SEC Staff Accounting
Bulletin 104 (codified in FASB ASC Topic 605). Sales revenue is recognized at the date of shipment to customers when a formal
arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations of ours exists
and collectability is reasonably assured. We provide sales incentive such as buy a dozen and get one free. We recognize the cost
of the free product at the time of sale. We do not provide unconditional return or any other sales incentives. Payments received
before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers.
Sales represent the invoiced value of products, net of value-added
tax ("VAT"). All of our products sold in Taiwan are subject to a value-added tax of 5% of the gross sales price. This
VAT may be offset by VAT paid by us on raw materials and other materials included in the cost of producing the finished product.
We record VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the
payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as we act as an agent for the
government.
Income Taxes
The Company accounts for income taxes
in accordance with ASC Topic 740, "Income Taxes." ASC 740 requires a company to use the asset and liability method
of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred
tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported
amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion
of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred
tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Under ASC 740, a tax position is recognized
as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50%
likely of being realized on examination. For tax positions not meeting the "more likely than not" test, no tax benefit
is recorded. The adoption had no effect on the Company's consolidated financial statements.
Recent Accounting Pronouncements
In May 2011, the FASB issued ASU 2011-04
to provide a consistent definition of FV and ensure the FV measurement and disclosure requirements are similar between US GAAP
and IFRS. ASU 2011-04 changes certain FV measurement principles and enhances the disclosure requirements particularly for Level
3 FV measurements.  This guidance was effective on January 1, 2012.  The adoption of ASU 2011-04 did not have a significant
impact on our consolidated financial statements.
22
In June 2011, the FASB issued ASU 2011-05,
Presentation of Comprehensive Income
. ASU 2011-05 revises the manner in which entities present comprehensive income in
their financial statements. The new guidance removes the presentation options in Accounting Standards Codification (ASC) 220,
Comprehensive Income
, and requires entities to report components of comprehensive income in either (1) a continuous
statement of comprehensive income or (2) two separate but consecutive statements. The new guidance does not change the items
that must be reported in other comprehensive income. In December 2011, the FASB issued ASU 2011-12 which defers the requirement
in ASU 2011-05 that companies present reclassification adjustments for each component of accumulated other comprehensive
income in both net income and other comprehensive income on the face of the financial statements. ASU 2011-05 is effective
for fiscal years and interim reporting periods within those years beginning after December 15, 2011, with early adoption
permitted. The adoption of ASU 2011-05, as amended by ASU 2011-12, did not have a significant impact on our consolidated
financial statements.
In September 2011, the FASB issued ASU 2011-08
which provides an entity the option to first assess qualitative factors to determine whether it is necessary to perform the two-step
test for goodwill impairment.  If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not
the FV of a reporting unit is less than its carrying amount, the quantitative impairment test is required.  Otherwise,
no further testing is required. The revised standard is effective for the Company for its annual and interim goodwill impairment
tests performed for fiscal years beginning after December 15, 2011.  The adoption of ASU 2011-08 did not significantly
impact our consolidated financial statements.
In July 2012, the FASB issued ASU 2012-02,
Intangibles-Goodwill and Other (Topic 350) - Testing Indefinite-Lived Intangible Assets for Impairment.  The ASU provides
entities with an option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely
than not the indefinite-lived intangible asset is impaired.  If an entity concludes it is more than 50% likely that an indefinite-lived
intangible asset is not impaired, no further analysis is required.  However, if an entity concludes otherwise, it would be
required to determine the FV of the indefinite-lived intangible asset to measure the amount of impairment, if any, as currently
required under US GAAP. The ASU is effective for annual and interim impairment tests performed for fiscal years beginning after
September 15, 2012.  Early adoption is permitted.
The adoption of this pronouncement will not
have a material impact on our financial statements.
Off-Balance Sheet Arrangements
None.
23
BUSINESS
We are a development stage company focusing
on the sales and distribution of enzymes products manufactured in Taiwan to public consumers across Taiwan, and we intend to commence
business operations by distributing and exporting our enzymes products to Hong Kong, mainland China, Singapore and Malaysia in
2013. Our primary current sales channel is through telephone selling and we intend to utilize a combination of various marketing
channels, including, without limitation, telephone sales, self-operated retail stores in and out of Taiwan, special counters located
in big shopping malls, third-party sales agents, e-commerce, sales on TV shopping channels and corporate strategic partnerships
and alliances. Our goal is to establish an international brand on enzymes products with high quality and name recognition. With
our competitive strengths discussed below, we expect to become a major player in dietary supplements industry and grow into an
internationally recognized brand on enzymes products.
We currently have a limited line of enzymes
products, consisting of five-phases enzymes products. We've been marketing the five enzymes products in one package to our
customers, as we have deliberately designed the formula for each of them to contain ingredients, especially certain Chinese traditional
medicine, allegedly with corresponding nutritional effect on each of five key organs of human bodies, namely, heart, liver, stomach,
lung and kidney. Each of the above-mentioned enzymes products, other than the water enzymes product, requires over 60 different
ingredients, which is substantially more than those in similar enzymes products distributed in Taiwan. Furthermore, we specifically
instructed our manufacturer to apply a six-stage fermentation manufacturing process on all of our enzymes products. Though the
production cycle for our enzymes products usually take approximately fourteen months, almost twice the time period for similar
enzymes products manufactured with one-stage traditional method in Taiwan, it creates the unique feature as well as superior quality
in certain key parameters of our enzymes products.
Our enzymes products fall into the dietary
supplements category and are solely for human consumption. To ensure the safety of our enzymes products, we have selected Bioenergy
Biotechnology Corp., one of the well-established Taiwanese companies specializing on enzymes production and with both International
Organization for Standardization (ISO) 9001: 2008 and Hazard Analysis Critical Control Point (HACCP) certifications, to be our
manufacturer. In addition, substantially all of raw material ingredients for our enzymes products are from local plantations in
Taiwan, where the climate, soil and environment are most suitable for the growing of such ingredients. Furthermore, to effectively
monitor quality of our enzymes products, we have voluntarily submitted sampled products in each manufacturing batch to well-recognized
inspection agencies, such as SGS, on a regular basis and implemented our Dr. Chip Biotech Examination, where micro-chip will be
pre-installed into to sampled products for later inspection, to ensure that there's no dead bacteria generated during the
manufacturing process.
We believe that the innovation and timely
introduction of new products is essential to catch the constantly changing consumption trend of our existing or potential customers.
As we are still at our early start-up stage, we do not have any information system or team for that matter now. We have maintained
close connections with National Pingtung University of Science and Technology ("NPUST"), a well-recognized university
in Taiwan, since our incorporation. In fact, we are currently cooperating with NPUST on a joint program focusing
on improving enterprise management and brand development of Yambear. Pursuant to this program, NPUST will commit its experienced
academic team to assist us with respect to the enterprise management and brand establishment.
We have established our business operation
within the Pingtung Agricultural Biotechnology Park, one and only bio-tech park established in Taiwan focusing on bio-tech agricultural
products, which is also located within the affinity of NPUST. We are currently cooperating with NPUST on a joint program focusing
on improving enterprise management and brand development, which, once approved by Department of Education of Taiwan, will be available
for government subsidies. Pursuant to this program, NPUST will commit its experienced academic team to assist us with respect
to the enterprise management and brand establishment. On November 1, 2012, we rented our current office and intend to use it as
our research and development center ("R&D Center") for our pipeline products in the future. From time to time,
we will recruit professional bio-tech personnel to work full time in our R&D Center.
24
We believe that our commitment to products
quality and investment in products research and development, combined with our multiple marketing channels, will enable us to
provide our customers with a unique shopping experience that will be distinct from our competitors and give us competitive advantage
to gradually grow into a well-recognized business.
We've generated revenues in the
amount of $21,502 for the period from inception (April 12, 2012) to December 31, 2012. We are not making any profit so far.
Unless context indicates otherwise, reference
to the "Company" throughout this prospectus refers to Yambear and Yambear Taiwan.
As a holding company with no business
other than holding equity interest of our operating subsidiary in Taiwan, Yambear Taiwan, we rely principally on dividends to
be paid by Yambear Taiwan.
Company Structure
Yambear was incorporated on April 12,
2012 under the laws of the state of Delaware by Hsin-Lung Lin, a Taiwanese citizen. Our executive office is located at 3F., No.
10, Yuanxi 2
nd
. Rd., Pingtung Agricultural Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of
China. Our telephone number is +00886 08 7621913.
Our
wholly owned subsidiary, Yambear Bio-technology Co., Ltd. (
番薯熊生技事业有限公司
)
("Yambear Taiwan") was founded on August 17, 2012 in Taiwan, the Republic of China. The registered capital of Yambear
Taiwan, in the amount of $96,386 (NT$2.8 million) has been fully contributed and we expect to invest another $592,083(NT$17.2
million) in the coming years.
On July 16, 2012, Yambear issued 12,500,000
shares of common stock, $0.0001 par value per share, to several non U.S. persons for their investment of $100,000 in cash in the
Company, among which, $93,560 has been contributed into Yambear Taiwan on July 19, 2012, the operating company in Taiwan, as registered
capital. The issuance was made pursuant to an exemption from registration contained in Regulation S under the Securities Act of
1933, as amended.
The following flow chart illustrates our
Company's organizational structure:
25
Industry and Market Overview
Enzymes products business is a rising
industry in Taiwan. According to the Strategies and Plans of Agricultural Bio-technology Industry published by Taiwan Institute
of Economic Research on December 31, 2005, the value for imported enzymes products (including industrial and dietary use) reached
$22,719,449 (NT$660 million) for the year 2005 and the domestic production value is $8,605,852 (NT$250 million). In 2002, the
value of global enzymes production (including dietary and feeding use) reached $1.176 billion.. According to the Global Markets
for Enzymes in Industrial Applications published by BCC Research on April 24, 2012, the market size for the global enzymes industry
is $3.9 billion in 2011. It is expected that the whole market size for global enzymes industry will increase to $6.1 billion by
the year of 2016. With ever-increasing pressures in modern life and people's growing awareness and pursuit to healthy life,
we anticipate that enzymes business will continue to prosper in a foreseeable future.
The enzymes business in Taiwan is subject
to fierce competition, especially for new players. The market share is largely dominated by two well-established companies and
many smaller companies competing for the remaining share. We expect competition to persist and intensify. We believe that our
commitment to products quality and investment in products research and development, combined with our multiple marketing channels,
will enable us to provide our customers with a unique shopping experience that will be distinct from our competitors and give
us competitive advantage to gradually capturing our market share in the future. Based on our understanding of the enzymes products
market, we expect several key demographic and lifestyle trends to drive the continued growth of enzymes industry. These trends
include:
Increasing awareness of enzymes products
benefits.
We believe that awareness of dietary supplement benefits, including those of enzymes products,
will continue rising as more and more people nowadays are paying more attention to the health and quality of life. Taiwan is relatively
small market with only over 23 million population, yet it has already attracted well-established companies as well as multiple
new entrants providing various enzymes products to the local market. Enzymes industry in Taiwan is still at its developing stage.
We believe as the local customers become more and more familiar to and knowledgeable about the enzymes products, they are likely
to appreciate more and more of enzymes products with high quality. We have also noticed that the historical trend in Taiwan of
enzymes products seems to repeat itself in mainland China and other potential markets with substantial higher potentials for dietary
supplements. We expect our competitive strength to distinguish our enzymes products and increase our market share in Taiwan as
well as those emerging markets.
Increasing appeal of enzymes products
across younger population
.    Currently we are targeting middle class individuals and family members within
the range of 35 - 50 years age. With the development of modern society and ever-increasing awareness and pursuit to healthier
lifestyle, we anticipate that more and more younger populations will start purchasing enzymes products, expanding the foundation
of our customer base for the future. In addition, we have also noticed that younger customers are more likely to continuously
purchase enzymes products once they like it, and generally have higher levels of disposable income to pursue healthier lifestyles.
Competitive Strengths
We believe that we are well-positioned
to capitalize on the favorable enzymes industry trends as a result of the following competitive strengths:
Unique product offerings.
Our current enzymes products line only
consists of five-phases enzymes products. The formulas of these five basic products have been the achievements of joint efforts
of our staffs teamed up with certain specialists, who have dedicated most of their leisure time to research. In addition to the
basic ingredients for enzymes products, we have added certain Chinese traditional medicine, allegedly with corresponding nutritional
effect on each of five key organs of human bodies, namely, heart, liver, stomach, lung and kidney, to each of our five enzymes
products. Therefore, each of the above-mentioned enzymes products, other than the water enzymes product, requires over 60 different
ingredients, which is substantially more than those in similar enzymes products distributed in Taiwan.
To ensure the high quality of our enzymes
products, we have selected a local enzymes manufacturer Bioenergy, one of the well-established Taiwanese companies specializing
on enzymes production and with both International Organization for Standardization (ISO) 9001: 2008 and Hazard Analysis Critical
Control Point (HACCP) certifications, to be the manufacturer of our enzymes products. Substantially all of raw material ingredients
used for our enzymes products are from local plantations in Taiwan, where the climate, soil and environment are most suitable
for the growing of such ingredients. Furthermore, to effectively monitor quality of our enzymes products, we have voluntarily
submitted sampled products in each manufacturing batch to well-recognized inspection agencies, such as SGS, on a regular basis
and implemented our Dr. Chip Biotech Examination, where micro-chip will be pre-installed into to sampled products for later inspection,
to ensure that there's no dead bacteria generated during the manufacturing process.
26
Furthermore, we specifically instructed
our manufacturer Bioenergy to apply a six-stage fermentation manufacturing process and the smashed raw materials for all of our
enzymes products. Though the production cycle for our enzymes products usually take two years, almost twice the time period for
similar enzymes products in Taiwan, it creates the unique feature as well as superior quality in certain key parameters of our
enzymes products.
Research and Development.
Product innovation is critical to our
growth, brand image superiority and competitive advantage. We have rented our current office and intend to use it as our research
and development center ("R&D Center") for our pipeline products in the future. After our R&D Center is fully
established, our research and development team will focus on the development and formulation of proprietary supplements of high
growth categories. We will seek to maintain the pace of Yambear's proprietary products innovation to get ahead of our competitors
and attract consumers with our newly-introduced products from time to time. Our in-house research and development team, once recruited,
will be able to commit all of their time and energy on products development, so as to enable us to quickly take a concept for
a new product from the idea stage, to product development, testing and trials, and ultimately to the shelf to be sold to our customers.
For the new products development, we will
make a quarterly review of our product line and get feedback from our customers. Based on such data and statistics, we shall determine
whether one or more new products are needed. Once we determine that new products are needed, our research and development team
will start their research work and develop new products to adapt to the changing requirement in the market.
Multiple marketing channels
Our multi-channel approach is unlike many
other competitors as we expect to derive revenues across a combination of distribution channels in multiple geographies, including
retail sales from self-operated retail stores, retail sales in big shopping centers, retail sales from yambear.com, sales on TV
shopping channels and revenue from third-party sales agents in different countries.
Our diverse sources of revenue will help
provide stability to our earnings and provide management numerous avenues through which they can pursue growth opportunities.
We are currently approaching certain candidates
who are specialized in sales and marketing, some of whom has more than thirty years experience in sales and marketing. Once these
people are formally recruited, we are going to have systematic training over our sales associates. We are aiming to have our sales
associates well-trained and capable of offering educated service and trusted advice to our customers. We will invest considerable
capital and human resources in providing comprehensive associate training. We expect that our expansive retail network, differentiated
products offering and quality customer service shall result in a unique shopping experience.
We are a development stage company. We
expect that with our commitment to products quality and investment in products research and development, combined with our multiple
marketing channels, Yambear will gradually grow into a well known brand in enzymes products industry and provide more and more
healthy, high quality, unique enzymes products to our customers in the future.
Our Growth Strategy
We plan to execute several strategies
in the future to promote growth in revenue and operating income, and capture market share, including:
We intend to take a series of activities
to stimulate the increase of our revenue and the growth of our business. These activities include the following aspects:
27
Building up our research and development
team and expand our line of products.
We currently do not have any full-time research and development team, but we've
managed to cooperate with certain specialists, through their leisure time, to jointly develop our products. We intend to recruit
these specialists along with the growth of our Company, subsequent to which, they will be able to commit all of their time and
energy on products development, so as to enable us to quickly take a concept for a new product from the idea stage, to product
development, testing and trials, and ultimately to the shelf to be sold to our customers. Our present offering of enzymes products
are fairly limited, and the nature of dietary supplements industry require the capability of the players to timely respond to
constant change of trend of customers and continuously offer a variety of products to attract all types of consumer groups. On
November 1, 2012, we leased approximately 572 square meters office space in Pingtung Agriculture Biotechnology Park, which is
within the affinity of NPUST. We are in the process of decorating this office into a research and development center, where we
will deploy our full-time research and development team to conduct experiments and develop our new products. Research and development
will always be an significant part of our business strategy in the long run.
Exploring multiple marketing channels
and expanding our sales and distribution network
. We intend to distribute and market our enzymes products to high-end consumers
by exploring a variety of marketing channels, including, without limitation, telephone sales, TV sales, as well as selling in
special counters located in big shopping malls and our self-operated stores. We expect to open a self-operated store in Taiwan
in 2013. We will recruit personnel specialized in sales and marketing and deploy them in key positions to lead our multiple marketing
channels.
Initiating promotional activities and
brand establishing
. Our promotion and brand establishing will primarily consist of the following parts: (i) we will enhance
the promotional functions of our official website and Yambear's facebook interface; (ii) we will explore a series of direct
promotional activities, such as free electronic mails, direct staff promotion, on-site store promotion, etc., (iii) we will invest
in advertisement through both traditional print media and Internet media; (iv) we will introduce special promotional sales events
on Chinese traditional holidays, such as the Dragon Boat Festival, the Mid-Autumn Festival and the Spring Festival; and (v) we
will apply for trademarks in the foreign markets where we will sell our enzymes products, to strengthen our brand recognition
and management.
Other than the above-mentioned internal
growth plan, we are also considering to set up strategic cooperation relationships in foreign markets, in particular, mainland
China, Hong Kong, Singapore and Malaysia. The strategic cooperation could be in the manner of sales agent on provincial or district
level, joint ventures, or other forms of alliance. After our business is materialized in such foreign markets, we will also consider
setting up branches or subsidiaries there.
New product lines
. We currently
have four new enzymes products in the testing stage, namely, (i) slimming enzymes product, designed for the consumers desiring
to lose weight; (ii) nerves-soothing enzymes product, designed for the consumers under high pressures and seeking tranquilization
effect; (iii) special enzymes product for the senior (stomach improvement effect), designed for the aged consumers with stomach
issues; and (iv) special enzymes product for the senior (joint improvement effect), designed for aged consumers with arthralgia
issues, all anticipated to be launched in the first quarter of 2013.
Other than the four new enzymes products
mentioned above, we are researching and developing another new enzymes product, enzymes facial mask, which is designed for high-end
female consumers in Taiwan. We believe that these high-end female consumers prefer a more healthy and effective way to pursue
beauty. We are also planning to expand our business in SPA industry under the same conception of facilitating female consumers
a more healthy and effective way to pursue beauty. In addition, we are exploring the possibility of an unique product, enzymes
coffee, all of these products are expected to be launched in first quarter of 2013.
Business Overview
Sales Channel
On November 1, 2012, we entered into a
cooperation agreement with Fitness & Beauty Corporation Limited (the "Fitness"), pursuant to which the Fitness
will be the exclusive distributor of Yambear products in China (including Hong Kong and Macau) through the following distribution
channels: (i) fitness clubs, (ii) facial and body SPA chain stores, and (ii) tea chain stores. Pursuant to such cooperation agreement,
the Fitness shall purchase a minimum of 5000 bottles of our five-phases enzymes products annually. The term of the cooperation
is two years.
28
Other than the cooperation agreement mentioned
above and the sales by hotlines, we have not started other sales channels so far.
Website
Currently our Yambear Taiwan's website
yambear.com only has the functions of presenting our enzymes products, brief introduction to Yambear Taiwan and contact information.
Our customers may place purchase orders through our selling hotlines specified on our website.
Manufacturing, Distribution Network
and Marketing
Our strategy is to focus on research and
development, distribution network and brand establishment, while outsourcing the whole manufacturing process to third party manufacturers.
To ensure the quality of our enzymes products, we are quite selective and strict when it comes to the engagement of our outsourced
manufacturers. As of December 31, 2012, we have outsourced the manufacturing of all of our enzymes products to Bioenergy Biotechnology
Corp., one of the well-established Taiwanese companies specializing on enzymes production and with both International Organization
for Standardization (ISO) 9001: 2008 and Hazard Analysis Critical Control Point (HACCP) certifications, To the knowledge of our
management team, there are several enzymes products manufactures in Taiwan competent for our manufacturing needs. In case there
is any a change or termination of the cooperation with our current manufacturer, we believe it is not difficult to find a replacement.
We have not yet devoted substantial resources in building up our distribution network and we intend to do so along with the development
and expansion of our business. Please refer to Our Growth Strategy section for details of our future sales and marketing strategies.
Customers
We are targeting middle class individuals
and their family members in the range of 35 - 50 years age to be our priority clients. All of our revenues are generated from
the sale of our enzymes products and we expect the continuous growth in this regard. However, we are also expecting an expansion
of our customer base. As discussed in details in Industry and Market Overview, we are hoping that younger population will grow
into another pillar for our customer base.
Manufacturing
All of our enzymes products are being
manufactured by a Taiwan local company, Bioenergy Biotechnology Corp. ("Bioenergy") pursuant to the orders we place
to them. Bienergy is one of the biggest enzymes products manufacturers in Taiwan and we've started our cooperation with
Bioenergy since our incorporation. Other than producing our enzymes products, Bioenergy also produces and sells enzymes products
of their own. Due to the different products positioning, our management team does not view the enzymes products of Bioenergy as
competitive to our own enzymes products. We've entered into confidential agreement with Bioenergy to prevent them from disclosing
our formula to the public or any third party or exploit it for its self-benefit.
Competition
The enzymes business in Taiwan is highly
fragmented by some major enzymes companies, among which two enzymes companies, Yamato Enzyme Co., Ltd. and Biozyme Biotechnology
Corp., have captured a dominating share of the market, while the other smaller enzymes companies competing for the remaining share.
Given the fact that we are a development stage company, our primary competitors are Sunmei Co. Ltd. (McHall's) Hsuan Yong
Biotechnology Co., Ltd. and One Power Biotechnology Co., Ltd. Competition in this market revolves around price, quality and reputation.
If we could properly execute our growth strategy and maintain our competitive strength, we believe that we could expand our market
share and gradually grow into a well-recognized brand name.
29
Insurance
We have purchased a product liability
insurance with a coverage of $688,468 (NT$20 million) from MSIG Mingtai Insurance Co., Ltd., a member of MS & AD Insurance
Group. The insurance policy is for a one-year term commencing from September 20, 2012 till September 20, 2013. We have also purchased
social insurance for all of our employees pursuant to the mandatory requirement of Taiwan laws and regulations.
Products and Services
We currently have a limited line of enzymes
products, consisting of five-phases enzymes products. We've been marketing the five enzymes products in one package to our
customers, as we have deliberately designed the formula for each of them to contain ingredients, especially certain Chinese traditional
medicine, allegedly with corresponding nutritional effect on each of five key organs of human bodies, namely, heart, liver, stomach,
lung and kidney. Each of the above-mentioned enzymes products, other than the water enzymes product, requires over 60 different
ingredients, which is substantially more than those in similar enzymes products distributed in Taiwan. Furthermore, we specifically
instructed our manufacturer to apply a six-stage fermentation manufacturing process on all of our enzymes products. Though the
production cycle for our enzymes products usually take approximately fourteen months, almost twice the time period for similar
enzymes products manufactured with one-stage traditional method in Taiwan, it creates the unique feature as well as superior quality
in certain key parameters of our enzymes products.
One of the unique features of our enzymes
products is that we have combined Chinese traditional medicine concept "Five Fundamental Elements", namely, gold,
wood, water, fire and earth, with our enzymes products. The Five Fundamental Elements concept is a well-known concept in Chinese
culture, where it believes that each element represents and corresponds to a key organ in our bodies. Therefore, in addition to
the basic ingredients used for enzymes products, we also added certain Chinese herbs with special effect on improvement and reconciliation
of function for the corresponded organs. The formula for each of our enzymes products is the result of extensive research and
experiments conducted by our staffs teamed up with certain specialists. Details of our five enzymes products are illustrated as
follows:
YAMIGO Five-phases Enzymes –
Metal
30
We do not manufacture
the above enzyme product.  It is specifically formulated for our distribution.  It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.  The brand name "YAMIGO Five-phases
- Metal" belongs to us, and the trademark applications for "YAMIGO" has been filed in Taiwan and Mainland China. 
We currently market this product as one of the Five-phases series package, but we also sell this product alone. We have earned
revenues of $2,304.06 (NT$66,933) from the sale of it during the
period from inception (April 12, 2012) to
December
31, 2012.
Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds to one of the five key
organs of human bodies. This enzyme product contains over 60 different ingredients, which is substantially more than those in
similar enzyme products distributed in Taiwan. Other than the enzymes fluids extracted from fruit and vegetables, such as yam,
sweet potato, pumpkin, eggplant, black bean, we have deliberately designed the formula for this product to contain certain Chinese
traditional herbs, such as wolfberry, chuan qiong, poria, licorice, angelia, atracylodes, tangerine, which, according to the Chinese
traditional medicine theory, are allegedly with corresponding nutritional effect on improvement of lung functions.
This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.
YAMIGO Five-phases Enzymes –
Wood
We do not manufacture
the above enzyme product.  It is specifically formulated for our distribution.  It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.  The brand name "YAMIGO Five-phases
– Wood" belongs to us, and the trademark applications for "YAMIGO" has been filed in Taiwan and Mainland
China.  We currently market this product as one of the Five-phases series package, but we also sell this product alone. We
have earned revenues of $6,619.83 (NT$192,306) from the sale of it during the
period from inception (April 12, 2012) to
December 31, 2012.
31
Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds with one of the five key
organs of human bodies. This enzyme product contains over 60 different ingredients, which is substantially more than those in
similar enzyme products distributed in Taiwan. Other than the enzymes fluids extracted from fruit and vegetables, such as yam,
sweet potato, pumpkin, eggplant, balck bean, lemon, grape, we have deliberately designed the formula for this product to contain
certain Chinese traditional herbs, such as wolfberry, chuan qiong, poria, licorice, angelia, atracylodes, tangerine peel, antrodia
cinnamomea, which, according to the Chinese traditional medicine theory, are allegedly with corresponding nutritional effect on
improvement of liver functions.
This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.
YAMIGO Five-phases Enzymes –
Water
We do not manufacture
the above enzyme product.  It is specifically formulated for our distribution.  It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.  The brand name "YAMIGO Five-phases
- Water" belongs to us, and the trademark applications for "YAMIGO" has been filed in Taiwan and Mainland China. 
We currently market this product as one of the Five-phases series package, but we also sell this product alone. We have earned
revenues of $4,128.85 (NT$119,943
)
from the sale of it during the
period from inception
(April 12, 2012) to
December 31, 2012.
Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds with one of the five key
organs of human bodies. This enzyme product is primarily made of pineapple enzymes fluids, glucosamine and collagen. We have deliberately
designed the formula, according to the Chinese traditional medicine theory, allegedly to have corresponding nutritional effect
on improvement of kidney functions.
This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.
32
YAMIGO Five-phases Enzymes –
Fire
We do not manufacture
the above enzyme product.  It is specifically formulated for our distribution.  It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.  The brand name "YAMIGO Five-phases
– Fire" belongs to us, and the trademark applications for "YAMIGO" has been filed in Taiwan and Mainland
China.  We currently market this product as one of the Five-phases series package, but we also sell this product alone. We
have earned revenues of $3,195.77 (NT$92,837) from the sale of it during the
period from inception (April 12, 2012) to
December 31, 2012.
Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds with one of the five key
organs of human bodies. This enzyme product contains over 60 different ingredients, which is substantially more than those in
similar enzyme products distributed in Taiwan. Other than the enzymes fluids extracted from fruit and vegetables, such as eggplant,
bitter gourd, melon, pumpkin, spinach, black bean, grapefruit, litchi, we have deliberately designed the formula for this product
to contain certain Chinese traditional herbs, such as rhodiola, jujube fine, black currant extract, glycine ferrous, and plant
collagen, which, according to the Chinese traditional medicine theory, are allegedly with corresponding nutritional effect on
improvement of heart functions.
This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.
33
YAMIGO Five-phases Enzymes –
Earth
We do not manufacture
the above enzyme product.  It is specifically formulated for our distribution.  It is packed under our private label
pursuant to the contractual manufacturing arrangements with Bioenergy Biotechnology Corp.  The brand name "YAMIGO Five-phases
– Earth" belongs to us, and the trademark applications for "YAMIGO" has been filed in Taiwan and Mainland
China.  We currently market this product as one of the Five-phases series package, but we also sell this product alone. We
have earned revenues of $4,300.55 (NT$124,931) from the sale of it during the
period from inception (April 12, 2012) to
December 31, 2012.
Our enzyme products are designed through
strict and extensive scientific researches as well as on the basis of Chinese traditional medicine Five-phases philosophy. Under
the Five-phases theory, each of the Five-phases, i.e., metal, wood, water, fire and earth, corresponds with one of the five key
organs of human bodies. This enzyme product contains over 60 different ingredients, which is substantially more than those in
similar enzyme products distributed in Taiwan. Other than the enzymes fluids extracted from fruit and vegetables ingredients,
such as black bean, pumpkin, spinach, cantaloupe, grape, potato, bitter gourd, eggplant, we have deliberately designed the formula
for this product to contain certain Chinese traditional herbs, such as atractylodes, poria, licorice, dandelion, pinellia ternata,
which, according to the Chinese traditional medicine theory, are allegedly with corresponding nutritional effect on improvement
of stomach and stomach functions.
This enzyme product is currently packaged
in glass bottles with a volume of 720 ml, roughly good for adult usage for four weeks.
In summary, our YAMIGO – Five-phases
enzyme products, namely Metal, Wood, Water, Fire and Earth, are displayed below:
34
We also have small package of the above
Five-phases enzymes products. The small package is designed for trial purchase. If the customers like our products, we expect
them to purchase big package products which are more cost-effective. The small package of Five-phases enzymes products are displayed
below, with 50 ml for each bottle.
We will make a quarterly review of our
product line and get feedback from our customers. Based on such data and statistics, we shall determine whether one or more new
products are needed. Once we determine that new products are needed, our research and development team will start their research
work.
Other than the five basic enzymes products
we are selling, we are also conducting an on-going new products research and development. We currently have four new enzymes products
in the testing stage, namely, (i) slimming enzymes product, designed for the consumers desiring to lose weight; (ii) nerves-soothing
enzymes product, designed for the consumers under high pressures and seeking tranquilization effect; (iii) special enzymes product
for the senior (stomach improvement effect), designed for the aged consumers with stomach issues; and (iv) special enzymes product
for the senior (joint improvement effect), designed for aged consumers with arthralgia issues, all anticipated to be launched
in the first quarter of 2013.
35
Other than the four new enzymes products
mentioned above, we are researching and developing another new enzymes product, enzymes facial mask, which is designed for high-end
female consumers in Taiwan. We believe that these high-end female consumers prefer a more healthy and effective way to pursue
beauty. We are also planning to expand our business in SPA industry under the same conception of facilitating female consumers
a more healthy and effective way to pursue beauty. In addition, we are exploring the possibility of a unique product, enzymes
coffee, all of these products are expected to be launched in first quarter of 2013.
We are providing full time, 24 hours per
day and seven days per week, hotline services. Our hotline receptionists are well trained with a comprehensive knowledge of our
products to address any of the Customers' enquiries about our products or take their orders over our hotline.
We intend to open special counters in
big shopping malls, serving as both an exhibition center as well as an education center for our products, where customers or potential
customers could have a more intuitive observation on and experience with all of our enzymes products. Meanwhile, our well-trained
staffs in such special counters could introduce our enzymes products to them more effectively.
Intellectual Property
We are currently applying for certain
trademarks both in Taiwan and in mainland China. Please refer to the following chart illustrating our trademarks application details:
Trademark
Categories
Status
Jurisdiction
35
Application filed on
September 5, 2012
Taiwan
05
Application filed on
September 5, 2012
Taiwan
36
05
Application filed on
September
    5, 2012
Taiwan
05
Application filed on
September 5, 2012
Taiwan
Trademark
Categories
Status
Jurisdiction
35
Application filed on
February 6, 2013
Chian Mainland
Yamigo
05
Application filed on
February 6, 2013
Chian Mainland
Yambear
35
Application filed on
February 6, 2013
Chian Mainland
Other than the trademark applications
described above, we may also apply trademarks in other jurisdictions where we are going to expand our business.
37
Our Taiwan subsidiary, Yambear Taiwan,
owns the domain name yambear.com.
We do not have patent rights regarding
the formula of our enzymes products since the formula, manufacturing process may not be patentable in the jurisdiction where we
conduct our business. Though some formula and manufacturing process may be patentable, we have determined that our business interests
are better served by trying to protect them as trade secrets or confidential information. We rely heavily on trade secret protection
and confidentiality agreements rather than patent laws to protect our rights in these formulas, manufacturing process, know-how
and data. We have taken a series of measures to keep the confidentiality of our formula, including entering into confidential
agreement with our employees and cooperation partners, segregating of duties among personnel involved in different stages of its
production process. This segregation reduces the risk that a breach of these protections by any single staff member would result
in a leakage of the entire production process of our enzymes products. We also implement other precautions, such as internal document
controls and network assurance procedures.
Research and Development Expenditures
We currently do not have any full-time
research and development team, but we've managed to cooperate with certain specialists, through their leisure time, to jointly
develop our products. We intend to recruit these specialists along with the growth of our Company, subsequent to which, they will
be able to commit all of their time and energy on products development, so as to enable us to quickly take a concept for a new
product from the idea stage, to product development, testing and trials, and ultimately to the shelf to be sold to our customers..
On November 1, 2012, we leased approximately 572 square meters office space in Pingtung Agriculture Biotechnology Park, which
is within the affinity of NPUST. We are in the process of decorating this office into a research and development center, where
we will deploy our full-time research and development team to conduct experiments and develop our new products.
Our current practice for research and
development is that we will make a quarterly review of our product line and get feedback from our customers. Based on such data
and statistics, we shall determine whether one or more new products are needed. Once we determine that new products are needed,
our research and development team will start their research work. Usually a new product requires one quarter a two quarters finishing
the research work. We anticipate that the cost is mostly in the range of $5,000 to $10,000 for the research and development of
each new product.
We have researched and developed certain
new enzymes products, among which, four are in the testing stage, namely, slimming enzymes product, nerves-soothing enzymes product,
special enzymes product for the senior (stomach improvement effect) and for the senior (joint improvement effect). We have invested
approximately $5,000 for each of the above-mentioned products. Other than the four new enzymes products mentioned above, we are
in the process of researching and developing other new enzymes products, enzymes facial mask and enzymes coffee, on which we have
invested approximately $5,000 and $10,000 respectively.
Research and development will always be
a significant part of our business strategy in the long run.
Employees
We currently have three employees to whom
we are paying salaries or other compensation, the chief executive officer, the head of human resources and the director of accounting.
Other than these three employees, we have certain part-time employees, who are shareholders of the Company, who do not receive
compensation. Depending on the business needs, we intend to recruit some additional full-time employees in the future.
All
of the Company's employees are employed by the Company's subsidiary Yambear Taiwan.
Stock Option Plan
As of December 31, 2012,
w
e do
not have any stock option plan.
38
Properties
Our business office is located at 3F.,
No.10, Yuanxi 2nd Rd., Pingtung Agriculture Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of China. Our
telephone number is +00886 08 7621913. We are paying a monthly rent of $1,669 (NT$48,480) for our office. Our offices occupy approximately
572 square meters. The term of the lease is two years, commencing from November 1, 2012 to October 31, 2014.
We are a development stage company with
very little assets.
Subsidiaries
Yambear Taiwan is the only wholly owned
subsidiary of Yambear. Other than that, Yambear does not own any subsidiary for the time being. We are considering establishing
branches or subsidiaries in mainland China, Hong Kong, Singapore and Malaysia with the expansion and development of our business
in the future.
Legal Proceedings
We are not currently a party to any legal
proceedings. Our address for service of process in Delaware is Suite 806, 1220 N. Market Street, Wilmington, DE 19801, County
of New Castle.
Regulation
Regulations of the Enzymes Industry
Taiwan Regulation on Consumer Protection
The current primary regulation protecting
consumers' rights in Taiwan is Consumer Protection Law, latest amended on February 5, 2005 (the "CP Law"), with a view
to better regulate the conduct of business operators and enforce consumer protection. The Industry Competent Authority at various
levels of the administration is responsible for the enforcement and supervision on any consumer protection related matters.
Pursuant to the CP Law, business operators
providing goods and services shall attach great value to consumers' health and safety, provide sufficient instruction on the goods
and services offered, maintain fairness of the trade and take any other necessary precautions to protect consumers' rights.
In addition, business operators who design, produce and manufacture goods or provide services shall guarantee that the goods or
services offered should meet the safety criteria which is reasonably expected from the technological and professional perspective
at the time of launching such goods or offering services in the market. In case of intentionally wrongdoings of the business operators,
punitive damages up to three times of the actual damage may be imposed against such business operators.
Taiwan Regulation on Food Sanitation
Management
The current primary regulation governing
food sanitation in Taiwan is the Food Sanitation Management Act, latest amended on August 8, 2012 (the "FSM Act"). The
Department of Health at various levels of the administration is responsible for the management and supervision on any food sanitation
related matters.
Under this FSM Act, any business operators
of food or food additives must obtain and maintain the proper licenses from relevant government authorities before they could
manufacture, process, deploy, package, transform, store, sell, import and export food or food additives. The licenses generally
have a valid duration from one year to five years, which is set by the relevant government authorities, and the application for
extension must be filed for approval within three months before expiration. The FSM Act also set forth specific rules demanding
the compliance with good hygienic practices and safety control system of food or food additives by the business operators.
39
General Regulations
Taiwan Regulation on Company Administration
The current primary regulation governing
companies in Taiwan is the Company Law, latest amended on January 16, 2013 by Legislative Yuan, which provided the fundamental
framework for regulating companies. The Ministry of Economic Affairs at various levels of the administration is responsible for
the management and supervision on any companies related matters.
Under the Company Law, a company refers
to any profit-driven juridical association, organized, registered and established in accordance with this Company Law. Under the
Company Law, companies have been divided into four categories: unlimited liability company, limited liability company, joint liability
company and company limited by shares.
Under the Company Law, a company cannot
be established unless properly registered with Ministry of Economic Affairs, and prior to such registration, no business or other
legal act can be conducted in the name of a company. In addition, the capital amount of a company must be fully contributed by
its shareholders of their own fund at the time of its establishment, rather than paid by installment or through external financing.
Furthermore, the capital contribution must be audited and certified by accountants.
A limited liability company is a company
organized by more than one shareholder, where the shareholders are only liable to the extent of their contributed capital to the
company. Director(s) of a limited liability company is responsible for the management and operation of the company and subject
to duty of care and duty of loyalty while executing his business judgment with respect to the operation of the company.
Taiwan Regulation on Foreign Exchange
Foreign exchange regulation in Taiwan
is primarily governed by the Ordinance of Foreign Exchange Administration, latest amended on April 29, 2009 (the "Foreign
Exchange Ordinance"). Under the Foreign Exchange Ordinance, foreign exchange refers to foreign currency, bills and marketable
securities. The authority managing the administration of foreign exchange is Ministry of Finance of Republic of China, while the
authority managing the practical operation of foreign exchange business is Central Bank of Republic of China. The Foreign Exchange
Ordinance also specifies the allocated power of Ministry of Finance and Central Bank, respectively. To the extent that any foreign
exchange receipts, payments or transactions reaches the threshold of $17,212 (NT$500,000) or equivalent in foreign currency, it
must be reported to the Central Bank or its designated authorities. Upon incurrence of any of the following events, the State
Council of Republic of China may determine and announce that for a period of time, to close the foreign exchange market, suspend
or restrict all or partial foreign exchange payment, order a mandatory sale or deposit of all or partial foreign exchange into
a designed bank, or dispose in any other manner as it deems necessary:
-
the disorder in domestic or international economy to the detriment
    of the stability of Taiwan's economy; or
-
Taiwan suffers serious trade deficit.
Taiwan Regulation on Foreign Investment
The current principal regulation governing
foreign investment is Foreign Investment Regulation latest amended on November 19, 1997 (the "Investment Regulation").
Under the Investment Regulation, investment refers to any activities involving (1) holding share capital of a company incorporated
in Taiwan; (2) establishing branches, wholly-owned or partnership enterprises in Taiwan; or (3) providing more than one-year term
loan to the above-mentioned investee enterprises. The authority in charge of foreign investment is Ministry of Economic Affairs
of Republic of China. The industries in Taiwan are categorized into permitted, restricted and prohibited foreign investment areas.
Investors may apply for settlement of exchange in accordance with the annual yield of their investment or the allocation of surplus.
Eminent domain
40
When the investment made by an investor
constitutes less than 45% of the total amount of capital of the investee enterprise, and the investee enterprise has been expropriated
or acquired by the government for the purpose of national defense, reasonable government compensation shall be paid to the investors.
However, if the capital contribution made by the investor constitutes equal to or more than 45% of the total amount of capital
of the investee enterprise and continues remaining above 45% for two decades since its establishment, then the government may
not exercise its eminent domain power over such investee enterprise.
Taiwan Regulations on Tax
The current principal regulations governing
tax in Taiwan include the following:
-
Income Tax Law, latest amended on August 8, 2012;
-
The Implementation Rules of Income Tax Law, latest amended on September
    7, 2011;
-
Value-Added and Non-Value-Added Business Tax Law, latest amended
    on November 23, 2011; and
-
The Implementation Rules of Value-Added And Non-Value-Added Business
    Tax Law, latest amended on March 6, 2012.
Under the Income Tax Law, there are two
kinds of income tax, comprehensive income tax for individuals and income tax for enterprises operating for profit, respectively.
Individuals who have income with a source
within Taiwan must pay comprehensive income tax on their income sourced within Taiwan; while non-resident individuals having income
with a source within Taiwan, except otherwise provided in the Income Tax Law, shall pay tax based on the amount attributable to
the sources of their income.
The enterprise with head office located
in Taiwan shall pay profit-seeking income tax on its global income both within and outside Taiwan; while the enterprises with
head office outside Taiwan shall only pay profit-seeking income tax on its business income sourced from within Taiwan.
-
Rate of income tax. The individual comprehensive income tax exemption
    threshold is NT$60,000 ($2,065) per person per year. Any income beyond such exemption threshold is subject to a progressive
    tax rate ranging from 5% to 40%.
-
With respect to enterprise operating for profit, the exemption
    threshold is NT$120,000 ($4,131). Any income beyond such exemption threshold is subject to 17% tax rate on its taxable income.
-
Sale of goods or service, import of goods in Taiwan shall be subject
    to Value-Added or Non-Value-Added Business Tax.
-
Rate of business tax. The rate of business tax, except otherwise
    stipulated in the relevant tax law, ranges from 5% to 10% as determined by the State Council of Taiwan.
41
MANAGEMENT
Executive Officers and Directors
On May 1, 2012, the sole member of the
board of directors, Hsin-Lung Lin, through an unanimous written consent, elects and appoints two individuals set forth below as
additional members of our board of directors and certain other individuals as executive officers. The following table sets forth,
as of December 31, 2012, the names and ages of our directors and executive officers. The directors will hold such office until
the next annual meeting of shareholders and until his or her successor has been elected and qualified.
Name
Age
Position
Hsin-Lung Lin
25
Chairman of the board of directors,
    Chief Executive Officer and Chief Financial Officer
Wen-Lang Chang*
53
Director and Head of Sales Management
Wei-Kung Lu
32
Director
Wei-Ming Tsai*
57
Project Vice General Manager
Wen-Hsin Chang*
49
Research and Development Technical
    Advisor
*Executive Office held at Yambear Taiwan.
Business Experience
The following summarizes the occupation
and business experience for our directors and executive officers.
Hsin-Lung LIN, Chairman of the Board
of Directors, Chief Executive Officer and Chief Financial Officer
Hsin-Lung Lin has acted as
the director of the Company since April 12, 2012 and as the Chief Executive Officer of Yambear Taiwan since September 1,
2012. Hsin-Lung has served as Chief Executive Officer and Chief Financial Officer of the Company since February 13, 2013. He
graduated from National Pingtung University of Science and Technology Institute of Finance, Taiwan with a master degree in
2012. His majors include stock market analysis and financial statements analysis. Hsin-Lung has conducted extensive
researches on and is familiar with the stock markets in various jurisdictions, which gives him an insightful understanding of
the unique features of different stock markets.
Wen-Lang CHANG, Director
Wen-Lang Chang has acted as the director
of the Company since February 13, 2013. Wen-Lang Chang has acted as the Head of Sales Management of Yambear Taiwan since June
2012. He graduated from National Pingtung University of Science and Technology, Taiwan with a major in Management EMBA in 2006.
Wen-Lang has been working with Hawley & Hazel Taiwan since 1985. During such period, Wen-Lang acted as Market Survey Executive
for the first two years, namely from 1985 to 1987. Then Wen-Lang focused on sales. He was promoted from the Sales Executive
(1987 – 1990) to Sales Supervisor (1990 – 1993), then further promoted to the Area Manager (1993 – 1999) and
Channel Manager (1999 -2001). Since 2001, Wen-Lang has been acting as the Senior Customer Development Manager. Wen-Lang started
his career acting as a Sales Representative at NICE Group from 1983 to 1985.
Wei-Kung LU, Director
Wei-Kung LU has acted as the director
of the Company since February 13, 2013. He graduated from National Pingtung University of Science and Technology, Taiwan with
a major in MBA in 2005. Wei-Kung had worked with ADATA Technology Co., Ltd. from 2007 to 2010 acted as a project sales manager.
From September 2010 to April 2011, Wei-Kung worked with BenQ Asia Pacific Corp acted as a business line manager. Wei-Kung has
been working with MSI Pacific International Holding Co., Ltd. from April 2011. During such period, Wei-Kung acted as a general
manager Malaysia Representative Office.
42
Wei-Ming TSAI, Project Vice General
Manager
Wei-Ming TSAI has acted as the Project
Vice General Manager of Yambear Taiwan since January 30, 2013. He graduated from National Pingtung University of Science and Technology,
Taiwan with a major in Management EMBA in 2010. Wei-Ming had worked with Kaohsiung City Government from 2001 to 2009 acted as
a director in Kaosuing Fine Art Museum and Library. From September 2009 to April 2010, Wei-Ming worked with Kaohsiung City Government
acted as a director. Wei-Ming had worked with Pingtung County Government from 2010 to 2012. During such period, he acted as a
director in Cultural Events.
Wen-Hsin CHANG, Research and Development
Technical Adviser
Wen-Hsin CHANG
has acted as the Research and Development Technical Adviser of Yambear Taiwan since June 2012. He
graduated
from National Central University Institute of Chemical Engineering, Taiwan with a doctor degree in 1995. Since 1997, Wen-Hsin
has been working with ICT Technology Co., Ltd. Taiwan, where he first worked as a manager in research and development department
from 1999 to 2008, then he has been acting as the deputy general manager in the environmental catalysts international division
since 2008.
Family relationships
There are no family relationship among
the directors and executive officers.
Independence
Wei-Kung Lu is a "independent director"
as defined by the NYSE Amex Stock Exchange.
Involvement in certain legal proceedings
No bankruptcy petition has been filed
by or against any business of which any of our executive officers was a general partner or executive officer either at the time
of the bankruptcy or within two years prior to that time.
No director has been convicted in a criminal
proceeding and is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses).
No director has been subject to any order,
judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily
enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities.
No director has been found by a court
of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal
or state securities or commodities law, that has not been reversed, suspended, or vacated.
Director Compensation
Our directors do not currently receive
compensation.
Audit Committee and Audit Committee
Financial Expert
Our board of directors functions as an
audit committee and performs some of the same functions as an audit committee including: (1) selection and oversight of our independent
accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal
controls and auditing matters; and (3) engaging outside advisors. We are not a "listed company" under SEC rules and
are therefore not required to have an audit committee comprised of independent directors. Our board of directors has determined
that its members do not include a person who is an "audit committee financial expert" within the meaning of the rules
and regulations of the SEC. Our board of directors has determined that each of its members is able to read and understand fundamental
financial statements and has substantial business experience that results in that member's financial sophistication. Accordingly,
the board of directors believes that each of its members have the sufficient knowledge and experience necessary to fulfill the
duties and obligations that an audit committee would have.
43
Indemnification
Under Delaware law and pursuant to our
articles of incorporation and bylaws, we may indemnify our officers and directors for various expenses and damages resulting from
their acting in these capacities. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted
to our officers or directors pursuant to those provisions, our counsel has informed us that, in the opinion of the SEC, this indemnification
is against public policy as expressed in the Securities Act, and is therefore unenforceable.
Executive Compensation
The following table sets forth all compensation
awarded to, earned by or paid to our named executive officers. We do not anticipate adjusting our compensations to executive officers
and directors in the foreseeable future.
44
SUMMARY COMPENSATION TABLE
Name and
principal position
Fiscal Year
Salary
($)
Bonus
($)
Stock
Awards
($)
Option
Awards
($)
Non-Equity
Incentive Plan
Compensation
($)
Nonqualified
Deferred
Compensation
Earnings
($)
All Other
Compensation
($)
Total
($)
Hsin-Lung Lin
Chairman,
    Chief Executive Officer, and Chief Financial Officer
2012
7,384
7,384
The above table identifies all compensation
received by the Company's named executive officer directly or indirectly from the Company or its subsidiaries.
45
Employment Agreements
Pursuant to an employment agreement between
Yambear Taiwan and Hsin-Lung Lin dated September 1, 2012 (the "Lin Agreement"), Hsin-Lung earns a salary of NT$32,000
(approximately $1,101.55) per month to serve as Chief Executive Officer of Yambear Taiwan. The Lin Agreement is for an indefinite
term. The Lin Agreement also provides certain holiday bonuses, paid vacation as well as social insurance as required by applicable
laws. Hsin-Lung is subject to a non-compete provision which prohibits him from competing with Yambear Taiwan during the term
of the Lin Agreement. Either party may terminate the Lin Agreement with at least 30 days prior notice. In addition, Yambear
Taiwan may terminate the Lin Agreement with immediate effect in case Hsin-Lung is in material breach of the Lin Agreement. Yambear
Taiwan and Hsin-Lung Lin also entered into a confidentiality agreement dated September 1, 2012. Pursuant to the Lin Agreement,
Hsin-Lung is entitled to participate in our future stock option plan.
Pursuant to an employment agreement between
Yambear Taiwan and Wei-Ming Tsai dated January 30, 2013 (the "Tsai Agreement"), Wei-Ming earns no salary other than
a monthly transportation subsidy in the amount of NT$5,000 (approximately $172.12) to serve as Project Vice General Manager of
Yambear Taiwan. The Tsai Agreement is for an indefinite term. Wei-Ming is also entitled to 3% of the aggregate annual sales
revenue of Yambear Taiwan attributable to the marketing channels that he assisted to develop and the direct sales made by him.
The Tsai Agreement also provides certain holiday bonuses, paid vacation as well as social insurance as required by applicable
laws. Wei-Ming is subject to a non-compete provision which prohibits him from competing with Yambear Taiwan during the term
of the Tsai Agreement. Either party may terminate the Tsai Agreement with at least 30 days prior notice. In addition, Yambear
Taiwan may terminate the Tsai Agreement with immediate effect in case Wei-Ming is in material breach of the Tsai Agreement. Yambear
Taiwan and Wei-Ming Tsai also entered into a confidentiality agreement dated January 30, 2013. Pursuant to the Tsai Agreement,
Wei-Ming is entitled to participate in our future stock option plan.
46
SECURITY OWNERSHIP
The following table sets forth, as of February 12, 2013, certain
information regarding the beneficial ownership of Common Stock by (i) each person who is known by us to own beneficially more
than five percent of the outstanding Common Stock, (ii) each of our director and named executive officers, and (iii) all directors
and named executive officers as a group. Unless otherwise specified, the address of each of the persons set forth below is in
care of 3F., No.10, Yuanxi 2nd Rd., Pingtung Agricultural Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic
of China.
Name and Address of
Amount and Nature of
Title of Class
Beneficial Owner
Beneficial Owner
Percent of Class (1)
Officers and Directors
Common Stock
Hsin-Lung LIN
Director/Chief Executive Officer
100,000
*
Common Stock
Wen-Lang CHANG
Director/Head of Sales Management
100,000
*
Common Stock
Wei-Kung LU
Director
10,000
*
Common Stock
Wei-Ming TSAI
Project Vice General Manager
0
*
Common Stock
Wen-Hsin CHANG
Research and Development Technical Adviser
50,000
*
Common Stock
All executive officers and directors (5) as a group
260,000
2.08
%
5% Beneficial Owners
Common Stock
Yambear Holding Limited
5,700,000
45.6
%
17/F, flat C, Siu Nin Bldg., 32 Tsat Tze Mui Road, North Point,  Hong Kong
Common Stock
Orange Chang Limited
1,200,000
9.6
%
Room 2101-2103, Futura Plaza, 111 How Ming Street, Kwun Tong, Hong Kong
Common Stock
Inkstone Capital Limited
1,200,000
9.6
%
26th Floor, Langham Place Office Tower, NO. 8. Argyle Street, Kowloon, Hong Kong
Common Stock
Pi-Chen Chang
1,130,000
9.04
%
No. 23, Yu'an St., Annan Dist., Tainan City 709, Taiwan, Republic of China
Common Stock
Guo Chen
1,125,000
9
%
701 No. 50 Meihua Cun, Zhongshanyi Road, Yuexiu District, Guangzhou City, People's Republic of China
* Less than 1%
(1) Based on 12,500,000 shares outstanding
as of February 12, 2013.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The Company does not currently have an
insider transaction policy.
We have not had a promoter at any time
since inception. Therefore, we have never entered into transactions with a promoter.
47
As of February 12, 2013, we had not entered
into any related party transaction and none of the following persons has any direct or indirect material interest in any transaction
to which we are a party since our incorporation or in any proposed transaction to which we are proposed to be a party:
(A)
Any of our directors or officers;
(B)
Any proposed nominee for election as
    our director;
(C)
Any person who beneficially owns, directly
    or indirectly, shares carrying more than 10% of the voting rights attached to our Common Stock; or
(D)
Any relative or spouse of any of the
    foregoing persons, or any relative of such spouse, who has the same house as such person or who is a director or officer of
    any parent or subsidiary of us.
DESCRIPTION OF SECURITIES
Common Stock
We are authorized to issue 100,000,000
shares of common stock, $0.0001 par value, of which 12,500,001 shares were issued and outstanding as of February 12, 2013.
Each outstanding share of common stock
entitles the holder thereof to one vote per share on all matters. Our bylaws provide that any vacancy occurring in the board of
directors may be filled by the affirmative vote of a majority of the remaining directors though less than a quorum of the board
of directors.
The holders of shares of our common stock
are entitled to dividends out of funds legally available when and as declared by our board of directors. Our board of directors
has never declared a dividend and does not anticipate declaring a dividend in the foreseeable future. Should we decide in the
future to pay dividends, as a holding company, our ability to do so and meet other obligations depends upon the receipt of dividends
or other payments from our operating subsidiary in Taiwan and other holdings and investments. In the event of our liquidation,
dissolution or winding up, holders of our common stock are entitled to receive, ratably, the net assets available to shareholders
after payment of all creditors.
All of the issued and outstanding shares
of our common stock are duly authorized, validly issued, fully paid and non-assessable. To the extent that additional shares of
our common stock are issued, the relative interests of existing shareholders will be diluted.
Preferred Stock
We do not have any issued and outstanding
or authorized preferred stock as of February 12, 2013.
Rule 144 Shares
As of the date of this registration statement,
we do not have any issued and outstanding common shares that are available for resale to the public market in accordance with
Rule 144.
SELLING STOCKHOLDERS
The shares being offered for resale by
the selling stockholders consist of 1,625,000 shares of our common stock held by 2 shareholders. Such shareholders include the
holders of 1,625,000 shares sold in our Regulation S offering which was completed on July 16, 2012. The following table sets forth
the name of the selling stockholders, the number of shares of common stock beneficially owned by each of the selling stockholders
as of February 12, 2013 and the number of shares of common stock being offered by the selling stockholders. The shares being offered
hereby are being registered to permit public secondary trading, and the selling stockholders may offer all or part of the shares
for resale from time to time. However, the selling stockholders are under no obligation to sell all or any portion of such shares
nor are the selling stockholders obligated to sell any shares immediately upon effectiveness of this prospectus. All information
with respect to share ownership has been furnished by the selling stockholders.
48
Amount
Percent
Shares
Beneficially
Beneficially
Beneficially
Shares
Owned
Owned
Owned Prior
to be
After
After
Name
To Offering
Offered
Offering
Offering
Jiang Wei
500,000
500,000
0
0
%
Chen Guo
1,125,000
1,125,000
0
0
%
None of the Selling Stockholders are broker-dealers
or affiliates of broker dealers.
Transfer Agent
The Company currently serves as its own transfer agent. The Company is in the process of engaging a registered transfer agent and
plans to engage a transfer agent prior to the effectiveness of this Registration Statement.
PLAN OF DISTRIBUTION
This prospectus relates to the registration
of the resale of 1,625,000 shares of our common stock on behalf of the selling stockholders named herein.
The selling stockholders may sell some
or all of their shares at a fixed price of $0.008 per share until our shares are quoted on the Over the Counter Electronic Bulletin
Board ("OTCBB") and thereafter at prevailing market prices or privately negotiated prices. Prior to being quoted on
the OTCBB, shareholders may sell their shares in private transactions to other individuals.
There is no established public trading
market for our securities. Our shares are not and have not been listed or quoted on any exchange or quotation system. In order
for our shares to be quoted, a market maker must agree to file the necessary documents with the National Association of Securities
Dealers, which operates the OTCBB. In addition, it is possible that, such application for quotation may not be approved and even
if approved it is possible that a regular trading market will not develop or that if developed, will be sustained.
Once a market has been developed for our
common stock, the shares may be sold or distributed from time to time by the selling stockholders directly to one or more purchasers
or through brokers or dealers who act solely as agents, at market prices prevailing at the time of sale, at prices related to such
prevailing market prices, at negotiated prices or at fixed prices, which may be changed. The distribution of the shares may be
effected in one or more of the following methods:
¨
ordinary brokers transactions, which may include long or short sales,
¨
Transactions involving cross or block trades on any securities or market where our common stock is trading,
¨
through direct sales to purchasers or sales effected through agents,
¨
through transactions in options, swaps or other derivatives (whether exchange listed or otherwise), or
¨
any combination of the foregoing.
The selling stockholders named in this
prospectus must comply with the requirements of the Securities Act and the Exchange Act in the offer and sale of the common stock
being offered by them.
The selling stockholders and any broker-dealers who
execute sales for the selling stockholders may be deemed to be an "underwriter" within the meaning of the Securities
Act in connection with such sales. During such times as the selling stockholders may be deemed to be engaged in a distribution
of the common stock, and therefore be considered to be an underwriter, they must comply with applicable laws and may
among other things:
49
1.   Not
engage in any stabilization activities in connection with our common stock;
2.  Furnish each broker or
dealer through which common stock may be offered, such copies of this prospectus from time to time,
as may be required by such broker or dealer, and
3.   Not
bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities permitted under the
Exchange Act.
Any commissions received by broker-dealers
and any profit on the resale of shares sold by them while acting as principals might be deemed to be underwriting discounts or
commissions under the Securities Act.
In addition, the selling stockholders may
enter into hedging transactions with broker-dealers who may engage in short sales, if short sales were permitted, of shares in
the course of hedging the positions they assume with the selling stockholders. The selling stockholders may also enter into option
or other transactions with broker-dealers that require the delivery by such broker-dealers of the shares, which shares may be resold
thereafter pursuant to this prospectus. The selling stockholders may be deemed to be underwriters with respect to the shares that
they are offering for resale.
Brokers, dealers, or agents participating
in the distribution of the shares may receive compensation in the form of discounts, concessions or commissions from the selling
stockholders and/or the purchasers of shares for whom such broker-dealers may act as agent or to whom they may sell as principal,
or both (which compensation as to a particular broker-dealer may be in excess of customary commissions). Neither the selling stockholders
nor we can presently estimate the amount of such compensation. We know of no existing arrangements between the selling stockholders
and any other stockholder, broker, dealer or agent relating to the sale or distribution of the shares.
We will not receive any proceeds from the
sale of the shares of the selling stockholders pursuant to this prospectus. We have agreed to bear the expenses of the registration
of the shares, including legal and accounting fees, and such expenses are estimated to be approximately $80,000.
LEGAL MATTERS
The Chiang Law Offices passed upon the
validity of the common stock being offered hereby.
EXPERTS
Included in the prospectus constituting
part of this registration statement are consolidated financial statements of (i) Yambear Bio-tech, Inc. and (ii) Yambear Bio-technology
Co., Ltd. for fiscal year ended December 31, 2012, which have been audited by Goldman Kurland Mohidin, LLP, an independent registered
public accounting firm, to the extent and for the periods set forth in their respective report appearing elsewhere herein. The
financial statements are included in reliance upon such report given upon the authority of such firms as experts in accounting
and auditing.
AVAILABLE INFORMATION
We have filed with the SEC a registration
statement on Form S-1 under the Securities Act with respect to the common stock offered hereby. This prospectus, which constitutes
part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits
and schedule thereto, certain parts of which are omitted in accordance with the rules and regulations of the SEC. For further information
regarding our common stock and us, please review the registration statement, including exhibits, schedules and reports filed as
a part thereof. Statements in this prospectus as to the contents of any contract or other document filed as an exhibit to the registration
statement, set forth the material terms of such contract or other document but are not necessarily complete, and in each instance
reference is made to the copy of such document filed as an exhibit to the registration statement, each such statement being qualified
in all respects by such reference.
50
After the effective date of this prospectus
we will also be subject to the informational requirements of the Exchange Act which requires us to file reports, proxy statements
and other information with the SEC. Such reports, proxy statements and other information along with the registration statement,
including the exhibits and schedules thereto, may be inspected at public reference facilities of the SEC at 100 F Street N.E, Washington
D.C. 20549. Copies of such material can be obtained from the Public Reference Section of the SEC at prescribed rates. You may call
the SEC at 1-800-SEC-0330 for further information on the operation of the public reference room. Because we file documents electronically
with the SEC, you may also obtain this information by visiting the SEC's Internet website at http://www.sec.gov.
No dealer, salesperson or other person
has been authorized to give any information or to make any representations other than those contained in this prospectus in connection
with the offering made by this prospectus, and, if given or made, such information or representations must not be relied upon as
having been authorized by the Company or the selling stockholders.  This prospectus does not constitute an offer to sell or
a solicitation of an offer to buy any securities other than those specifically offered hereby or an offer to sell or a solicitation
of an offer to buy any of these securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation. 
Except where otherwise indicated, this prospectus speaks as of the effective date of the registration statement.
51
FINANCIAL STATEMENTS
YAMBEAR BIO-TECH, INC. AND SUBSIDIARY
Consolidated Financial Statements
From Inception (April 12, 2012) to December
31, 2012
Contents
Page
Report of Independent Registered Public Accounting Firm
F-1
Financial Statements:
Consolidated Balance Sheet as of December 31, 2012
F-2
Consolidated Statement of Operations and Other Comprehensive
Loss from inception (April 12, 2012) to December 31, 2012
F-3
Consolidated Statement of Stockholders' Equity from inception
(April 12, 2012) to December 31, 2012
F-4
Consolidated Statement of Cash Flows from inception
(April 12, 2012) to December 31, 2012
F-5
Notes to Consolidated Financial Statements
F-6
52
Report of Independent Registered
Public Accounting Firm
Board of Directors and Stockholders of
Yambear Bio-Tech, Inc.
We have audited the accompanying consolidated
balance sheets of Yambear Bio-Tech, Inc. and subsidiary as of December 31, 2012, and the related consolidated statements of operations
and other comprehensive loss, stockholders' equity, and cash flows from inception (April 12, 2012) to December 31, 2012. These
financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial
statements based on our audit.
We conducted our audit in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.
The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. Our
audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate
in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control
over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that
our audit provides a reasonable basis for our opinion.
In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the consolidated financial position of Yambear Bio-Tech,
Inc. and subsidiary as of December 31, 2012, and the consolidated results of their operations and their consolidated cash flows
from inception (April 12, 2012) to December 31, 2012, in conformity with U.S. generally accepted accounting principles.
The accompanying financial statements have
been prepared assuming the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company
has an accumulated deficit of $29,391, as of December 31, 2012 and has used cash in operations of $84,992. These matters, among
others, raise substantial doubt about the Company's ability to continue as a going concern. Management's plans concerning
these matters are described in Note 1. These accompanying financial statements do not include any adjustments that might result
from the outcome of this uncertainty.
Goldman Kurland and Mohidin LLP
Encino, California
February 1, 2013
F-
1
YAMBEAR BIO-TECH, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEET
AS OF DECEMBER
31, 2012
ASSETS
CURRENT ASSETS:
Cash
$
16,302
Accounts receivable, net of allowance for doubtful accounts of $0
8,519
Other receivables
1,667
Inventory
40,539
Deposits
7,063
Total current assets
74,090
INTANGIBLE ASSETS, net
757
OTHER LONG-TERM ASSETS
2,239
TOTAL ASSETS
$
77,086
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Salaries payable
$
2,080
Advances from customers
1,672
Other payables
185
Total current liabilities
3,937
STOCKHOLDERS' EQUITY:
Common stock, $0.0001 per share; 100,000,000 shares authorized, 12,500,000 shares issued and outstanding
1,250
Additional paid-in capital
98,750
Accumulated other comprehensive income
2,540
Retained Earnings
(29,391
)
Total stockholders' equity
73,149
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
77,086
The accompanying notes are an integral part
of these consolidated financial statements
F-
2
YAMBEAR BIO-TECH, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENT OF OPERATIONS
AND
OTHER COMPREHENSIVE (LOSS)
FROM INCEPTION (APRIL 12, 2012) TO DECEMBER
31, 2012
Revenue
$
21,502
Cost of revenue
8,933
Gross profit
12,569
Operating expenses
Selling expenses
5,153
General and administrative expenses
36,883
Total operating expenses
42,036
Loss from operations
(29,467
)
Non-operating income (expense):
Other income (expense)
34
Interest income
42
Total non-operating income
76
Loss before provision for income taxes
(29,391
)
Provision for income taxes
-
Net loss
(29,391
)
Other comprehensive loss
Foreign currency translation gain
2,540
Comprehensive loss
$
(26,851
)
Weighted average shares outstanding :
Basic
12,500,000
Diluted
12,500,000
Loss per share:
Basic
$
(0.00
)
Diluted
$
(0.00
)
The accompanying notes are an integral part
of these consolidated financial statements
F-
3
YAMBEAR BIO-TECH, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENT OF STOCKHOLDERS'
EQUITY
FROM INCEPTION (APRIL 12, 2012) TO DECEMBER
31, 2012
Accumulated
Other
Total
Common Stock
Additional Paid
Comprehensive
Accumulated
Stockholders'
Shares
Amount
in Capital
Income
Deficit
Equity
Balance, April 12, 2012
-
$
-
$
-
$
-
$
-
$
-
Purchase of common stock for cash
12,500,000
1,250
98,750
-
-
100,000
Change in foreign currency translation gain
-
-
-
2,540
-
2,540
Net loss
-
-
-
-
(29,391
)
(29,391
)
Balance, December 31, 2011
12,500,000
$
1,250
$
98,750
$
2,540
$
(29,391
)
$
73,149
The accompanying notes are an integral part
of these consolidated financial statements
F-
4
YAMBEAR BIO-TECH, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENT OF CASH FLOWS
FROM INCEPTION (APRIL 12, 2012) TO DECEMBER
31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$
(29,391
)
Adjustments to reconcile net loss to net cash used in operating activities:
(Increase) / decrease in assets:
Accounts receivable
(8,445
)
Other receivables
(1,652
)
Inventory
(40,186
)
Deposits
(7,001
)
Other assets
(2,219
)
Increase / (decrease) in current liabilities:
Salaries payable
2,062
Advances from customers
1,657
Other payables
183
Net cash used in operating activities
(84,992
)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for intangible assets
(750
)
Net cash used in investing activities
(750
)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock
100,000
Net cash provided by financing activities
100,000
Effect of exchange rate changes on cash and cash equivalents
2,044
NET INCREASE IN CASH
16,302
CASH, BEGINNING OF PERIOD
-
CASH, END OF PERIOD
$
16,302
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid
$
-
Income taxes paid
$
-
The accompanying notes are an integral part
of these consolidated financial statements
F-
5
Note 1 - Organization and Basis of Presentation
Organization and Line of Business
Yambear Bio-Tech, Inc. (the "Company" or "Yambear")
was incorporated in the State of Delaware on April 12, 2012. The Company, through its subsidiary is engaged in selling enzymes
products to public consumers across Taiwan, and the Company intends to expand business operations by distributing and exporting
its enzymes products to Hong Kong, mainland China, Singapore and Malaysia in 2013. The Company's goal is to distribute and
market its enzymes products to high-end consumers by exploring a variety of marketing channels, including, without limitation,
telephone sales, sales on TV shopping channels, as well as selling in special counters located in big shopping malls and self-operated
stores.
Going Concern
The accompanying consolidated financial statements
have been prepared in conformity with accounting principles generally accepted in the United States of America, which
contemplate continuation of the Company as a going concern. The Company has an accumulated deficit of $29,391, as of December
31, 2012 and has used cash in operations of $84,992 from its inception to December 31, 2012. These conditions raise
substantial doubt as to the Company's ability to continue as a going concern. These consolidated financial statements
do not include any adjustments that might result from the outcome of this uncertainty. These consolidated financial
statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going
concern. The Company plans to open a retail location in a shopping mall to create brand image and brand awareness and is
currently negotiating an agency agreement with an insurance company in Taiwan. Major shareholders will continue to fund the
Company until it is able to sustain positive cash flows from operations.
Principles of Consolidation
The accompanying consolidated financial statements include the
accounts of Yambear and its wholly-owned subsidiary, Yambear Bio-Tech Co. Ltd. Taiwan ("Yambear Taiwan"). All significant
intercompany transactions and balances were eliminated in consolidation.
Basis of Presentation
The accompanying consolidated financial statements were prepared
in conformity with accounting principles generally accepted in the United States ("US GAAP"). The Company's functional
currency is the Taiwanese Dollar ("Taiwan $"); however, the accompanying consolidated financial statements were translated
and presented in United States Dollars ("$" or "USD").
Foreign Currency Translation
The accounts of the Taiwanese subsidiary are maintained in the
Taiwan $ and the accounts of the U.S. parent company are maintained in the USD. The accounts of the Taiwanese subsidiary are translated
into USD in accordance with ASC Topic 830 "Foreign Currency Matters," with the Taiwan $ as the functional currency
for the Taiwanese subsidiary.
According to Topic 830, all assets and liabilities are translated at the
exchange rate on the balance sheet date, stockholders' equity is translated at historical rates and statement of operations
items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under
other comprehensive income in accordance with ASC Topic 220, "Comprehensive Income." Gains and losses resulting from
the translations of foreign currency transactions and balances are reflected in the statement of operations.
F-
6
Note 2 - Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with US
GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Equivalents
Cash and equivalents include cash in hand and cash in time deposits,
certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.
Accounts Receivable
The Company maintains reserves for potential credit losses on
accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations,
customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these
reserves. Reserves are recorded primarily on a specific identification basis.
Inventory
Inventory is valued at the lower of the inventory's cost
or the current market price of the inventory. Management compares the cost of inventory with its market value and an allowance
is made to write down inventory to market value, if lower.
Long-Lived Assets
The Company applies ASC Topic 360, "Property, Plant, and
Equipment," which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360
requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and
the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that
event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss
on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced to recognize the
cost of disposal. Based on its review, the Company believes that as of December 31, 2012, there was no significant impairment of
its long-lived assets.
Intangible Assets
The Company evaluates intangible assets for impairment, at least
on an annual basis and whenever events or changes in circumstances indicate the carrying value may not be recoverable from its
estimated future cash flows. Recoverability of intangible and other long-lived assets is measured by comparing their net book value
to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results,
budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related
undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss.
F-
7
Fair Value of Financial Instruments
For certain of the Company's financial instruments, including
cash, accounts receivable, other receivables, salaries payable, advances from customers and other payables, the carrying amounts
approximate their fair values due to their short maturities. The carrying amounts of the line of credit and other long-term liabilities
approximate their fair values based on current rates of interest for instruments with similar characteristics.
ASC Topic 820, "Fair Value Measurements and Disclosures,"
requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, "Financial Instruments,"
defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure
requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for receivables and current
liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period
of time between the origination of such instruments and their expected realization and their current market rate of interest. The
three levels of valuation hierarchy are defined as follows:
·
Level 1 inputs to the valuation methodology are quoted
prices for identical assets or liabilities in active markets.
·
Level 2 inputs to the valuation methodology include
quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets,
and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the
financial instrument.
·
Level 3 inputs to the valuation methodology use one
or more unobservable inputs which are significant to the fair value measurement.
The Company analyzes all financial instruments with features
of both liabilities and equity under ASC Topic 480, "Distinguishing Liabilities from Equity," and ASC Topic 815, "Derivatives
and Hedging."
As of December 31, 2012, the Company did not identify any assets
and liabilities required to be presented on the balance sheet at fair value.
Revenue Recognition
The Company's revenue recognition policies comply with
SEC Staff Accounting Bulletin 104 (codified in FASB ASC Topic 605). Sales revenue is recognized at the date of shipment to customers
when a formal arrangement exists, the price is fixed or determinable, the delivery is completed, no other significant obligations
of the Company exist and collectability is reasonably assured. The Company provides sales incentive such a buy a dozen and get
one free. The Company recognizes the cost of the free product at the time of sale. The Company does not provide unconditional return
or any other sales incentives. Payments received before all of the relevant criteria for revenue recognition are satisfied are
recorded as advances from customers.
Sales represent the invoiced value of products, net of value-added
tax ("VAT"). All of the Company's products sold in Taiwan are subject to a value-added tax of 5% of the gross
sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing
the finished product. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax
return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid
as the Company acts as an agent for the government.
F-
8
Income Taxes
The Company accounts for income taxes in accordance with ASC
Topic 740, "Income Taxes." ASC 740 requires a company to use the asset and liability method of accounting for income
taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized
for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities
and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely
than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are
adjusted for the effects of changes in tax laws and rates on the date of enactment.
Under ASC 740, a tax position is recognized as a benefit only
if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination
being presumed to occur. The amount recognized is the largest amount of tax benefit that is more than 50% likely of being realized
on examination. For tax positions not meeting the "more likely than not" test, no tax benefit is recorded. The adoption
had no effect on the Company's consolidated financial statements.
Basic and Diluted Earnings (Loss) Per Share
Earnings per share is calculated
in accordance with the ASC Topic 260, "Earnings Per Share." Basic earnings per share ("EPS") is based upon
the weighted average number of common shares outstanding. Diluted EPS is based on the assumption that all dilutive convertible
shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method,
warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained
thereby were used to purchase common stock at the average market price during the period.
There were no options, warrants
or other instruments convertible into common stock outstanding as of December 31, 2012, therefore basic and diluted loss per share
are the same.
Foreign Currency Translation
The accounts of the Company's Taiwanese subsidiary are
maintained in
Taiwan $
and the accounts of the U.S. parent company are maintained in USD. The
accounts of the Taiwanese subsidiary were translated into USD in accordance with ASC Topic 830, "Foreign Currency Matters,"
with the
Taiwan $
as the functional currency for the Taiwanese subsidiary.
According
to ASC Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date, stockholders'
equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate
for the year. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic
220, "Comprehensive Income." Gains and losses resulting from the translations of foreign currency transactions and
balances are reflected in the statement of operations.
Foreign Currency Transactions and Comprehensive Income
US GAAP generally requires recognized revenue, expenses, gains
and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities,
such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such
items, along with net income, are components of comprehensive income. The functional currency of the Company's Taiwanese
subsidiary is the Taiwan $. Translation gains of $2,540 at December 31, 2012, are classified as an item of other comprehensive
income in the stockholders' equity section of the consolidated balance sheet.
F-
9
Statement of Cash Flows
In accordance with ASC Topic 230, "Statement of Cash Flows,"
cash flows from the Company's operations are calculated based upon the local currencies using the average translation rates.
As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily
agree with changes in the corresponding balances on the consolidated balance sheets.
Recent Accounting Pronouncements
In May 2011, the FASB issued ASU 2011-04
to provide a consistent definition of FV and ensure the FV measurement and disclosure requirements are similar between US GAAP
and IFRS. ASU 2011-04 changes certain FV measurement principles and enhances the disclosure requirements particularly for Level
3 FV measurements.  This guidance was effective for the Company on January 1, 2012.  The adoption of ASU 2011-04 did
not have a significant impact on the Company's consolidated financial statements.
In June 2011, the FASB issued ASU 2011-05,
Presentation of Comprehensive Income
. ASU 2011-05 revises the manner in which entities present comprehensive income in their
financial statements. The new guidance removes the presentation options in Accounting Standards Codification (ASC) 220,
Comprehensive
Income
, and requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive
income or (2) two separate but consecutive statements. The new guidance does not change the items that must be reported in
other comprehensive income. In December 2011, the FASB issued ASU 2011-12 which defers the requirement in ASU 2011-05
that companies present reclassification adjustments for each component of accumulated other comprehensive income in both net income
and other comprehensive income on the face of the financial statements. ASU 2011-05 is effective for fiscal years and interim
reporting periods within those years beginning after December 15, 2011, with early adoption permitted. The adoption of ASU 2011-05,
as amended by ASU 2011-12, did not have a significant impact on the Company's consolidated financial statements.
In September 2011, the FASB issued ASU 2011-08
which provides an entity the option to first assess qualitative factors to determine whether it is necessary to perform the two-step
test for goodwill impairment.  If an entity believes, as a result of its qualitative assessment, that it is more-likely-than-not
the FV of a reporting unit is less than its carrying amount, the quantitative impairment test is required.  Otherwise,
no further testing is required. The revised standard is effective for the Company for its annual and interim goodwill impairment
tests performed for fiscal years beginning after December 15, 2011.  The adoption of ASU 2011-08 did not significantly
impact the Company's consolidated financial statements.
In July 2012, the FASB issued ASU 2012-02,
Intangibles-Goodwill and Other (Topic 350) - Testing Indefinite-Lived Intangible Assets for Impairment.  The ASU provides
entities with an option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely
than not the indefinite-lived intangible asset is impaired.  If an entity concludes it is more than 50% likely that an indefinite-lived
intangible asset is not impaired, no further analysis is required.  However, if an entity concludes otherwise, it would be
required to determine the FV of the indefinite-lived intangible asset to measure the amount of impairment, if any, as currently
required under US GAAP. The ASU is effective for annual and interim impairment tests performed for fiscal years beginning after
September 15, 2012.  Early adoption is permitted.
The adoption of this pronouncement will not have
a material impact on its financial statements.
F-
10
Note 3 - Inventory
Inventory at December 31, 2012 consisted of the following:
Packing Material
$
11,317
Finished goods
29,222
$
40,539
Note 4 - Intangible Assets
Intangible assets at December 31, 2012 consisted of the following:
Trademark
$
757
Less: Accumulated amortization
(-
)
Intangible assets, net
$
757
The Company's intangible asset consists of a trademark
application fee which will be amortized over its estimate life of 10 years beginning when the trademark is approved.
Amortization of intangible assets is as follows:
Year ending December 31,
2013
$
76
2014
76
2015
76
2016
76
2017
76
Thereafter
377
$
757
Note 5 – Stockholders' Equity
The Company has authorized 100,000,000 shares of common stock
with a par value of $0.0001 per shares. July 16, 2012, the Company issued 12,500,000 shares of its common stock for $100,000.
F-
11
Note 6 - Income Taxes
The Company's subsidiary is governed by the Income Tax
Law of Taiwan, and is generally subject to tax at 17% on income reported in the statutory financial statements after appropriate
adjustments.
Income tax expense reflected in the consolidated statements
of operations and other comprehensive loss consists of the following for the period from inception (April 12, 2012) to December
31, 2012:
Current expense:
Federal
$
-
State
-
Foreign
-
-
Deferred expense:
Federal
-
State
-
Foreign
-
-
Total income tax expense
$
-
The components of deferred income tax assets and liabilities
as of December 31, 2012 are as follows:
Deferred tax assets:
Net operating loss
$
4,996
Total deferred tax assets
4,996
Less valuation allowance
(4,996
)
$
-
F-
12
A reconciliation of tax at United States federal statutory rate
to provision for income tax recorded in the financial statements is as follows:
Tax provision at statutory rate
-34
%
Foreign tax rate difference
17
%
Taiwanese current NOL for which no benefit is realized
17
%
Effective rate
0
%
The Company has a net operating loss carryforward in Taiwan
of approximately $29,000 that expires in 2017.
Note 7 – Commitments and Contingencies
The Company leases office space located at 3F., No.10, Yuanxi
2nd Rd., Pingtung Agriculture Biotechnology Park, Changzhi Township, Pingtung 908, Taiwan, Republic of China for $1,669 (NT$48,480)
per month Which expire on October 31, 2014. Future annual minimum lease payments for this non cancelable operating lease are as
follows:
Year ending December 31,
2013
$
20,028
2014
16,690
$
36,718
Employment Agreements
Pursuant to an employment agreement between the Yambear Taiwan
and Hsin-Lung Lin dated September 1, 2012, Hsin-Lung earns a salary of NT$32,000 (approximately $1,102) per month to serve as Chief
Executive Officer of Yambear Taiwan.
In addition, pursuant to an employment agreement between Yambear
Taiwan and Wei-Ming Tsai dated January 30, 2013, Wei-Ming earns no salary other than a monthly transportation subsidy in the amount
of NT$5,000 (approximately $172) to serve as Project Vice General Manager of Yambear Taiwan. The agreement is for an indefinite
term. Wei-Ming is also entitled to 3% of the aggregate annual sales revenue of Yambear Taiwan attributable to the marketing channels
that he assisted to develop and the direct sales made by him.
F-
13
1,625,000 Shares of
Common Stock
Yambear Bio-tech, Inc.
PROSPECTUS
______________, 20__
DEALER PROSPECTUS DELIVERY OBLIGATION
Until __________, all dealers that effect
transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This
is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold
allotments or subscriptions.
F-
14
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13.  Other Expenses of Issuance
and Distribution.
The estimated expenses of this offering
in connection with the issuance and distribution of the securities being registered, all of which are to be paid by the Registrant,
are as follows:
Registration Fee
$
1.77
Legal Fees and Expenses
50,000
Accounting Fees and Expenses
20,000
Printing
5,000
Miscellaneous Expenses
5,000
Total
$
80,002
Item 14.  Indemnification of Directors
and Officers
Section 145 of the Delaware General Corporation
Law authorizes a corporation's board of directors to grant, and authorizes a court to award, indemnity to officers, directors
and other corporate agents.
As permitted by Section 102(b)(7) of the
Delaware General Corporation Law, our company's certificate of incorporation includes provisions that eliminate the personal
liability of its directors for monetary damages for breach of their fiduciary duty as directors. To the extent Section 102(b)(7)
is interpreted, or the Delaware General Corporation Law is amended, to allow similar protections for officers of a corporation,
such provisions of our company's certificate of incorporation shall also extend to those persons.
In addition, as permitted by Section 145
of the Delaware General Corporation Law, the bylaws, and certificate of incorporation of our company provide that:
·
Any director of the Company shall not
be liable to the Company or its stockholders for monetary damages from breach of fiduciary duty as a director, except to the extent
such exemption from liability or limitation thereof is not permitted under the General Corporation Law of the State of Delaware
as the same exists or may hereafter be amended.
·
Except the advances in connection with
indemnification, no loan shall be made by the Company to any director unless it is authorized by vote of the stockholders without
counting any shares of the director who would be the borrower or unless the director who would be the borrower is the sole shareholder
of the Company.
·
The Company will not be obligated pursuant
to the bylaws to indemnify a person with respect to proceedings initiated by that person, except with respect to proceedings authorized
by our company's board of directors.
·
The rights conferred in the bylaws are
not exclusive, and our company is authorized to enter into indemnification agreements with its directors, officers, employees and
agents and to obtain insurance to indemnify such persons.
·
The Company may not retroactively amend
the bylaw provisions to reduce its indemnification obligations to directors, officers, employees and agents.
53
These indemnification provisions may be
sufficiently broad to permit indemnification of our company's officers and directors for liabilities (including reimbursement
of expenses incurred) arising under the Securities Act of 1933.  The Company may at the discretion of the board of directors
purchase and maintain insurance on behalf of any person who holds or who has held any position identified in the paragraph above
against any and all liability incurred by such person in any such position or arising out of his status as such.
Insofar as indemnification by us for liabilities
arising under the Securities Act may be permitted to our directors, officers or persons controlling the company pursuant to provisions
of our articles of incorporation and bylaws, or otherwise, we have been advised that in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification
by such director, officer or controlling person of us in the successful defense of any action, suit or proceeding is asserted by
such director, officer or controlling person in connection with the securities being offered, we will, unless in the opinion of
our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue.
Item 15.  Recent Sales of Unregistered
Securities
On July 16, 2012, we issued a total of
12,500,000 shares of our common stock, $0.0001 par value per share, to 26 non U.S. persons in consideration for their previous
investment of $100,000 to the Company. The issuance was made
pursuant to an exemption from registration contained in Regulation S under the Securities Act of 1933, as amended.
Item 16. Exhibits and Financial Statement
Schedules
Exhibit
Number
Description of Exhibit
3.1
Certificate of Incorporation
3.2
Bylaws
5.1*
Opinion of The Chiang Law Offices
10.1
Form of
Stock Purchase Agreement
10.2
Translation of Employment Agreement between the Company and
    Hsin-Lung Lin
10.3
Translation of Employment Agreement between the Company and
    Wei-Ming Tsai
10.4
Translation of Tenancy Contract dated January 10, 2011
10.5
Translation of Distribution Agreement between the Company and
    Fitness & Beauty Corporation Limited,     dated     November     1,     2012
21
Subsidiaries of the registrant
23.1
Consent of Goldman Kurland Mohidin, LLP
23.2
Consent of The Chiang Law Offices (contained in Exhibit 5.1)
24
Powers of Attorney (included on the signature page)
* To be filed by amendment
Item 17.  Undertakings
(a) The undersigned registrant hereby undertakes:
(1) To file, during
any period in which offers or sales are being made, a post-effective amendment to this registration statement to:
(i) include any prospectus
required by Section 10(a)(3) of the Securities Act of 1933;
(ii) reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment
thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (§ 230.424(b)
of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate
offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement;
54
(iii) include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement;
(2) That, for the purpose
of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering.
(3) To remove from
registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.
(b) That, for the purpose of determining
liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:
The undersigned registrant undertakes that
in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of
the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
such securities to such purchaser:
(1) Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424 (§
230.424 of this chapter);
(2) Any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
registrant;
(3) The portion of
any other free writing prospectus relating to the offering containing material information about the undersigned registrant or
its securities provided by or on behalf of the undersigned registrant; and
(4) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.
(c) Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant
to the foregoing provisions, the registrant has been advised that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by
the final adjudication of such issue.
(d) The undersigned registrant hereby
undertakes that, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed
pursuant to Rule 424(b) as part of a registration statement relating to an offering shall be deemed to be part of and included
in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in
a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to
a purchaser with a time of contract of sale prior to such a first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date
of first use.
55
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in Changzhi Township, Pingtung, Taiwan, Republic of China, on the 14th day of February 2013.
Yambear Bio-tech, Inc.
By:
/s/ Hsin-Lung Lin
Hsin-Lung Lin, Chief Executive Officer and Chief Financial Officer
KNOW ALL PERSONS BY
THESE PRESENTS that each person whose signature appears below hereby constitutes and appoints Hsin-Lung Lin as his true and lawful
attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities,
to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with
all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to
be done in connection therewith, as fully to all intents and purposes as he might or could do them in person, hereby ratifying
and confirming all that said attorney-in-fact and agent or any of them, or their or his substitute or substitutes, shall do or
cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates
indicated:
Signature
Title
Date
/s/ Hsin-Lung Lin
Director, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)
February 14, 2013
Hsin-Lung Lin
/s/ Wen-Lang Chang
Director
February 14, 2013
Wen-Lang Chang
/s/ Wei-Kung Lu
Director
February 14, 2013
Wei-Kung Lu
56